Document and Entity Information
Document and Entity Information | 12 Months Ended |
Dec. 31, 2018shares | |
Document and entity information [abstract] | |
Document Type | 20-F |
Amendment Flag | false |
Document Period End Date | Dec. 31, 2018 |
Document Fiscal Year Focus | 2018 |
Document Fiscal Period Focus | FY |
Trading Symbol | DBVT |
Entity Registrant Name | DBV TECHNOLOGIES S.A. |
Entity Central Index Key | 0001613780 |
Current Fiscal Year End Date | --12-31 |
Entity Well-known Seasoned Issuer | No |
Entity Current Reporting Status | Yes |
Entity Filer Category | Accelerated Filer |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 30,157,777 |
Consolidated Statements of Fina
Consolidated Statements of Financial Position - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Non-Current assets | |||
Intangible assets | € 29 | € 123 | € 96 |
Property, plant, and equipment | 20,219 | 17,808 | 12,482 |
Other non-current financial assets | 6,033 | 3,012 | 2,745 |
Total non-current assets | 26,281 | 20,942 | 15,323 |
Current assets | |||
Inventories | 1,566 | ||
Customer accounts receivable and related receivables | 1,265 | 1,250 | |
Other current assets | 21,131 | 17,721 | 14,454 |
Cash and cash equivalents | 122,770 | 137,880 | 256,473 |
Total current assets | 145,468 | 156,865 | 272,177 |
TOTAL ASSETS | 171,749 | 177,807 | 287,500 |
Shareholders' equity | |||
Share Capital | 3,016 | 2,499 | 2,465 |
Premiums related to the Share Capital | 539,292 | 406,709 | 405,882 |
Reserves | (254,946) | (131,592) | (50,968) |
Net (loss) | (166,076) | (147,693) | (114,531) |
Total shareholders' equity | 121,286 | 129,923 | 242,849 |
Non-current liabilities | |||
Long-term financial debt | 1,278 | 1,825 | 4,049 |
Non-current provisions | 1,536 | 1,260 | 853 |
Other non-current liabilities | 4,105 | 8,869 | 10,746 |
Total non-current liabilities | 6,919 | 11,954 | 15,649 |
Current liabilities | |||
Bank overdrafts | 0 | 0 | 0 |
Short-term financial debt | 1,201 | 2,325 | 591 |
Current provisions | 1,270 | 913 | |
Supplier accounts payable | 28,567 | 16,941 | 13,720 |
Other current liabilities | 12,506 | 15,751 | 14,692 |
Total current liabilities | 43,543 | 35,930 | 29,002 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | € 171,749 | € 177,807 | € 287,500 |
Consolidated Statements of (Los
Consolidated Statements of (Loss) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Operating income | |||
Revenues | € 0 | € 0 | € 0 |
Other income | 14,537 | 11,909 | 9,084 |
Total income | 14,537 | 11,909 | 9,084 |
Operating expenses | |||
Cost of goods sold | 0 | 0 | 0 |
Research & Development | (107,171) | (105,232) | (78,828) |
Sales & Marketing | (32,169) | (15,824) | (11,282) |
General & Administrative | (41,399) | (35,837) | (35,005) |
Total expenses | (180,739) | (156,892) | (125,115) |
Operating (loss) | (166,202) | (144,983) | (116,031) |
Financial revenues | 493 | 616 | 1,516 |
Financial expenses | (351) | (3,325) | (16) |
Financial profit (loss) | 141 | (2,709) | 1,500 |
Income tax | (15) | (1) | 0 |
Net (loss) | € (166,076) | € (147,693) | € (114,531) |
Basic/diluted (loss) per share (€/share) | € (5.74) | € (5.97) | € (4.68) |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive (Loss) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Statement of comprehensive income [abstract] | |||
Net (loss) | € (166,076) | € (147,693) | € (114,531) |
Actuarial gains and losses on employee benefits, net of corporate tax | 19 | (177) | (249) |
Profit (loss) directly recognized in shareholders' equity | 19 | (177) | (249) |
Other comprehensive income | (683) | 3,280 | (743) |
Total comprehensive (loss) | € (166,740) | € (144,590) | € (115,523) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Statement of cash flows [abstract] | |||
Net (loss) for the period | € (166,076) | € (147,693) | € (114,531) |
Cash flows used in operating activities: | |||
Amortization and provision | 2,830 | 2,926 | 1,349 |
Retirement pension obligations | 295 | 230 | 115 |
Expenses related to share-based payments | 25,904 | 30,781 | 34,353 |
Other elements | 752 | 130 | 147 |
Operating cash flows before change in working capital | (136,294) | (113,626) | (78,566) |
Inventories | (1,566) | ||
Customer accounts receivable | 1,229 | 3 | (1,250) |
Other current assets | (2,591) | (3,458) | (2,931) |
Supplier accounts payable | 9,095 | 3,333 | 3,645 |
Other current and non-current liabilities | (6,493) | (566) | 19,564 |
Change in working capital requirement | (326) | (687) | 19,028 |
Net cash flow used in operating activities | (136,620) | (114,314) | (59,538) |
Cash flows used in investing activities: | |||
Acquisitions of property, plant, and equipment | (4,710) | (7,246) | (7,992) |
Acquisitions of intangible assets | (41) | (299) | (215) |
Acquisitions of non-current financial assets | (3,890) | (289) | (93) |
Net cash flows used in investing activities | (8,641) | (7,834) | (8,300) |
Cash flows provided by financing activities: | |||
(Decrease) in conditional advances | (1,800) | (578) | (275) |
Treasury shares | (479) | (25) | (54) |
Capital increases, net of transaction costs | 133,099 | 861 | 2,016 |
Other cash flows related to financing activities | (144) | 28 | (21) |
Net cash flows provided by financing activities | 130,676 | 286 | 1,666 |
(Decrease) in cash | (14,586) | (121,863) | (66,172) |
Net Cash and cash equivalents at the beginning of the period | 137,880 | 256,473 | 323,381 |
Impact of exchange rate fluctuations | (525) | 3,269 | (735) |
Net cash and cash equivalents at the close of the period | € 122,770 | € 137,880 | € 256,473 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholder's Equity - EUR (€) € in Thousands | Total | Share capital [Member] | Share premium [Member] | Reserve [Member] | Profit (loss) [Member] |
Beginning balance at Dec. 31, 2015 | € 322,076 | € 2,421 | € 403,910 | € (39,580) | € (44,674) |
Beginning balance at Dec. 31, 2015 | 24,205,129 | ||||
Net (loss) | (114,531) | (114,531) | |||
Foreign exchange translation | (743) | (743) | |||
Profit (loss) directly recognized in shareholders' equity | (249) | (249) | |||
Total comprehensive (loss) | (115,523) | (992) | (114,531) | ||
Allocation of prior (loss) | (44,674) | 44,674 | |||
Increase in capital | 1,439 | € 44 | 1,395 | ||
Increase in capital, shares | 443,699 | ||||
Treasury shares | (74) | (74) | |||
Issue of share warrants | 577 | 577 | |||
Share-based payments | 34,353 | 34,353 | |||
Ending balance at Dec. 31, 2016 | 242,849 | € 2,465 | 405,882 | (50,968) | (114,531) |
Ending balance at Dec. 31, 2016 | 24,648,828 | ||||
Net (loss) | (147,693) | (147,693) | |||
Foreign exchange translation | 3,280 | 3,280 | |||
Profit (loss) directly recognized in shareholders' equity | (177) | (177) | |||
Total comprehensive (loss) | (144,590) | 3,103 | (147,693) | ||
Allocation of prior (loss) | (114,531) | 114,531 | |||
Increase in capital | 571 | € 34 | 536 | ||
Increase in capital, shares | 341,994 | ||||
Treasury shares | 23 | 23 | |||
Issue of share warrants | 290 | 290 | |||
Share-based payments | 30,781 | 30,781 | |||
Ending balance at Dec. 31, 2017 | 129,923 | € 2,499 | 406,709 | (131,592) | (147,693) |
Ending balance at Dec. 31, 2017 | 24,990,822 | ||||
Net (loss) | (166,076) | (166,076) | |||
Foreign exchange translation | (683) | (683) | |||
Profit (loss) directly recognized in shareholders' equity | 19 | 19 | |||
Total comprehensive (loss) | (166,740) | (665) | (166,076) | ||
Allocation of prior (loss) | (147,693) | 147,693 | |||
Increase in capital | 132,936 | € 517 | 132,419 | ||
Increase in capital, shares | 5,166,955 | ||||
Treasury shares | (900) | (900) | |||
Issue of share warrants | 164 | 164 | |||
Share-based payments | 25,904 | 25,904 | |||
Ending balance at Dec. 31, 2018 | € 121,286 | € 3,016 | € 539,292 | € (254,946) | € (166,076) |
Ending balance at Dec. 31, 2018 | 30,157,777 | 30,157,777 |
The Company
The Company | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
The Company | Note 1: The Company Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies,” or the “Company”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin ® ® ® Viaskin ® Peanut The Company’s lead product candidate, Viaskin ® ® ® ® In August 2017, the Company initiated Part A of the EPITOPE (EPIT ® ® two-part, ® ® ® Viaskin ® Milk The Company is developing its second product candidate, Viaskin ® ® (intent-to-treat, ® Viaskin ® Egg In February 2015, the Company announced the development of a third product candidate, Viaskin ® ® Other Viaskin ® application In addition to our development programs in food allergies, we are exploring the use of our Viaskin ® proof-of-concept ® Main events in 2018 1. FINANCING On March 23, 2018, the Company announced the closing of an underwritten global offering of an aggregate of 3,527,752 ordinary shares in (i) a public offering of 1,392,015 ordinary shares in the form of 2,784,030 American Depositary Shares (“ADSs”) in the United States, Canada and certain other countries outside Europe at a public offering price of $21.26 per ADS (on the basis of an exchange rate of $1.2246=€1.00) and (ii) a concurrent private placement of 2,135,737 ordinary shares in Europe (including France) at a public offering price of €34.71 per ordinary share. Each ADS represents the right to receive one-half In addition, on March 26, 2018, the Company announced the issuance and the settlement and delivery of an aggregate of an additional 529,162 ordinary shares, including 208,802 ordinary shares in the form of 417,604 ADSs, on the same terms and conditions as the securities previously sold in the global offering, pursuant to the exercise of the underwriters’ option to purchase additional ordinary shares, including in the form of ADSs, in the Company’s previously announced global offering (the “Option Closing”). Following the Option Closing, the gross proceeds to the Company from the global offering were approximately $172.5 million (approximately €140.8 million), before deducting underwriting commissions and estimated offering expenses. 2. CLINICAL PROGRAMS Viaskin ® Peanut On February 14, 2018, the Company provided an update on the regulatory progress for Viaskin ® ® The FDA provided written responses to the clinical pre-BLA ® On October 22, 2018, the Company announced the submission of a BLA to the FDA for Viaskin ® ® On December 19, 2018, the Company announced that, after discussions with the FDA, the Company voluntarily withdrew its BLA for Viaskin ® ® On September 12, 2018, the Company announced that the independent DSMB completed its planned safety review of Part A of the EPITOPE (EPIT ® ® ® two-part, ® ® Viaskin ® Milk On February 26, 2018, the Company announced preliminary results from Part B, or Phase II, of a Phase I/II study evaluating the efficacy and safety of three dose regimens of Viaskin ® IgE-mediated (intent-to-treat ® 3. CHANGE IN THE GROUP’S EXECUTIVE COMMITTEE MEMBERSHIP AND BOARD MEMBERS On May 16, 2018, the Company announced that Michel de Rosen was appointed to the Company’s Board of Directors, in replacement of George Horner III. Michel de Rosen’s appointment was confirmed at the Company’s Ordinary and Extraordinary General Meeting on June 22, 2018, in Montrouge, France. With this addition, DBV’s Board is now comprised of eight directors. On June 22, 2018, the Company announced that Joan Schmidt, our current Chief Legal Officer, was appointed as the Company’s Executive Vice President, General Counsel. She is responsible for all legal affairs and compliance at DBV, reporting to the Deputy Chief Executive Officer, David Schilansky. Joan Schmidt also serves as a member of the Executive Committee. On July 26, 2018, the Company announced the appointment of Kevin Trapp as the Company’s Chief Commercial Officer. Kevin Trapp is responsible for all worldwide commercial functions at DBV Technologies, including the potential launch of the Company’s lead product candidate, Viaskin ® On November 16, 2018, the Company announced that its Board of Directors unanimously appointed Daniel Tassé as its Chief Executive Officer (“CEO”), effective November 29, 2018. Dr. Pierre-Henri Benhamou, who co-founded Non-Executive |
General Information and Stateme
General Information and Statement of Compliance | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
General Information and Statement of Compliance | Note 2: General Information and Statement of Compliance Preliminary remarks DBV Technologies Inc. was incorporated in Delaware on April 7, 2015 (the “US subsidiary”). The share capital of this US subsidiary is 100% owned by DBV Technologies S.A. (“DBV Technologies”). DBV Australia Pty Ltd. was incorporated in New South Wales, Australia on July 3, 2018 (the “Australian subsidiary”). The share capital of this Australian subsidiary is 100% owned by DBV Technologies S.A. (“DBV Technologies”). DBV Canada Ltd. was incorporated in Ottawa, Ontario on August 13, 2018 (the “Canadian subsidiary”). The share capital of this Canadian subsidiary is 100% owned by DBV Technologies S.A. (“DBV Technologies”). DBV Pharma was incorporated in Paris on December 21, 2018 (the “French subsidiary”). The share capital of this French subsidiary is 100% owned by DBV Technologies S.A. (“DBV Technologies”). General principles The accompanying consolidated financial statements and related notes (the “Financial Statements”) present the operations of DBV Technologies S.A. and its subsidiaries (the “Group”) as of December 31, 2018. The Company is a corporate venture under French law ( société anonyme Our Financial Statements as of December 31, 2018 have been prepared under the responsibility of DBV Technologies’ management. The Financial Statements were approved by the Board of Directors of DBV Technologies on March 31, 2019. All amounts are expressed in thousands of euros, unless stated otherwise. For consolidation purposes, DBV Technologies S.A. and its subsidiaries have prepared individual financial statements for the periods ended December 31, 2016, December 31, 2017 and December 31, 2018. Statement of Compliance Our Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board (“IASB”) and whose application is mandatory for the year ended December 31, 2018. Comparative figures are presented for December 31, 2016 and 2017. Due to the listing of the Company’s ordinary shares on the Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the financial statements of the Group are also prepared in accordance with IFRS, as adopted by the European Union (“EU”). The following amendments are mandatorily effective for annual periods beginning on or after January 1 st • IFRS 15 – Revenue from Contracts with Customers; • Amendments to IFRS 15 – Clarifications to IFRS 15 Revenue from contracts with customers; • IFRS 9 – Financial Instruments; • Amendments to IFRS 4 – Applying IFRS 9 Financial Instruments with IFRS 4 Insurance Contracts; • Amendments to IFRS 2 – Classification and measurement of share-based payment transactions; • Amendments to IAS 40 – Transfers of Investment Property; • IFRIC 22 – Foreign Currency Transactions and Advance Consideration; • Annual improvements – 2014-2016 cycle. The impacts of the first-time application of IFRS 15 are described in detail in Note 3.12. The impact from the fist-time adoption of IFRS 9 resulted in the change in accounting category, from “fair value to “amortised at cost” for the financial assets on the balance sheet. There is no valuation impact on IFRS 9 given the nature of the assets. The other standards and amendments have not had any impact on the Financial Statements as of December 31, 2018. As of December 31, 2018, there are no differences in the IFRS published and mandated by the IASB and EU. As a result, the Financial Statements comply with IFRS as published by the IASB and as adopted by the EU. IFRS include International Financial Reporting Standards (“IFRS”), International Accounting Standards (the “IAS”), as well as the interpretations issued by the Standing Interpretations Committee (the “SIC”), and the International Financial Reporting Interpretations Committee (“IFRIC”). The main accounting methods used to prepare the Financial Statements are described below. These methods were used for all years presented. The Company did not elect for early application of the new standards, amendments and interpretations which were adopted but not mandatory as of December 31, 2018: • IFRS 16 – Leases; • Amendments to IFRS 9 – Prepayment features with negative compensation; • IFRIC 23 – Uncertainty over Income Tax Treatments. Management assessment concludes that the application of these standards and amendments would not have any impact on the Company’s results on financial position or cash flows. New and revised standards and amendments that may be relevant to the Company’s operations but are not yet effective: • Amendments to IFRS 4 – Applying IFRS 9 with IFRS 4; • IFRS 16 – Leases; • IFRS 17 – Insurance contracts; • IFRS 14 – Regulatory deferral accounts; • IFRIC 23 – Uncertainty over Income Tax Treatments. With respect to the application of IFRS 16 on leases, the Group carried out preliminary analyses and it intends to apply the modified retrospective approach, resulting in an estimated increase in its financial liabilities of approximately 25 to 30 million euros. Management is in the process of evaluating the impact of the other standards and amendments and is therefore, not currently able to estimate reliably the impact of their adoption on the Company’s results on financial position or cash flows. The accounting policies and measurement principles adopted for the Financial Statements as of and for the year ended December 31, 2018 are the same as those used as of and for the years ended December 31, 2016 and 2017, exept for the first application of IFRS 15 as described in detail in Note 3.12. |
Accounting Principles
Accounting Principles | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Accounting Principles | Note 3: Accounting Principles Going concern To date, we have not generated any product revenue and we continue to prepare the potential launch of our Viaskin ® cash-on-hand We expect to seek additional funds, most likely from equity and/or debt financings. However, no assurance can be given at this time as to whether we will be able to achieve these financing objectives. Our financial statements have been prepared on a going concern basis assuming that we will be successful in our financing objectives. As such, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should we not be able to continue as a going concern. Refer to the liquidity risk disclosed in Note 23. Methods of consolidation The Financial Statements incorporate the standalone financial statements of DBV Technologies S.A and its subsidiaries which are controlled by the Company. Control is achieved when the Company: • has power over the subsidiary; • is exposed, or has rights, to variable returns from its involvement with the subsidiary; and • has the ability to use its power to affect its returns. The Company reassesses whether or not it controls a subsidiary if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. Consolidation of subsidiaries begins when the Company obtains control over the subsidiary and ceases when the Company loses control over the subsidiary. Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non- non-controlling non-controlling When necessary, adjustments are made to the financial statements of subsidiaries to align their accounting policies with the Group’s accounting policies. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are neutralized in consolidation. Translation of financial statements in foreign currencies In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary For the purpose of presenting these consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated into euros using exchange rates prevailing at the end of each reporting period. Income and expense items are translated at the average exchange rates at the dates of the transactions. Exchange differences arising, if any, are recognized in other comprehensive income and accumulated in equity. 3.1 Intangible Assets In application of the provisions in IAS 38 Intangible Assets Research and Development Expenses Research expenses are recorded in the Financial Statements as expenses. In accordance with IAS 38, development expenses are recorded in the Financial Statements as intangible assets only if all the following criteria are met: (a) technical feasibility necessary for the completion of the development project; (b) intention on the part of the Company to complete the project and to utilize it; (c) capacity to utilize the intangible asset; (d) proof of the probability of future economic benefits associated with the asset; (e) availability of the technical, financial, and other resources for completing the project; and (f) reliable evaluation of the development expenses. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, the Company believes that the six criteria stipulated by IAS 38 are only fulfilled once the Market Access Authorization has been obtained from the competent authorities. The application of this principle has resulted in all development costs being expensed as incurred. Software The costs related to the acquisition of licenses to software are posted to assets on the basis of the costs incurred to acquire and to implement the software in question. They are amortized using the straight-line method over a period of one to three years depending on the anticipated period of use. 3.2 Property, Plant, and Equipment Property, plant, and equipment are recorded at their acquisition cost or, if applicable, at their production cost. Property, plant, and equipment are depreciated on the basis of the straight-line method over the estimated use period of the property. The fixtures of property rented are depreciated over the term of their own lifetime or of the term of the rental agreement, whichever is shorter. The depreciation periods used are the following: PROPERTY, PLANT, AND EQUIPMENT ITEM PERIOD DEPRECIATION Fixtures and improvements in structures 9 years Research and development / production tools 5 years Research equipment and technical facilities 5 years Computer equipment 3 years Office equipment and furniture 5 years 3.3 Financial Assets IFRS 9 replaces IAS 39—Financial Instruments: Recognition and Measurement. IFRS 9 defines the rules applicable to the classification and recognition of financial instruments, the impairment of financial assets (using a model of expected losses to replace the model of losses incurred) as well as hedge accounting. This new standard is mandatorily effective for annual periods beginning on or after January 1 st As part of the application of IFRS 9, the Company reviewed the method of accounting for financial instruments that were previously classified as “Available-for-sale profit or loss The Company do not hold any hedging instrument as of January 1, 2018 and as of December 31, 2018. As of December 31, 2018, financial assets can be classified into three categories: Financial assets at amortized cost Financial assets at amortized cost are mainly cash and cash equivalent, loans and receivables, measured at amortized cost using the effective interest rate method, adjusted for expected credit losses and at initial recognition at their fair value (acquisition cost and transaction costs). Interest recognized at the effective interest rate is recognized under “Other financial income and expenses” in the statement of profit and loss. Financial assets at fair value through profit or loss: Financial assets at fair value through profit or loss is comprised of: • instruments whose contractual cash flows represent payments of interest or repayments of principal, but which are managed other than with a view to collecting cash flows and/or selling the asset; • instruments that management has designated as ‘fair value through profit or loss” on initial recognition. Gains and losses arising from changes in fair value are recognized in profit or loss within the line items Financial income or Financial expenses. Financial assets at fair value through other comprehensive income mainly comprise: Financial assets at fair value through other comprehensive income is mainly comprised is composed of debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items Financial income or Financial expenses. The Company does not hold this type of instrument as of January 1, 2018 and as of December 31, 2018. Impairment of financial assets measured at amortized cost The Company considers that a financial asset is impaired according to the expected loss method in order to take into account any defaults during the asset holding period. The amount of the expected loss is recognized in the balance sheet. Impairment losses are recognized in profit or loss. 3.4 Recoverable Amount of the Intangible Assets and Property, Plant, and Equipment The property, plant, and equipment and intangible assets that have an established lifetime are subjected to an impairment test when the recoverability of their book value is called into question by the existence of indications of impairment. An impairment is posted to the accounts up to the amount of the excess of the book value over the recoverable value of the asset. The recoverable value of an asset corresponds to its fair value minus the costs of sale or its use value, whichever is higher. 3.5 Inventories and Work in Progress Inventories are measured at production costs calculated using the first-in, first-out Depreciation may be recorded on finished goods and work in progress (i) if their production value is greater than their net realizable value, we estimate that the estimated costs for finalization and the estimated costs for the sale, or (ii) if certain products are no longer used by the company, otherwise they are perishable. At December 31, 2018, inventories were exclusively composed of work in progress relating to the production of the first batches that may be used for the commercialization and secondly to requalified batches that are not intended to be commercialized, which were fully depreciated. 3.6 Share Capital Common shares are classified under Shareholders’ Equity. The costs of share capital transactions that are directly attributable to the issue of new shares or options are recorded in the Financial Statements in Shareholders’ Equity as a deduction from the revenue from the issue, net of tax. 3.7 Payments in Shares Since its incorporation, the Company has established several plans for compensation paid in equity instruments in the form of employee warrants ( bons de souscription de parts de créateur d’entreprise “ bons de souscription d’actions non-employee Pursuant to IFRS 2 Share-based payment The Company has applied IFRS 2 to all equity instruments granted since 2002 to corporate officers, members of the Scientific Committee and employees of the Company, as well as to certain persons bound by a service or investment contract. consultant to the Company. The options are not subject to any market conditions. The characteristics of the options are presented in Note 17. 3.9 Recognition and measurement of Financial Liabilities Non-derivative Other non-derivative Borrowings and debt Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within Financial expenses in the income statement over the term of the debt using the effective interest method. 3.10 Subsidies and Conditional Advances Subsidies The Company receives assistance in the form of subsidies, which are grants that are not repayable by the Company. The subsidies are recognized when there is reasonable assurance that: • the Company will comply with the conditions attached to the subsidies, and • the subsidies will be received. Subsidies that are upfront non-refundable A public subsidy that is to be received (e.g. from OSEO, the French Agency for Innovation) either as compensation for expenses or for losses already incurred, or for immediate financial support of the Company without associated expenses or losses, is recognized as other income ratably over the duration of the funded project. Conditional advances The Company also receives from time to time assistance in the form of conditional advances, which are advances repayable in whole or in part based upon acknowledgment by the funder of a technical or commercial success of the related project by the funding entity. The details concerning the conditional advances are provided in Note 11. The amount resulting from the deemed benefit of the interest-free nature of the award is considered a subsidy for accounting purposes. This deemed benefit is determined by applying a discount rate equal to the rate of fungible treasury bonds over the time period that corresponds to the time period of the repayment of the advances. In the event of a change in payment schedule of the stipulated repayments of the conditional advances, the Company makes a new calculation of the net book value of the debt resulting from the discounting of the expected new future cash flows. The adjustment that results therefrom is recognized in the income statement for the fiscal year during which the modification is recognized. The conditional advances that can be subject to this type of modification are the with Compagnie Française d’Assurance pour le Commerce Extérieur (“COFACE”) advances presented in Note 11. The agreement with COFACE terminated on December 31, 2016. 3.11 Provisions Provisions for Risks and Expenses The provisions for risks and lawsuits correspond to the commitments resulting from lawsuits and various risks whose due dates and amounts are uncertain. A provision is posted to the accounts when the Company has a legal or implicit obligation to a third party resulting from a past event, concerning which it is likely or certain that it will cause an outflow of resources to that third party, without consideration that is anticipated to be at least equivalent to the latter, and that the future outflows of liquid assets can be estimated reliably. The amount recorded in the accounts as a provision is the best estimation of the expenses necessary to extinguish the obligation. Pension Retirement Obligations The employees of the Company receive the retirement benefits stipulated by law in France: • obtaining a compensation paid by the Company to employees upon their retirement (defined-benefit plan); • payment of retirement pensions by the Social Security agencies, which are financed by the contributions made by companies and employees (defined-contribution plans). For the defined-benefit plans, the costs of the retirement benefits are estimated by using the projected credit unit method. According to this method, the cost of the retirement pensions is recognized in the Consolidated Statement of (Loss) so that it is distributed uniformly over the term of the services of the employees. The retirement benefit commitments are valued at the current value of the future payments estimated using, for the discounting, the market rate based on the long-term obligations of the first-category companies with a term that corresponds to that estimated for the payment of the services provided. The Company relies on external actuaries to conduct an annual review of the valuation of these plans. The difference between the amount of the provision at the beginning of a fiscal year and at the close of that year is recognized through profit or loss for the portion representing the costs of services rendered and through other comprehensive income for the portion representing the actual gains and losses. The Company’s payments for the defined-contribution plans are recognized as expenses on the income statement of the period with which they are associated. 3.12 Revenue IFRS 15 became applicable on January 1, 2018, requiring the Company to update its accounting policies on revenue. The concepts of “transfer of control,” which is used primarily to determine the date of revenue recognition, and “performance obligations” do not call for any change in the accounting treatment of the Company’s contracts. The concept of “variable consideration” does not materially alter the principles and methods used to measure net sales. 3.13 Other Income Subsidies Since it was formed, because of its innovative character, the Company has received a certain number of sources of assistance or subsidies from the central government or from local public authorities such as OSEO or the Banque Publique d’Investissement, intended to finance its operations or the recruitment of specific personnel. When the obtention of the subsidy is reasonably certain, these subsidies are recognized as “Other income” during the calendar year over which the corresponding expenses or expenditures were recorded. Research Tax Credit The Research Tax Credit ( Crédit d’Impôt Recherche, The Company has received the Research Tax Credit annually since it was formed. The Company received the reimbursement of the 2015 Research Tax Credit for an amount of €5.7 million during the year 2016. The Company received the reimbursement of the 2016 Research Tax Credit for an amount of €7.3 million during the year 2017. The Company received the reimbursement of the 2017 Research Tax Credit for an amount of €9.5 million during the year 2018. The Company will request the reimbursement of the 2018 Research Tax Credit for an amount of €10.8 million during the year 2019, under the community tax rules for small and medium firms in compliance with the regulatory texts applicable. Collaboration agreement with Nestlé Health Science On May 31, 2016, the Company announced its entry into an exclusive global collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use non-refundable Regarding the first application of IFRS 15 on January 1, 2018, an analysis has been completed on performance conditions, revenue recognition method for milestones payment and on the sale price allocation for the collaboration contract signed with Nestlé in 2016. It has been determined that the license and developments to be made by the Company are a unique performance obligation. As a result, the Company has concluded that under IFRS 15, revenue related to the contract will be recognized progressively, up to the costs incurred by the Company at the end of 2018. No margin is recognized at this stage of the development. Deferred revenue is recognized and reversed over the period in which there is a contractual obligation. This this agreement is not considered an onerous contract for the year-ended December 31,2018. As a result, the application of IFRS 15 had no impact on the financial statements as at December 31, 2018, and retrospectively as at December 31, 2017. 3.14 Rental Agreements The rental agreements involving property, plant, and equipment are classified as finance lease agreements when the Company bears a substantial portion of all the benefits and risks inherent in the ownership of the property. The assets that are covered under financing lease agreements are capitalized as of the beginning date of the rental agreement on the basis of the fair value of the rented asset or the discounted values of the future minimum payments, whichever is lower. Each rental payment is distributed between the debt and the financial cost in such a manner as to determine a constant interest rate on the principal that remains due. The corresponding rental obligations, net of the financial expenses, are classified as financial liabilities. The portion of the financial expense that corresponds to the interest is recognized as an expense over the term of the agreement. The property, plant, or equipment acquired within the framework of a finance lease agreement is amortized over the use period or the term of the lease agreement, whichever is shorter. The rental agreements for which a significant portion of the risks and advantages is preserved by the lessor are classified as ordinary rental agreements. The payments made for these ordinary rental agreements, net of any incentive measures, are recognized as expenses on the income statement in a linear manner over the term of the agreement. 3.15 Taxes Income Tax Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of the assets and liabilities that appear in the financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward. The tax rates that have been ratified by a legal text as of the closing date are utilized to determine the deferred taxes. The deferred tax assets are recorded in the accounts only to the extent that it is likely that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforward in the Consolidated Statements of Financial Position. 3.16 Segment Information The Company operates in a single operating segment: the conducting of research and development of epicutaneous immunotherapy products in order to market them in the future. The assets, liabilities, and operating losses recognized are primarily located in France. 3.17 Other Items in the Comprehensive (or Loss) The revenue and expense items for the period that are not posted in the Consolidated Statements of (Loss) as stipulated by the applicable standards are presented, as necessary, under the rubric “Other items in the comprehensive (or loss).” 3.18 Use of Estimates The preparation of our Financial Statements requires the management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. Estimates and assumptions are based on historical experience and other factors that management believes to be reasonable under the circumstances. Estimates and assumptions are measured on an ongoing basis. Actual results may differ from these estimates. These estimates and judgments mainly involve: • an estimate of time and costs required to complete the collaboration agreement with Nestlé Health Science; • a valuation of the fair value of the employee warrants (BSPCEs) granted to employees and/or executives and share warrants (BSAs) granted to non-employee • an estimate of the expected dates of achievement of the performance conditions for the duration of the spillover from the granting of stock options and free shares; • an estimate of the Research Tax Credit based on internal and external expenses incurred by the Company during the year. Only eligible research expenses are included in the calculation of the research tax credit; • an estimate of provisions. 3.19 Presentation of Financial Assets and Financial Liabilities Measured at Fair Value In accordance with the amendments to IFRS 7, financial instruments are presented in three categories based on a hierarchical method used to determine their fair value: • level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; • level 2: fair value calculated using valuation techniques based on observable market data such as prices of similar assets and liabilities or parameters quoted in an active market; • level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as prices in an inactive market or a valuation based on multiples for unlisted securities. 3.20 Subsequent events The Consolidated Statements of Financial Position and the Consolidated Statements of (Loss) of the Company are adjusted to reflect the subsequent events that alter the amounts related to the situations that exist as of the closing date. The adjustments are made until the date the financial statements are approved and authorized for issuance by the Board of Directors. |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Intangible Assets | Note 4: Intangible Assets The intangible assets are broken down as follows: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Patents, licenses, trademarks 196 414 201 Software 376 450 703 Total historical cost 572 864 905 Accumulated amort. of patents, licenses, and trademarks (125 ) (340 ) (200 ) Accumulated depreciation of software packages (351 ) (401 ) (675 ) Accumulated amortization and depreciation (476 ) (741 ) (875 ) Net total 96 123 29 There has been no recognition of impairment losses in application of IAS 36 Impairment of Assets |
Property, Plant, and Equipment
Property, Plant, and Equipment | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Property, Plant, and Equipment | Note 5: Property, Plant, and Equipment 1/1/2016 Increase Decrease 12/31/2016 (Amounts in thousands of Euros) Laboratory equipment 2,357 740 — 3,097 Building fixtures 938 3,672 — 4,610 Office equipment 209 398 — 607 Computer equipment 470 516 — 986 Property, plant, and equipment in progress 3,672 2,713 — 6,385 Total, gross 7,646 8,039 — 15,685 Accumulated depreciation of laboratory equipment 948 557 — 1,505 Accumulated depreciation of the building fixtures 782 327 — 1,109 Accumulated depreciation of office equipment 131 81 — 212 Accumulated depreciation of computer equipment 205 172 — 377 Total accumulated amortization and depreciation 2,065 1,137 — 3,203 Total, net 5,581 6,901 — 12,482 1/1/2017 Increase Decrease 12/31/2017 (Amounts in thousands of Euros) Laboratory equipment 3,097 2,806 (83 ) 5,820 Building fixtures 4,610 534 (46 ) 5,098 Office equipment 607 275 (116 ) 766 Computer equipment 986 116 (30 ) 1,073 Property, plant, and equipment in progress 6,385 3,384 (55 ) 9,714 Total, gross 15,685 7,114 (329 ) 22,470 Accumulated depreciation of laboratory equipment 1,505 802 (63 ) 2,244 Accumulated depreciation of the building fixtures 1,109 484 (14 ) 1,580 Accumulated depreciation of office equipment 212 213 (105 ) 320 Accumulated depreciation of computer equipment 377 172 (30 ) 520 Total accumulated amortization and depreciation 3,202 1,671 (211 ) 4,663 Total, net 12,482 5,443 (118 ) 17,808 1/1/2018 Increase Decrease 12/31/2018 (Amounts in thousands of Euros) Laboratory equipment 5,820 6,305 (12 ) 12,113 Building fixtures 5,098 133 — 5,231 Office equipment 766 25 — 790 Computer equipment 1,073 434 — 1,507 Property, plant, and equipment in progress 9,714 7,623 (9,750 ) 7,587 Total, gross 22,470 14,520 (9,762 ) 27,228 Accumulated depreciation of laboratory equipment 2,244 1,567 — 3,811 Accumulated depreciation of the building fixtures 1,580 352 (12 ) 1,919 Accumulated depreciation of office equipment 320 129 — 449 Accumulated depreciation of computer equipment 520 310 — 830 Total accumulated amortization and depreciation 4,663 2,358 (12 ) 7,009 Total, net 17,808 12,162 (9,750 ) 20,219 Over the three years presented, the acquisitions correspond primarily to building fixtures and to laboratory and production equipment and material. The investments made in the design and development of industrial machines have declined between the two periods following the completion of the setup of our main industrial machines (mainly Gen 4) in early 2018. The increase during 2018 of the property, plant, and equipment in progress is related to the purchase of materials for the design and development of industrial machinery (mainly Gen 3.2, 3.3 and 4Bis). |
Non-Current Financial Assets
Non-Current Financial Assets | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Non-Current Financial Assets | Note 6: Non-Current December 31, 2016 2017 2018 (Amounts in thousands of Euros) Deposits 824 577 1,374 Pledged securities and other non-current 611 1,102 4,226 Liquidity contract 1,310 1,333 432 Total non-current 2,745 3,012 6,033 The non-current Under the liquidity contract, 41,159 treasury shares were allocated as a reduction of Shareholders’ Equity as at December 31, 2018 with the cash balance being maintained in financial assets. |
Inventories and Work in Progres
Inventories and Work in Progress | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Inventories and Work in Progress | Note 7: Inventories and Work in Progress December 31, 2016 2017 2018 (Amounts in thousands of Euros) Inventories of raw materials 69 — — Work in progress — — 2,338 Allowance for inventory write-down (charged to income statement) (69 ) — (772 ) Total net value of the inventories — — 1,566 As of December 31, 2016, the inventories and work in progress involved the Diallertest Milk product. The Company discontinued its commercial partnership with respect to the product during the second half of 2015. The inventories have been discarded during the year 2017. As of December 31, 2018, inventories are exclusively composed of work in progress for €1,566 thousand relate to the production of the first batches potentially intended for the commercialization, if approved. An allowance for inventory write-down was recorded at December 31, 2018 for non-commercial ® |
Customer Accounts Receivable an
Customer Accounts Receivable and Other Current Assets | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Customer Accounts Receivable and Other Current Assets | Note 8: Customer Accounts Receivable and Other Current Assets 8.1 Customer Accounts Receivable and Related Receivables December 31, 2016 2017 2018 (Amounts in thousands of Euros) Accounts receivable 1,263 1,265 — Valuation allowance (charged to income statement) (13 ) — — Total net value of accounts receivable 1,250 1,265 — All the customer accounts receivable have payment terms of less than one year. As of December 31, 2016, and 2017, the accounts receivable corresponds primarily to the amounts due under the collaboration agreement with Nestlé Health Science. 8.2 Other current assets The other current assets are broken down as follows: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Research tax credit 7,228 9,217 10,829 Other tax claims 2,618 5,258 4,292 Other receivables 1,883 1,192 1,745 Prepaid expenses 2,725 2,054 4,265 Total 14,454 17,721 21,131 The other tax debt claims are primarily related to the deductible VAT as well as the reimbursement of VAT that has been requested. Prepaid expenses are comprised primarily of rental and insurance expenses, as well as legal and scientific consulting fees. Prepaid expenses also include upfront payments which are recognized over the term of the ongoing clinical studies. Research Tax Credit The Company benefits from the provisions in Articles 244 quater septies The changes in this Research Tax Credit over the last three years are presented as follows: Amount in Opening Balance Sheet Receivable as of January 1, 2016 5,702 + Other income 7,228 - Payment received (5,702 ) - Adjustment — Closing Balance Sheet Receivable as of December 31, 2016 7,228 Amount in Opening balance sheet receivable as of January 1, 2017 7,228 + Operating revenue 9,217 - Payment received (7,341 ) - Adjustement 113 Closing balance sheet receivable as of December 31, 2017 9,217 Amount in thousands of Euros Opening balance sheet receivable as of January 1, 2018 9,217 + Operating revenue 10,829 - Payment received (9,479 ) - Adjustement 262 Closing balance sheet receivable as of December 31, 2018 10,829 Following a tax inspection led by the French tax authorities on fiscal years 2012, 2013 and 2014, the Company received on July 4, 2016 a proposition of adjustments primarily affecting the 2014 Research Tax credit. The proposed adjustment amounted to €0.9 million and had been accrued in the financial statements as of December 31, 2017. On June 25, 2018, the Company received the final reassessment for €58 thousand. The accrual initially recognized for €0.9 million has been reversed in the December 31, 2018 financial statements. A tax audit covering all the tax declarations for the period from January 1, 2015 to December 31, 2016, extended to December 31, 2017 for VAT, was conducted in the third quarter of 2018. The conclusions of this tax audit were received in November 2018 without major financial consequences for the Group. |
Cash and Cash Equivalents
Cash and Cash Equivalents | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Cash and Cash Equivalents | Note 9: Cash and Cash Equivalents The cash and cash equivalents item is broken down as follows (in thousands of Euros): December 31, 2016 2017 2018 (Amounts in thousands of Euros) Cash 146,374 32,054 77,236 Cash equivalent term deposits 110,100 105,826 45,534 Total cash and cash equivalent as reported in statement of financial position 256,473 137,880 122,770 Bank overdrafts — — — Total net cash and cash equivalents as reported in the statement of cash flow 256,473 137,880 122,770 Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements. |
Capital
Capital | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Capital | Note 10: Capital 10.1 Share Capital Issued The share capital, as of December 31, 2018, is set at the sum of €3,015,777.70. It is divided into 30,157,777 fully authorized, subscribed and paid-up This number does not include share warrants (“BSA”), employee warrants (“BSPCE”), stock-options (“SO”) and performance shares (“AGA”) granted to certain investors and to certain natural persons, both employees and non-employees All the shares give their owners the right to a proportional share of the income and the net assets of the Company. The table below presents the historical changes in the share capital of the Company as of December 31, 2016 , 2017 and 2018: Date Nature of the Transactions Share Capital Share premium Number of Nominal Balance as of January 1, 2016 K€ 2,420.5 K€ 403,910.4 24,205,129 € 0.10 01/05/16 Capital increase by issuance of common shares K€ 0.6 K€ 32.7 6,495 02/16/16 Issue of share subscription warrants K€ K€ 471.1 € 0.10 04/06/16 Capital increase by incorporation of reserve K€ 10.2 K€ (10.2 ) 101,829 € 0.10 05/27/16 Capital increase by issuance of common shares K€ 0.2 K€ 7.5 1,500 € 0.10 06/03/16 Capital increase by issuance of common shares K€ 15.6 K€ (15.6 ) 156,000 € 0.10 06/06/16 Capital increase by issuance of common shares K€ 6.0 K€ 301.2 59,890 € 0.10 06/10/16 Capital increase by issuance of common shares K€ 3.5 K€ 176.0 34,985 € 0.10 07/18/16 Capital increase by issuance of common shares K€ 2.0 K€ 100.7 20,010 € 0.10 08/21/16 Issue of share subscription warrants K€ K€ 106 € 08/04/16 Capital increase by issuance of common shares K€ 1.0 K€ 50.4 10,020 € 0.10 08/24/16 Capital increase by issuance of common shares K€ 0.7 K€ 37.1 7,380 € 0.10 08/30/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 08/31/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/01/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/02/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/05/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/06/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/06/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/08/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/09/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/12/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/12/16 Capital increase by issuance of common shares K€ 0.5 K€ 23.1 4,590 € 0.10 11/25/16 Capital increase by issuance of common shares K€ 0.6 K€ 30.2 6,000 € 0.10 Balance as of December 31, 2016 K€ 2,464.9 K€ 405,882.5 24,648,828 € 0.10 Date Nature of the Transactions Share Capital Share premium Number of Nominal Balance as of January 1, 2017 K€ 2,464.9 K 405,882.5 24,648,828 € 0.10 02/03/17 Capital increase by issuance of common shares K€ 2.0 K€ 100.7 20,010 € 0.10 02/09/17 Issue of share subscription warrants K€ K€ 237.4 € 05/16/17 Capital increase by issuance of common shares K€ 4.0 K€ 170.7 40,365 € 0.10 07/12/17 Capital increase by issuance of common shares K€ 0.2 K€ 8.3 1,650 € 0.10 08/04/17 Capital increase by issuance of common shares K€ 0.1 K€ 64.6 1,200 € 0.10 09/14/17 Capital increase by issuance of common shares K€ 3.6 K€ 208.2 35,925 € 0.10 09/14/17 Issue of share subscription warrants K€ K€ 53.1 € 09/29/17 Capital increase by issuance of common shares K€ 0.1 K€ 4.0 500 € 0.10 09/30/17 Capital increase by incorporation of reserve K€ 23.1 K€ (23.1 ) 230,843 € 0.10 10/02/17 Capital increase by issuance of common shares K€ 0.1 K€ 4.0 500 € 0.10 12/15/17 Capital increase by incorporation of reserve K€ 1.1 K€ (1.1 ) 11,001 € 0.10 Balance as of December 31, 2017 K€ 2,499.1 K€ 406,709.3 24,990,822 € 0.10 Date Nature of the Transactions Share Capital Share premium Number of Nominal Balance as of January 1, 2018 K€ 2,499.1 K€ 406,709.3 24,990,822 € 0.10 01/08/18 Capital increase by issuance of common shares K€ 0.7 K€ 52.3 7,000 € 0.10 01/09/18 Capital increase by issuance of common shares K€ 0.5 K€ 25.2 5,010 € 0.10 01/16/18 Capital increase by issuance of common shares K€ 2.0 K€ 100.4 19,950 € 0.10 01/18/18 Capital increase by issuance of common shares K€ 12.9 K€ 963.6 129,000 € 0.10 01/30/18 Capital increase by issuance of common shares K€ 1.3 K€ 97.1 13,000 € 0.10 01/31/18 Capital increase by issuance of common shares K€ 2.0 K€ 149.4 20,000 € 0.10 02/16/18 Capital increase by incorporation of reserve K€ 23.8 K€ (23.8 ) 238,337 € 0.10 03/13/18 Capital increase by incorporation of reserve K€ 23.8 K€ (23.8 ) 238,319 € 0.10 03/23/18 Capital increase by issuance of common shares K€ 352.8 K€ 122,095.5 3,527,752 € 0.10 03/26/18 Capital increase by issuance of common shares K€ 52.9 K€ 18,314.3 529,162 € 0.10 04/05/18 Capital increase by issuance of common shares K€ 1.2 K€ 91.9 12,302 € 0.10 04/06/18 Capital increase by incorporation of reserve K€ 5.8 K€ (5.8 ) 57,500 € 0.10 04/06/18 Capital increase by issuance of common shares K€ 1.4 K€ 105.6 14,138 € 0.10 04/09/18 Capital increase by issuance of common shares K€ 0.4 K€ 26.6 3,560 € 0.10 04/16/18 Capital increase by issuance of common shares K€ 0.8 K€ 88.0 7,500 € 0.10 07/02/18 Capital increase by incorporation of reserve K€ 19.3 K€ (19.3 ) 193,000 € 0.10 08/21/18 Issue of share subscription warrants K€ K€ 163.7 € 07/05/18 Capital increase by issuance of common shares K€ 3.3 K€ 164.1 32,625 € 0.10 07/11/18 Capital increase by issuance of common shares K€ 6.4 K€ 478.1 64,000 € 0.10 08/16/18 Capital increase by incorporation of reserve K€ 1.0 K€ (1.0 ) 10,000 € 0.10 09/01/18 Capital increase by incorporation of reserve K€ 0.5 K€ (0.5 ) 5,000 € 0.10 09/21/18 Capital increase by issuance of common shares K€ 0.5 K€ 37.4 5,000 € 0.10 10/27/18 Capital increase by incorporation of reserve K€ 1.5 K€ (1.5 ) 15,000 € 0.10 12/09/18 Capital increase by incorporation of reserve K€ 2.0 K€ (2.0 ) 19,800 € 0.10 12/31/18 Fees charged to share premium K€ K€ (10,292.6 ) € Balance as of December 31, 2018 K€ 3,015.8 K€ 539,292.0 30,157,777 € 0.10 On March 20 and 21, 2018, the Company announced the launch and the price of an underwritten global offering of an aggregate of 3,527,752 new ordinary shares, in (i) a public offering of 1,392,015 ordinary shares in the form of 2,784,030 American Depositary Shares (ADSs, each ADS represents the right to receive one-half In addition, the Company has granted the underwriters a 30-day The pricing of the underwritten global offering was set at (i) a public offering price of $21.26 per ADS in the United States, Canada and certain other countries outside Europe (based on an exchange rate of $1.2246=€1.00) and at (ii) a public offering price of €34.71 per ordinary share in Europe (including France). The price of the global offering is equal to the volume weighted-average of the trading prices of the Company’s ordinary shares on Euronext Paris over the three (3) trading days prior to the launch of the global offering less a discount of 4.99%. On March 23, 2018, the Company announced the closing of the underwritten global offering of new ordinary shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares. The issuance and the settlement and delivery of the new ordinary shares on Euronext Paris took place on March 26, 2018. As part of the closing of the underwritten global offering of new ordinary shares and Full Exercise of Underwriters’ Option public offering, share capital increased by the issuance of 4,056,914 shares (K€405.7) with a corresponding increase of €130.1 million in share premium (€140.4 million gross, or €130.1 million net after deduction of fees and expenses of €10.3 million). No fees and banks commissions related to share capital increases in 2016 and 2017 were posted in deduction of the share premium. 10.2 Share Warrants and Employee Warrants The Company has issued share warrants (BSAs), employee warrants (BSPCEs), performance shares (AGAs) and stock-options (SO) as follows: Date Type Number of Number of Number of Maximum Strike price 12/07/2007 BSA 1,717 572 859 12,885 € 4.33 01/21/2009 BSA/BSPCE 16,380 — 2,997 44,955 € 4.33 01/21/2009 BSPCE 2,296 — — — € 4.33 06/25/2010 BSA 1,825 — 730 10,950 € 4.33 01/28/2011 BSA 10,039 7,529 — — € 5.13 06/24/2011 BSA/BSPCE 32,000 — 10,440 156,600 € 5.13 11/22/2011 BSA/BSPCE 11,377 — 2,509 37,635 € 5.13 01/17/2012 BSA 89,835 — — — € 5.13 04/02/2012 AGA 669,796 1,860 — — € — 07/25/2012 AGA 134,081 — — — € — 09/25/2012 BSA 30,000 — 10,000 10,000 € 8.59 11/28/2012 AGA 35,360 — — — € — 07/25/2013 BSA 73,000 — 13,000 13,000 € 8.10 09/12/2013 AGA 501,500 113,333 — — € — 09/18/2013 SO 518,000 47,000 471,000 471,000 € 7.57 06/03/2014 BSA 10,000 — 5,000 5,000 € 18.79 06/03/2014 AGA 186,000 30,000 — — € — Date Type Number of Number of Number of Maximum Strike price 06/03/2014 SO 75,000 — 40,000 40,000 € 19.01 03/24/2015 BSA 10,000 — 10,000 10,000 € 43.00 06/23/2015 SO 120,000 — 120,000 120,000 € 48.90 09/30/2015 AGA 708,500 13,000 695,500 695,500 € — 11/19/2015 SO 195,000 25,000 170,000 170,000 € 66.06 11/19/2015 BSA 22,500 7,500 15,000 15,000 € 66.06 12/15/2015 AGA 42,000 6,000 36,000 36,000 € — 12/15/2015 BSA 90,000 16,500 73,500 73,500 € 64.14 01/04/2016 SO 75,000 — 75,000 75,000 € 65.68 04/06/2016 AGA 63,750 5,000 58,750 58,750 € — 04/21/2016 SO 33,000 — 33,000 33,000 € 62.82 05/02/2016 SO 22,000 — 22,000 22,000 € 59.04 06/21/2016 SO 110,000 — 110,000 110,000 € 53.96 06/21/2016 BSA 20,000 — 20,000 20,000 € 52.97 06/21/2016 AGA 208,000 — 208,000 208,000 € — 08/01/2016 SO 10,000 — 10,000 10,000 € 62.24 09/15/2016 SO 9,300 — 9,300 9,300 € 62.80 10/17/2016 SO 16,500 — 16,500 16,500 € 64.39 10/27/2016 AGA 15,000 — 15,000 15,000 € — 11/15/2016 SO 8,300 — 8,300 8,300 € 68.33 12/09/2016 SO 74,960 — 74,960 74,960 € 69.75 12/09/2016 AGA 23,600 — 23,600 23,600 € — Total 4,275,616 273,294 2,360,945 2,606,435 Date Type Number of Number of Number of Maximum Strike price 12/07/2007 BSA 1,717 572 — — € 4.33 01/21/2009 BSA/BSPCE 16,380 — — — € 4.33 01/21/2009 BSPCE 2,296 — — — € 4.33 06/25/2010 BSA 1,825 — — — € 4.33 01/28/2011 BSA 10,039 7,529 — — € 5.13 06/24/2011 BSA/BSPCE 32,000 — 8,996 134,940 € 5.13 11/22/2011 BSA/BSPCE 11,377 — 2,509 37,635 € 5.13 01/17/2012 BSA 89,835 — — — € 5.13 04/02/2012 AGA 669,796 1,860 — — € — 07/25/2012 AGA 134,081 — — — € — 09/25/2012 BSA 30,000 — 7,500 7,500 € 8.59 11/28/2012 AGA 35,360 — — — € — 07/25/2013 BSA 73,000 — 9,500 9,500 € 8.10 09/12/2013 AGA 501,500 113,333 — — € — 09/18/2013 SO 518,000 47,000 471,000 471,000 € 7.57 06/03/2014 BSA 10,000 — 2,500 2,500 € 18.79 Date Type Number of Number of Number of Maximum Strike price 06/03/2014 AGA 186,000 30,000 — — € — 06/03/2014 SO 75,000 — 40,000 40,000 € 19.01 03/24/2015 BSA 10,000 — 10,000 10,000 € 43.00 06/23/2015 SO 120,000 — 120,000 120,000 € 48.90 09/30/2015 AGA 708,500 23,000 454,657 454,657 € — 11/19/2015 SO 195,000 25,000 170,000 170,000 € 66.06 11/19/2015 BSA 22,500 7,500 15,000 15,000 € 66.06 12/15/2015 AGA 42,000 9,000 21,999 21,999 € — 12/15/2015 BSA 90,000 16,500 73,500 73,500 € 64.14 01/04/2016 SO 75,000 — 75,000 75,000 € 65.68 04/06/2016 AGA 63,750 6,250 57,500 57,500 € — 04/21/2016 SO 33,000 — 33,000 33,000 € 62.82 05/02/2016 SO 22,000 — 22,000 22,000 € 59.04 06/21/2016 SO 110,000 7,500 101,300 101,300 € 53.96 06/21/2016 BSA 20,000 — 20,000 20,000 € 52.97 06/21/2016 AGA 208,000 — 208,000 208,000 € — 08/01/2016 SO 10,000 — 10,000 10,000 € 62.24 09/15/2016 SO 9,300 — 9,300 9,300 € 62.80 10/17/2016 SO 16,500 7,200 9,300 9,300 € 64.39 10/27/2016 AGA 15,000 — 15,000 15,000 € — 11/15/2016 SO 8,300 — 8,300 8,300 € 68.33 12/09/2016 SO 74,960 2,000 72,000 72,000 € 69.75 12/09/2016 AGA 23,600 1,900 21,700 21,700 € — 12/09/2016 BSA 59,000 24,992 34,008 34,008 € 69.75 12/15/2016 SO 1,100 — 1,100 1,100 € 69.35 01/16/2017 SO 19,100 — 19,100 19,100 € 66.11 03/14/2017 AGA 22,500 2,500 20,000 20,000 € — 03/15/2017 SO 7,200 — 7,200 7,200 € 66.25 04/18/2017 SO 16,500 — 16,500 16,500 € 60.77 04/20/2017 AGA 24,000 — 24,000 24,000 € — 06/15/2017 SO 126,000 7,500 118,500 118,500 € 59.05 06/15/2017 SO 111,600 — 111,600 111,600 € 60.54 06/15/2017 BSA 9,000 — 9,000 9,000 € 59.05 07/17/2017 SO 30,900 — 30,900 30,900 € 71.61 09/15/2017 SO 52,600 — 52,600 52,600 € 74.22 12/05/2017 SO 625,200 — 625,200 625,200 € 39.00 12/15/2017 SO 8,300 — 8,300 8,300 € 38.08 Total 5,388,616 341,196 3,148,469 3,309,539 Date Type Number of Number of Number of Maximum Strike price 12/07/2007 BSA 1,717 572 — — € 4.33 01/21/2009 BSA/BSPCE 16,380 — — — € 4.33 01/21/2009 BSPCE 2,296 — — — € 4.33 06/25/2010 BSA 1,825 — — — € 4.33 01/28/2011 BSA 10,039 7,529 — — € 5.13 06/24/2011 BSA/BSPCE 32,000 — 7,666 114,990 € 5.13 11/22/2011 BSA/BSPCE 11,377 — — — € 5.13 01/17/2012 BSA 89,835 — — — € 5.13 04/02/2012 AGA 669,796 1,860 — — € — 07/25/2012 AGA 134,081 — — — € — 09/25/2012 BSA 30,000 — 5,000 5,000 € 8.59 Date Type Number of Number of Number of Maximum Strike price 11/28/2012 AGA 35,360 — — — € — 07/25/2013 BSA 73,000 — 7,000 7,000 € 8.10 09/12/2013 AGA 501,500 113,333 — — € — 09/18/2013 SO 518,000 47,000 203,000 203,000 € 7.57 06/03/2014 BSA 10,000 — — — € 18.79 06/03/2014 AGA 186,000 30,000 — — € — 06/03/2014 SO 75,000 — 40,000 40,000 € 19.01 03/24/2015 BSA 10,000 — 10,000 10,000 € 43.00 06/23/2015 SO 120,000 — 120,000 120,000 € 48.90 09/30/2015 AGA 708,500 23,000 — — € — 11/19/2015 SO 195,000 25,000 170,000 170,000 € 66.06 11/19/2015 BSA 22,500 7,500 15,000 15,000 € 66.06 12/15/2015 AGA 42,000 9,000 — — € — Date Type Number of Number of Number of Maximum Strike price 12/15/2015 BSA 90,000 16,500 73,500 73,500 € 64.14 01/04/2016 SO 75,000 — 75,000 75,000 € 65.68 04/06/2016 AGA 63,750 6,250 — — € — 04/21/2016 SO 33,000 11,000 22,000 22,000 € 62.82 05/02/2016 SO 22,000 22,000 — — € 59.04 06/21/2016 SO 110,000 21,300 87,500 87,500 € 53.96 06/21/2016 BSA 20,000 — 20,000 20,000 € 52.97 06/21/2016 AGA 208,000 — — — € — 08/01/2016 SO 10,000 — 10,000 10,000 € 62.24 09/15/2016 SO 9,300 — 9,300 9,300 € 62.80 10/17/2016 SO 16,500 7,200 9,300 9,300 € 64.39 10/27/2016 AGA 15,000 — — — € — 11/15/2016 SO 8,300 — 8,300 8,300 € 68.33 Date Type Number of warrants issued as of 12/31/2018 Number of warrants null and void as of 12/31/2018 Number of warrants null and outstanding as of 12/31/2018 Maximum number of shares to be issued Strike price per share 12/09/2016 SO 74,960 22,965 51,995 51,995 € 69.75 12/09/2016 AGA 23,600 3,800 — — € — 12/09/2016 BSA 59,000 24,992 34,008 34,008 € 69.75 12/15/2016 SO 1,100 — 1,100 1,100 € 69.35 01/16/2017 SO 19,100 — 19,100 19,100 € 66.11 03/14/2017 AGA 22,500 5,500 17,000 17,000 € — 03/17/2017 SO 7,200 — 7,200 7,200 € 66.25 04/18/2017 SO 16,500 9,300 7,200 7,200 € 60.77 04/20/2017 AGA 24,000 — 24,000 24,000 € — 06/15/2017 SO 126,000 35,000 91,000 91,000 € 59.05 06/15/2017 SO 111,600 — 111,600 111,600 € 60.54 06/15/2017 BSA 9,000 — 9,000 9,000 € 59.05 07/17/2017 SO 30,900 23,700 7,200 7,200 € 71.61 Date Type Number of warrants issued as of 12/31/2018 Number of warrants null and void as of 12/31/2018 Number of warrants null and outstanding as of 12/31/2018 Maximum number of shares to be issued Strike price per share 09/15/2017 SO 52,600 7,200 45,400 45,400 € 74.22 12/05/2017 SO 625,200 85,125 540,075 540,075 € 39.00 12/15/2017 SO 8,300 — 8,300 8,300 € 38.18 01/15/2018 SO 15,500 7,200 8,300 8,300 € 43.60 04/16/2018 SO 16,500 — 16,500 16,500 € 38.64 05/16/2018 SO 16,500 — 16,500 16,500 € 40.84 06/15/2018 SO 23,600 — 23,600 23,600 € 38.92 06/22/2018 SO 50,000 — 50,000 50,000 € 37.22 06/22/2018 AGA 486,153 21,125 465,028 465,028 € — 07/02/2018 BSA 44,000 — 44,000 44,000 € 37.24 07/16/2018 SO 28,800 — 28,800 28,800 € 33.81 08/15/2018 SO 33,500 — 33,500 33,500 € 32.90 09/06/2018 SO 65,000 — 65,000 65,000 € 36.96 Date Type Number of warrants issued as of 12/31/2018 Number of warrants null and void as of 12/31/2018 Number of warrants null and outstanding as of 12/31/2018 Maximum number of shares to be issued Strike price per share 06/09/2018 AGA 450 — 450 450 € — 09/17/2018 SO 80,900 — 80,900 80,900 € 40.94 10/15/2018 SO 76,700 — 76,700 76,700 € 37.28 11/01/2018 AGA 57,000 10,500 46,500 46,500 € — 11/15/2018 SO 26,000 — 26,000 26,000 € 32.57 11/29/2018 SO 350,000 — 350,000 350,000 € 30.02 12/12/2018 SO 34,000 — 34,000 34,000 € 27.96 12/12/2018 AGA 19,250 — 19,250 19,250 € — 12/17/2018 SO 7,200 — 7,200 7,200 € 26.76 Total 6,819,669 605,451 3,258,972 3,366,296 The totals presented above do not include the warrants cancelled prior to December 31, 2009. As part of the initial public offering on Euronext, the nominal value of the shares underwent a fifteen-for-one The impact of the share-based payments on the net income (or loss) is presented in Note 17. |
Financial and Other Non-Current
Financial and Other Non-Current Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Financial and Other Non-Current Liabilities | Note 11: Financial and Other Non-Current 11.1 Conditional Advances The conditional advances from public institutions are subject to contracts with OSEO and COFACE. As of December 31, 2018, the Company had two advance contracts with OSEO Innovation. These advances are 100% repayable at their nominal value in the event of technical and/or commercial success and do not bear interest. The Company also benefited from a third grant from BpiFrance Financement in November 2014. The agreement with COFACE terminated on December 31, 2016, generating an exceptional income of €146 thousand corresponding to allowances which could not be reimbursed along with Company takings, and which therefore remain acquitted to the Company. The portion of the conditional advances for terms longer than one year is classified as non-current The table below presents the details of the debts recorded on the statement of financial position by the type of conditional advance: 3rd OSEO 4th OSEO BPI COFACE Total Balance sheet debt at start of period 01/01/2016 318 1,669 2,666 156 4,809 Receipts — — — — — Repayments (128 ) — — (147 ) (275 ) Other transactions 2 16 85 (9 ) 95 Balance sheet debt as at 12/31/2016 192 1,684 2,751 — 4,628 Of which—Non-current 4,049 Of which—Current portion 578 Stated interest rate No 2.05 % No No Discount rate 0.4%-1.9 % 1.5%-1.8 % 3.20 % 4.25 % Maturity (in years) 0-3 7-9 2-7 0 3rd OSEO 4th OSEO BPI Total Balance sheet debt at start of period 01/01/2017 192 1,684 2,751 4,627 Receipts — — — — Repayments (128 ) — (450 ) (578 ) Other transactions 1 16 84 101 Balance sheet debt as at 12/31/2017 64 1,700 2,386 4,150 Of which—Non-current 1,825 Of which—Current portion 2,325 Stated interest rate No 2.05 % No Discount rate 0.4%-1.9 % 1.5%-1.8 % 3.2 % Maturity (in years) 0-3 7-9 2-7 3rd OSEO 4th OSEO BPI Total Balance sheet debt at start of period 01/01/2018 64 1,700 2,386 4,150 Receipts — — — — Repayments (64 ) (1,136 ) (600 ) (1,800 ) Other transactions — 60 69 129 Balance sheet debt as at 12/31/2018 — 624 1,854 2,479 Of which—Non-current 1,278 Of which—Current portion 1,201 Stated interest rate No 2.05 % No Discount rate 0.4%-1.9 % 1.5%-1.8 % 3.2 % Maturity (in years) 0-3 7-9 2-7 The changes appearing in “Other transactions” are comprised of the effect of discounting conditional advances. Third OSEO Advance In 2011, the Company was notified by OSEO Innovation of a new grant in the form of a conditional advance of up to €640,000 to finance the development of its program to treat the allergy to proteins in cow’s milk. The amount of the assistance was paid as follows: • €256,000 after the contract was signed (payment was received in 2011); • €256,000 from June 30, 2012 upon a call for funds (payment was received in 2013); • the balance of €128,000 after confirmation of the end of the program notified on December 31, 2013 (payment was received in 2014). In the event of technical or commercial success of the program, the repayment schedule will be the following: • Four quarterly repayments of €64,000 each starting no later than September 30, 2014; • Twelve quarterly repayments of €32,000 each starting no later than September 30, 2015. A fixed sum of €256,000 has been repaid in four quarterly installments of €64,000 beginning on September 30, 2014. The agreement with OSEO terminated on June 30, 2018. Fourth OSEO Advance In 2013, OSEO has provided assistance in the form of conditional advances for €3,206,162 to the Company as part of a collaborative research and clinical development in mite allergy in young children. ImmunaVia, the program, will be funded according to the following schedule, subject to the progress of the program: • €903,500 paid in April 2013; • €903,500 in October 2014 (funds which were to be paid in October 2014 were finally received on January 22, 2015 for an amount of €864,989); • €918,000 in October 2015 (not received); • €481,162 in April 2018 (not received). The funds that the Company actually received amounts to €1,768,489. Such conditional advance bears interest at an annual rate of 2.05%. In case of technical or commercial success of the project, the repayment schedule, for a total amount of €3,750,000 (including interest), is as follows: • €400,000 on or before June 30, 2021; • €800,000 on or before June 30, 2022; • €1,100,000 no later than June 30, 2023; • €1,450,000 no later than June 30, 2024. Following the defection of a sponsor, the Immunavia project was interrupted in September 2017. The Company was required to reimburse the remaining amounts of conditional advances. The reimbursment been rescheduled in 13 monthly repayments, commencing on May 31, 2018, through May 31, 2019. BpiFrance Financement Interest-Free Loan In 2014, BpiFrance Financement granted an interest-free Innovation loan of €3,000,000 to DBV Technologies to help financing the pharmaceutical development of Viaskin ® The planned repayment is scheduled in 20 quarterly repayments of €150,000 each, starting on June 30, 2017. COFACE Advance On September 6, 2007, DBV Technologies signed a prospecting insurance contract with Compagnie Française d’Assurance pour le Commerce Extérieur (“COFACE”) in order to promote its Diallertest product internationally. Under the terms of that contract, the Company received conditional advances of up to €147 thousands. DBV Technologies must repay these advances in amounts of up to 7% of its revenue from the export sales of its Diallertest product, until April 30, 2017. The agreement with COFACE was terminated on December 31, 2016, and has generated an income of €146 thousand corresponding to the remaining amount of the advance, which will not be refunded. 11.2 Other non-current Other non-current non-current non-current non-current non-current 11.3 Due Dates of the Financial Liabilities and other non-current Due dates of the financial liabilities recognized as of December 31, 2016: Gross Less than One One to Five More than (Amounts in thousands of Euros) Non-current 4,049 — 2,531 1,518 Non-current — — — — Other non-current 10,746 — 10,370 377 Current conditional advances 578 578 — — Current financial rent debts 12 12 — — Other current liabilities 14,692 14,692 — — Supplier accounts payable and related payables 13,720 13,720 — — Total financial liabilities 43,798 29,003 12,900 1,895 Due dates of the financial liabilities recognized as of December 31, 2017: Gross Less than One One to Five More than (Amounts in thousands of Euros) Non-current 1,825 — 1,825 — Non-current — — — — Other non-current 8,869 — 8,421 448 Current conditional advances 2,325 2,325 — — Current financial rent debts — — — — Other current liabilities 15,751 15,751 — — Supplier accounts payable and related payables 16,941 16,941 — — Total financial, current and non-current 45,711 35,017 10,246 448 Due dates of the financial liabilities recognized as of December 31, 2018: Gross Less than One One to Five More than Five Years (Amounts in thousands of Euros) Non-current 1,278 — 1,278 — Non-current — — — — Other non-current 4,105 — 3,991 114 Current conditional advances 1,201 1,201 — — Current financial rent debts — — — — Other current liabilities 12,506 12,506 — — Supplier accounts payable and related payables 28,567 28,567 — — Total financial, current and non-current 47,657 42,273 5,269 114 As detailed in Note 13, other current liabilities mainly include social security and current part of deferred revenues from the collaboration agreement with Nestlé Health Science as well as subsidies and conditional advances. |
Non-Current Provisions
Non-Current Provisions | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Non-Current Provisions | Note 12: Non-Current December 31, 2016 2017 2018 Pension retirement obligations 853 1,260 1,536 Total 853 1,260 1,536 Commitments for Compensation Payable to Employees Upon Their Retirement Amounts in As of January 1, 2016 (490 ) Costs of services rendered (operating expense) (104 ) Interest expense (financial expense) (10 ) Benefit paid — Actuarial losses (249 ) As of December 31, 2016 (853 ) Costs of services rendered (operating expense) (219 ) Interest expense (financial expense) (11 ) Benefit paid — Actuarial losses (177 ) As of December 31, 2017 (1,260 ) Costs of services rendered (operating expense) (412 ) Interest expense (financial expense) (24 ) Benefit paid 141 Actuarial losses 19 As of December 31, 2018 (1,536 ) As part of the estimation of the retirement commitments, the following assumptions were used for all categories of employees: December 31, 2016 2017 2018 % social security contributions 50.0 % 50.0 % 50.0 % Salary increases 2.0 % 2.0 % 2.0 % Discount rate 1.31 % 1.30 % 1.57 % Assumptions for the years ended December 31, 2016 • Retirement age: 65 years old; • Terms of retirement: voluntary retirement; • Life table: INSEE 2010; • Collective agreement: Convention Collective Nationale de l’Industrie Pharmaceutique (National Collective Agreement in the Pharmaceutical Industry); • Turn-over of the personnel declining with age. Assumptions for the years ended December 31, 2017 and 2018 • Retirement age: 65 years old; • Terms of retirement: voluntary retirement; • Life table: TGH05-TGF05; • Collective agreement: Convention Collective Nationale de l’Industrie Pharmaceutique (National Collective Agreement in the Pharmaceutical Industry); • Turn-over of the personnel declining with age. The discount rates come from the corporate AA zero coupon yield curve. No employee has retired during the last three fiscal years presented. |
Supplier Accounts Receivable an
Supplier Accounts Receivable and Other Current Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Supplier Accounts Receivable and Other Current Liabilities | Note 13: Supplier Accounts Receivable and Other Current Liabilities 13.1 Supplier Accounts Payable and Related Payables No discounting was performed on the supplier accounts payable and related payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal year presented. 13.2 Other Current Liabilities 2016 2017 2018 (Amounts in thousands of Euros) Social security 10,794 12,094 6,343 Tax liabilities 504 428 448 Other debts 146 440 1,354 Deferred revenues 3,248 2,789 4,360 Total 14,692 15,751 12,506 The other liabilities include the short-term debts to employees, as well as social welfare and tax agencies. Deferred revenues include subsidies, conditional advances and current part of deferred revenues from the collaboration agreement with Nestlé Health Science. |
Financial Instruments Recognize
Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) | Note 14: Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) 2016 Book value in Fair value Loans and Debt At Fair value Financial assets Long-term financial assets 2,745 1,310 1,435 — 2,745 Customer accounts receivables and related receivables 1,250 — 1,250 — 1,250 Other current financial assets 516 — 516 — 516 Cash and cash equivalents 256,473 256,473 — — 256,473 Total financial assets 260,985 257,783 3,202 — 260,985 Financial liabilities Long-term conditional advances 4,049 — — 4,049 4,049 Long term financial rent debt — — — — — Other long-term liabilities 10,746 — — 10,746 10,746 Short-term conditional advances 578 — — 578 578 Short term financial rent debt 12 — — 12 12 Other short-term liabilities 14,692 — — 14,692 14,692 Account payable and other liabilities 13,720 — — 13,720 13,720 Total financial liabilities 43,798 — — 43,798 43,798 2017 Book value in Fair value Loans and Debt At Fair value Financial assets Long-term financial assets 3,012 1,333 1,679 — 3,012 Customer accounts receivables and related receivables 1,265 — 1,265 — 1,265 Other current financial assets 378 — 378 — 378 Cash and cash equivalents 137,880 137,880 — — 137,880 Total financial assets 142,534 139,213 3,321 — 142,534 Financial liabilities Long-term conditional advances 1,825 — — 1,825 1,825 Long term financial rent debt — — — — — Other long-term liabilities 8,869 — — 8,869 8,869 Short-term conditional advances 2,325 — — 2,325 2,325 Short term financial rent debt — — — — — Other short-term liabilities 15,751 — — 15,751 15,751 Account payable and other liabilities 16,941 — — 16,941 16,941 Total financial liabilities 45,711 — — 45,711 45,711 2018 Book value in Fair value Financial assets Non-derivative Fair value (2) Financial assets Long-term financial assets 6,033 432 5,601 — 6,033 Customer accounts receivables and related receivables — — — — — Other current financial assets 912 — 912 — 912 Cash and cash equivalents 122,770 — 122,770 — 122,770 Total financial assets 129,715 432 129,283 — 129,715 Financial liabilities Long-term conditional advances 1,278 — — 1,278 1,278 Long term financial rent debt — — — — — Other long-term liabilities 4,105 — — 4,105 4,105 Short-term conditional advances 1,201 — — 1,201 1,201 Short term financial rent debt — — — — — Other short-term liabilities 12,506 — — 12,506 12,506 Account payable and other liabilities 28,567 — — 28,567 28,567 Total financial liabilities 47,656 — — 47,656 47,656 (1) The fair value of financial assets as fair value through Consolidated Statements of (Loss) is determined based on Level 1 fair value measurements and corresponds to the market value of the assets. (2) The fair value of “financial assets at amortized cost” as per IFRS 9 or “loans and receivables” as per IAS 39 corresponds to the value reported in the Consolidated Statements of Financial Position. (3) The book amount of “Non-derivative |
Operating Income
Operating Income | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Operating Income | Note 15: Operating Income The operating income is broken down in the following manner: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Revenues — — — Research tax credit 7,228 9,330 11,034 Subsidies 303 271 152 Other operating income 1,554 2,308 3,351 Total 9,084 11,909 14,537 The Company recognized as other income a portion of the upfront fee and milestones agreed under the contract with Nestlé which are deferred over the performance obligation. As of December 31, 2018, the end of the service obligation period over which the revenue from Nestlé will be deferred is expected by 2022. |
Operating Expenses
Operating Expenses | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Operating Expenses | Note 16: Operating Expenses The research and development expenses are broken down as follows: December 31, 2016 2017 2018 Research and development expenses (Amounts in thousands of Euros) Personnel expenses 32,777 37,112 37,912 Sub-contracting, 34,413 54,397 52,927 Small equipments and other supplies 3,909 4,110 4,771 Rental 1,903 2,018 2,703 Conferences, travel expenses 2,387 2,807 2,591 Depreciation and amortization 1,141 2,424 2,492 Others 2,298 2,364 3,776 Total research and development expenses 78,828 105,232 107,171 The sales and marketing expenses are broken down as follows: December 31, 2016 2017 2018 Sales and marketing expenses (Amounts in thousands of Euros) Personnel expenses 4,954 6,976 12,553 Fees 4,447 2,480 5,148 Communication and travel expenses 1,393 5,984 14,021 Others 487 384 446 Total sales and marketing expenses 11,282 15,824 32,169 By nature, the breakdown of general and administrative expenses is as follows: December 31, 2016 2017 2018 General and administrative expenses (Amounts in thousands of Euros) Personnel expenses 22,613 19,742 19,101 Fees 7,701 10,347 12,718 Rental 501 584 911 Insurance policies 1,853 1,367 1,930 Communication and travel expenses 1,136 1,599 1,576 Depreciation and amortization 181 422 1,720 Others 1,020 1,776 3,442 Total general and administrative expenses 35,005 35,837 41,399 Personnel Expenses The Company had 315 employees at December 31, 2018, in comparison with 242 employees at December 31, 2017 and 164 employees at December 31, 2016. The personnel expenses are broken down as follows: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Wages and salaries 14,651 22,451 31,684 Social security contributions 3,903 7,157 8,858 Expenses for pension commitments 982 1,583 2,095 Employer contribution to bonus shares 6,456 1,857 1,026 Share-based payments 34,353 30,781 25,904 Total 60,345 63,830 69,567 The increase in personnel charges is mainly due to the increase in the Company’s headcount. This increase was partially offset by the decrease of the share-based payments expense and employer contribution to free shares. |
Share-Based Payments
Share-Based Payments | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Share-Based Payments | Note 17: Share-Based Payments The Board of Directors has been authorized by the general meeting of the shareholders to grant employee warrants ( Bons de Souscription de Parts de Créateur d’Entreprise • With the authorization of the General Meeting of Shareholders on January 21, 2009, the Board of Directors issued 2,296 BCEX (“BCEX”); • With the authorization of the General Meeting of Shareholders on June 14, 2007, December 16, 2010 and December 9, 2011, the board of Directors issued 194,552 BSA (“BSA”); • With the authorization of the General Meeting of Shareholders on January 21, 2009, the Board of Directors issued 10,716 BSA (“BSA2”); • With the authorization of the General Meeting of Shareholders on January 21, 2009, the Board of Directors issued 5,358 BCE (“BCE4”); • With the authorization of the General Meeting of Shareholders on December 16, 2010, the Board of Directors issued 19,377 BSA (“BSA2010”); • With the authorization of the General Meeting of Shareholders on January 21, 2009, the Board of Directors issued 2,131 BSA (“BSAX”); • With the authorization of the General Meeting of Shareholders on December 16, 2010, the Board of Directors issued 34,039 BSPCE (“BSPCE2010”); • With the authorization of the General Meeting of Shareholders on December 9, 2011, the Board of Directors issued 518,000 options (“OPTIONS 2013”); • With the authorization of the General Meeting of Shareholders on December 9, 2011, the Board of Directors issued 1,340,737 Free shares (“Free shares”); • With the authorization of the General Meeting of Shareholders on June 4, 2013, the Board of Directors issued 73,000 BSA; • With the authorization of the General Meeting of Shareholders on June 3, 2014, the Board of Directors issued 20,000 BSA; • With the authorization of the General Meeting of Shareholders on June 3, 2014, the Board of Directors issued 918,960 options; • With the authorization of the General Meeting of Shareholders on June 3, 2014, the Board of Directors issued 186,000 free shares; • With the authorization of the General Meeting of Shareholders on June 23, 2015, the Board of Directors issued 88,500 BSA; • With the authorization of the General Meeting of Shareholders on September 21, 2015, the Board of Directors granted 1,107,350 Free shares which 241,844 have been issued as of December 31, 2017; • With the authorization of the General Meeting of Shareholders on June 21, 2016, the Board of Directors issued 54,008 BSA; • With the authorization of the General Meeting of Shareholders on June 15, 2017, the Board of Directors issued 9,000 BSA; • With the authorization of the General Meeting of Shareholders on June 15, 2017, the Board of Directors issued 900,700 options which 72,100 have been issued as of first half 2018; • With the authorization of the General Meeting of Shareholders on June 22, 2018, the Board of Directors issued 562,853 free shares; • With the authorization of the General Meeting of Shareholders on June 2, 2018, the Board of Directors issued 752,100 options; 17.1 BSA Date of Grant 12/07/2007 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to one fourth (1/4) of the BSA on the first anniversary of the date of grant; • up to one fourth (1/4) of the BSA on the second anniversary of the date of grant; • up to one fourth (1/4) of the BSA on the third anniversary of the date of grant; • up to one fourth (1/4) of the BSA on the fourth anniversary of the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 01/17/2012 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 89,835 BSA (all the BSA) on January 17, 2016; and • at the latest within ten (10) years from the date of grant. Date of Grant 09/25/2012 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 30,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 07/25/2013 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 73,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 06/03/2014 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 10,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 24/03/2015 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 10,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 19/11/2015 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 15,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 15/12/2015 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 73,500 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 06/21/2016 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 20,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 12/09/2016 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 34,008 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 06/15/2017 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 9,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Date of Grant 05/02/2018 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 44,000 BSA (all the BSA) on the date of grant; and • at the latest within ten (10) years from the date of grant. Details of BSA Date of grant (Board of 12/07/2007 12/07/2007 12/07/2007 12/07/2007 01/17/2012 01/17/2012 01/17/2012 01/17/2012 Vesting period (years) 1 2 3 4 1 2 3 4 Plan expiration date 12/08/2017 12/08/2017 12/08/2017 12/08/2017 01/17/2022 01/17/2022 01/17/2022 01/17/2022 Number of BSA granted 431 431 428 427 22,459 22,459 22,459 22,458 Share entitlement per BSA(1) 15 15 15 15 1 1 1 1 Exercise price 65 65 65 65 5.13 5.13 5.13 5.13 Valuation method used Black—Scholes Grant date share fair value 65 65 65 65 5.13 5.13 5.13 5.13 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSA 4.5 5.0 5.5 6.0 5.5 6.0 6.5 7.0 Discount rate(2) 4.06 % 4.09 % 4.09 % 4.10 % 2.33 % 2.33 % 2.61 % 2.61 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BSA 22.18 23.62 24.95 26.22 2.05 2.14 2.26 2.34 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA. Date of grant (Board of Directors) 09/25/2012 09/25/2012 09/25/2012 09/25/2012 07/25/2013 06/03/2014 Vesting period (years) 1 2 3 4 0 0 Plan expiration date 09/25/2022 09/25/2022 09/25/2022 09/25/2022 07/25/2023 06/03/2024 Number of BSA granted 7,500 7,500 7,500 7,500 73,000 10,000 Share entitlement per BSA 1 1 1 1 1 1 Exercise price 8.59 8.59 8.59 8.59 8.1 18.79 Valuation method used Black—Scholes Grant date share fair value 8.4 8.4 8.4 8.4 8.15 19.01 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSA 5.5 6.0 6.5 7.0 5.0 5.0 Discount rate(1) 1.21 % 1.21 % 1.53 % 1.53 % 1.16 % 0.71 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA Fair value per BSA 2.29 2.43 2.61 2.74 2.18 4.98 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA. Date of grant (Board of Directors) 03/24/2015 11/19/2015 12/15/2015 06/21/2016 Vesting period (years) Plan expiration date 03/24/2025 11/19/2025 12/15/2015 06/21/2016 Number of BSA granted 10,000 15,000 90,000 (1) 20,000 Share entitlement per BSA 1 1 1 1 Exercise price 43.00 66.06 64.14 52.97 Valuation method used Black—Scholes Grant date share fair value 43 66.06 42.61 61.25 Expected volatility 36 % 50.91 % 51 % 47 % Average life of BSA 5.0 5.0 5.0 5.0 Discount rate(1) 0.68 % 0.81 % -0.09 % -0.41 % Expected dividends 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA Fair value per BSA 9.90 22.60 7.28 21.59 Date of grant (Board of Directors) 12/09/2016 06/15/2017 05/02/2018 Vesting period (years) 0 0 0 Plan expiration date 12/09/2026 06/15/2027 05/02/2028 Number of BSA granted 59,000 9,000 44,000 Share entitlement per BSA 1 1 1 Exercise price 69.75 59.05 37.24 Valuation method used Black—Scholes Grant date share fair value 63.18 73.32 37.74 Expected volatility 40 % 39 % 50 % Average life of BSA 5.0 5.0 5.0 Discount rate(1) -0.04 % -0.12 % -0.15 % Expected dividends 0 % 0 % 0 % Performance conditions NA NA NA Fair value per BSA 12.94 24.02 9.02 Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA. Change in Number of BSA Outstanding Year ended December 31, Number of BSA 2016 2017 2018 Balance at beginning of period 143,694 147,359 181,008 Granted during the period 93,500 68,000 44,000 Forfeited during the period — 24,902 — Exercised during the period 89,835 9,359 7,500 Expired during the period — — — Balance at end of period 147,359 181,008 217,508 Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BSA Outstanding Outstanding Outstanding Exercisable Outstanding Exercisable BSA2010 with exercise price of €65 859 859 — — — — BSA2010 with exercise price of €5.13 — — — — — — BSA2010 with exercise price of €8.59 10,000 10,000 7,500 7,500 5,000 5,000 BSA2010 with exercise price of €8.10 13,000 13,000 9,500 9,500 7,000 7,000 BSA2010 with exercise price of €18.79 5,000 5,000 2,500 2,500 — — BSA with exercise price of €43.00 10,000 10,000 10,000 10,000 10,000 10,000 BSA with exercise price of €66.06 15,000 15,000 15,000 15,000 15,000 15,000 BSA with exercise price of €64.14 73,500 73,500 73,500 73,500 73,500 73,500 BSA with exercise price of €52.97 20,000 20,000 20,000 20,000 20,000 20,000 BSA with exercise price of €69.75 — — 34,008 34,008 34,008 34,008 BSA with exercise price of €59.05 — — 9,000 9,000 9,000 9,000 BSA with exercise price of €37.24 — — — — 44,000 44,000 Total 147,359 147,359 181,008 181,008 217,508 217,508 17.4 BCE 4 The BCE4 may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 2,411 BCE4 on the date of grant; • up to 1,340 BCE4 on the first anniversary of the date of grant; • up to 536 BCE4 on the second anniversary of the date of grant; • up to 536 BCE4 on the third anniversary of the date of grant; • up to 535 BSA on the fourth anniversary of the date of grant; and • at the latest within ten (10) years from the date of grant. By a decision by the Board of Directors meeting held on November 22, 2011, the BCE4 warrants became exercisable beginning on the date of the first quotation of the shares of the Company on the Euronext regulated market in Paris. Details of BCE4 Date of grant (Board of Directors) 01/21/2009 01/21/2009 01/21/2009 01/21/2009 01/21/2009 Vesting period (years) 0 1 2 3 4 Plan expiration date 01/20/2019 01/20/2019 01/20/2019 01/20/2019 01/20/2019 Number of BCE4 granted 2,411 1,340 536 536 535 Share entitlement per BCE4(1) 15 15 15 15 15 Exercise price 65 65 65 65 65 Valuation method used Black—Scholes Grant date share fair value 70 70 70 70 70 Expected volatility 40 % 40 % 40 % 40 % 40 % Average life of BCE4 5.0 5.5 6.0 6.5 7.0 Discount rate(2) 2.71 % 2.71 % 2.98 % 2.98 % 3.11 % Expected dividends 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA Fair value per BCE4 29.06 30.33 31.90 33.06 34.35 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE4 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE4 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BCE4. Change in Number of BCE4 Outstanding Year ended December 31, Number of BCE4 2016 2017 2018 Balance at beginning of period 2,691 2,691 — Granted during the period — — — Forfeited during the period — — — Exercised during the period — 2,691 — Expired during the period — — — Balance at end of period 2,691 — — Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BCE4 Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BCE4 with exercise price of €65 2,691 2,691 — — — — Total 2,691 2,691 — — — — 17.5 BSA2010 Date of Grant 01/28/2011 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 2,510 BSA on the 12/23/2011; • up to 2,510 BSA on the 12/23/2012; • up to 2,510 BSA on the 12/23/2013; • up to 2,509 BSA on the 12/23/2014; and • at the latest before the 01/28/2021. Date of Grant 06/24/2011 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to one fourth (1/4) of the BSA on the 12/23/2011; • up to one fourth (1/4) of the BSA on the 12/23/2012; • up to one fourth (1/4) of the BSA on the 12/23/2013; • up to one fourth (1/4) of the BSA on the 12/23/2014; and • at the latest before the 11/22/2021. Date of Grant 11/22/2011 The BSA may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 335 BSA on the 11/22/2012; • up to 335 BSA on the 11/22/2013; • up to 334 BSA on the 11/22/2014; • up to 334 BSA on the 11/22/2015; and • at the latest before the 11/22/2021. Details of BSA2010 Date of grant (Board of 01/28/2011 01/28/2011 01/28/2011 01/28/2011 06/24/2011 06/24/2011 06/24/2011 06/24/2011 Vesting period (years) 0.9 1.9 2.9 3.9 0.5 1.5 2.5 3.5 Plan expiration date 01/27/2021 01/27/2021 01/27/2021 01/27/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BSA2010 granted 2,510 2,510 2,510 2,509 2,000 2,000 2,000 2,000 Share entitlement per BSA2010(1) 15 15 15 15 15 15 15 15 Exercise price 77 77 77 77 77 77 77 77 Valuation method used Black—Scholes Black—Scholes Grant date share fair value 77 77 77 77 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSA2010 5.5 6.0 6.5 7.0 5.5 6.0 6.5 7.0 Discount rate(2) 2.70 % 2.82 % 2.82 % 3.04 % 2.55 % 2.68 % 2.68 % 2.87 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BSA2010 31.33 32.90 34.23 35.84 31.15 32.70 34.02 35.57 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA2010. Date of grant (Board of Directors) 11/22/2011 11/22/2011 11/22/2011 11/22/2011 Vesting period (years) 1.0 2.0 3.0 4.0 Plan expiration date 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BSA2010 granted 335 335 334 334 Share entitlement per BSA(1) 15 15 15 15 Exercise price 77 77 77 77 Valuation method used Black—Scholes Grant date share fair value 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % Average life of BSA 5.5 6.0 6.5 7.0 Discount rate(2) 2.23 % 2.60 % 2.60 % 2.85 % Expected dividends 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA Fair value per BSA 30.70 32.58 33.89 35.54 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA2010. Change in Number of BSA2010 Outstanding Year ended December 31, Number of BSA 2016 2017 2018 Balance at beginning of period 1,044 610 500 Granted during the period — — — Forfeited during the period — — — Exercised during the period 434 110 — Expired during the period — — — Balance at end of period 610 500 500 Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BSA2010 Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BSA2010 with exercise price of €77 610 610 500 500 500 500 Total 610 610 500 500 500 500 17.6 BSAX Date of Grant 01/21/2009 and 06/25/2010 The BSAX may be exercised by the beneficiary on the basis of the following vesting schedule: • up to one fourth (1/4) of the BSAX on the first anniversary of the date of grant; • up to one fourth (1/4) of the BSAX on the second anniversary of the date of grant; • up to one fourth (1/4) of the BSAX on the third anniversary of the date of grant; • up to one fourth (1/4) of the BSAX on the fourth anniversary of the date of grant; and • at the latest within ten (10) years from the date of grant. By a decision by the Board of Directors meeting held on November 22, 2011, the BSAX warrants became exercisable beginning on the date of the first quotation of the shares of the Company on the Euronext regulated market in Paris. Details of BSAX Date of grant (Board of 01/21/2009 01/21/2009 01/21/2009 21/01/2009 06/25/2010 06/25/2010 06/25/2010 06/25/2010 Vesting period (years) 1 2 3 4 1 2 3 4 Plan expiration date 01/20/2019 01/20/2019 01/20/2019 01/20/2019 06/24/2020 06/24/2020 06/24/2020 06/24/2020 Number of BSAX granted 77 77 77 75 457 457 456 455 Share entitlement per BSAX(1) 15 15 15 15 15 15 15 15 Exercise price 65 65 65 65 65 65 65 65 Valuation method used Black—Scholes Grant date share fair value 70 70 70 70 70 70 70 70 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSAX 5.5 6.0 6.5 7.0 5.5 6.0 6.5 7.0 Discount rate(2) 2.71 % 2.98 % 2.98 % 3.11 % 2.04 % 2.23 % 2.23 % 2.50 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BSAX 30.32 31.89 33.05 33.45 29.47 30.88 31.99 33.44 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSAX warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSAX plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSAX. Change in Number of BSAX Outstanding Year ended December 31, Number of BSAX 2016 2017 2018 Balance at beginning of period 1,036 1,036 — Granted during the period — — — Forfeited during the period — — — Exercised during the period — 1,036 — Expired during the period — — — Balance at end of period 1,036 — — Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BSAX Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BSAX with exercise price of €65 1,036 1,036 — — — — Total 1,036 1,036 — — — — 17.7 BCE2010 Date of Grant 06/24/2011 The BCE may be exercised by the beneficiary on the basis of the following vesting schedule: • up to one fourth (1/4) of the BCE on the 12/23/2011; • up to one fourth (1/4) of the BCE on the 12/23/2012; • up to one fourth (1/4) of the BCE on the 12/23/2013; • up to one fourth (1/4) of the BCE on the 12/23/2014; and • at the latest within before the 11/22/2021. Date of Grant 11/22/2011 The BSPCE may be exercised by the beneficiary on the basis of the following vesting schedule: • up to one fourth (1/4) of the BSPCE on the 11/22/2012; • up to one fourth (1/4) of the BSPCE on the 11/22/2013; • up to one fourth (1/4) of the BSPCE on the 11/22/2014; • up to one fourth (1/4) of the BSPCE on the 11/22/2015; and • at the latest within before the 11/22/2021. Details of BCE2010 Date of grant (Board of Directors) 06/24/2011 06/24/2011 06/24/2011 06/24/2011 11/22/2011 11/22/2011 11/22/2011 11/22/2011 Vesting period (years) 0.5 1.5 2.5 3.5 1 2 3 4 Plan expiration date 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BCE2010 granted 6,000 6,000 6,000 6,000 2,510 2,510 2,510 2,509 Date of grant (Board of Directors) 06/24/2011 06/24/2011 06/24/2011 06/24/2011 11/22/2011 11/22/2011 11/22/2011 11/22/2011 Share entitlement per BCE2010(1) 15 15 15 15 15 15 15 15 Exercise price 77 77 77 77 77 77 77 77 Valuation method used Black and Scholes Grant date share fair value 77 77 77 77 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BCE2010 5.5 6.0 6.5 7.0 5.4 5.9 6.4 6.9 Discount rate(2) 2.55 % 2.68 % 2.68 % 2.87 % 2.05 % 2.42 % 2.42 % 2.66 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BCE2010 31.16 32.71 34.03 35.58 30.42 32.29 33.58 35.2 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BCE2010. Change in Number of BCE2010 Outstanding Year ended December 31, Number of BCE2010 2016 2017 2018 Balance at beginning of period 15,974 12,339 11,005 Granted during the period — — — Forfeited during the period — — — Exercised during the period 3,635 1,334 3,839 Expired during the period — — — Balance at end of period 12,339 11,005 7,166 Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BCE2010 Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BCE2010 with exercise price of €77.00 12,339 12,339 11,005 11,005 7,166 7,166 Total 12,339 12,339 11,005 11,005 7,166 7,166 17.8 OPTIONS Grant of 09/18/2013 The share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 518,000 SO (all the SO) on the fourth anniversary of the date of grant; and • at the latest within ten (10) years from the date of grant. Grant of 06/03/2014 The share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 75,000 SO (all the SO) on the 06/04/2016; and • at the latest before the 06/03/2024. Grant of 06/23/2015 The share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 30,000 SO on the 06/24/2016; • up to 30,000 additional SO on the 06/24/2017; • up to 30,000 additional SO on the 06/24/2018; • up to 30,000 additional SO on the 06/24/2019; • and at the latest before the 06/24/2025. Grant of 09/30/2015 The 195,000 share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 25% of the SO on the 09/30/2016; • up to additional 25% of the SO on the 09/30/2017; • up to additional 25% of the SO on the 09/30/2018; • up to additional 25% of the SO on the 09/30/2019; • and at the latest before the 09/30/2025. Grant of 12/15/2015 The 75,000 share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 25% of the SO on the 12/15/2016; • up to additional 25% of the SO on the 12/15/2017; • up to additional 25% of the SO on the 12/15/2018; • up to additional 25% of the SO on the 12/15/2019; • and at the latest before the 12/15/2025. Grant of 04/06/2016 The 55,000 share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 8,250 SO on the 04/021//2017; • up to additional 8,250 SO on the 04/21//2018; • up to additional 8,250 SO on the 04/21//2019; • up to additional 8,250 SO on the 04/21//2020; • up to 5,500 SO on the 05/02//2017; • up to additional 5,500 SO on the 05/02//2018; • up to additional 5,500 SO on the 05/02//2019; • up to additional 5,500 SO on the 05/02//2020; • and at the latest before 10 years of the date of the Grant. Grant of 06/21/2016 The 154,100 share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 25% of the SO as of one year after the Grant date; • up to additional 12.5% of the SO as of 18 months after the Grant date; • up to additional 12.5% of the SO as of 24 months after the Grant date; • up to additional 12.5% of the SO as of 30 months after the Grant date; • up to additional 12.5% of the SO as of 36 months after the Grant date; • up to additional 12.5% of the SO as of 42 months after the Grant date; • up to additional 12.5% of the SO as of 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. Grant of 12/09/2016 The 74,960 share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 18,740 SO as of one year after the Grant date; • up to additional 9,370 SO as of 18 months after the Grant date; • up to additional 9,370 SO as of 24 months after the Grant date; • up to additional 9,370 SO as of 30 months after the Grant date; • up to additional 9,370 SO as of 36 months after the Grant date; • up to additional 9,370 SO as of 42 months after the Grant date; • up to additional 9,370 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. Grant of 12/15/2016 The 1,100 share options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 25% SO as of one year after the Grant date; • up to additional 12.5% SO as of 18 months after the Grant date; • up to additional 12.5 % SO as of 24 months after the Grant date; • up to additional 12.5 % SO as of 30 months after the Grant date; • up to additional 12.5 % SO as of 36 months after the Grant date; • up to additional 12.5 % SO as of 42 months after the Grant date; • up to additional 12.5 % 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. Grant of 19,100 options as of 01/16/2017, 7,200 options as of 03/15/2017, 16,500 options as of 04/18/2017, 237,600 options as of 06/15/2017, 30,900 options as of 07/17/2017, 52,600 options as of 09/15/2017, 625,200 options as of 12/05/2017 and 8,300 options as of 12/15/2017. All the 2017 options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 25% SO as of one year after the Grant date; • up to additional 12.5% SO as of 18 months after the Grant date; • up to additional 12.5 % SO as of 24 months after the Grant date; • up to additional 12.5 % SO as of 30 months after the Grant date; • up to additional 12.5 % SO as of 36 months after the Grant date; • up to additional 12.5 % SO as of 42 months after the Grant date; • up to additional 12.5 % 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. Grant of 15,500 options as of 01/15/2018, 16,500 options as of 04/16/2018, 16,500 options as of 05/15/2018, 23,600 options as of 06/15/2018. All these options may be exercised by the beneficiary on the basis of the following vesting schedule: • up to 25% SO as of one year after the Grant date; • up to additional 12.5% SO as of 18 months after the Grant date; • up to additional 12.5 % SO as of 24 months after the Grant date; • up to additional 12.5 % SO as of 30 months after the Grant date; • up to additional 12.5 % SO as of 36 months after the Grant date; • up to additional 12.5 % SO as of 42 months after the Grant date; • up to additional 12.5 % 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. Grant of 50,000 options as of 06/22/2018, 28,800 options as of 07/16/2018, 33,500 options as of 08/15/2018, 65,000 options as of 09/06/2018, 80,900 options as of 09/17/2018, 76,700 options as of 10/15/2018, 26,000 options as of 11/15/2018, 34,000 options as of 12/12/2018 and 7,200 options as of 12/17/2018. All the 2018 options From June 22, 2018 will be exercised by the beneficiary subject to the fulfillment of a presence condition and the following performance conditions : “ authorization to market Viaskin ® • up to 25% SO as of one year after the Grant date; • up to additional 12.5% SO as of 18 months after the Grant date; • up to additional 12.5 % SO as of 24 months after the Grant date; • up to additional 12.5 % SO as of 30 months after the Grant date; • up to additional 12.5 % SO as of 36 months after the Grant date; • up to additional 12.5 % SO as of 42 months after the Grant date; • up to additional 12.5 % 48 months after the Grant date; • and at the latest before 10 years of the date of the Grant. A turnover rate is applied per plan according to the characteristics and compositions of the plan. Details of SO Date of grant (Board of Directors) 09/18/2013 06/03/2014 06/23/2015 11/19/2015 01/04/2016 04/21/2016 05/02/2016 Vesting period (years) 4 2 1-4 1-4 1-4 1-4 1-4 Plan expiration date 09/18/2023 06/03/2024 06/23/2025 11/19/2025 01/04/2026 04/21/2026 05/02/2026 Number of SO granted 518,000 75,000 120,000 195,000 75,000 33,000 22,000 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price 7.57 19.01 48.9 66.06 65.68 62.82 59.04 Valuation method used Black—Scholes Grant date share fair value 7.9 19.01 48.9 66.06 65.68 62.82 58.62 Expected volatility 40 % 40 % 51 % 51 % 49.3%-49.8 % 49.4%-50.7 % 49.3%-50.6 % Average life of SO 7 6 7 7 5-7 5-7 5-7 Discount rate(1) 1.72 % 0.89 % 0.89 % 0.81 % 0.39 % 0.04 % 0.10 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA Fair value per SO 3.57 7.46 25.28 34.05 29.5-32.6 28.3-30.9 26.4-28.8 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of grant 06/21/2016 08/01/2016 09/15/2016 10/17/2016 11/15/2016 12/09/2016 12/15/2016 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 06/21/2026 08/01/2026 09/15/2016 10/17/2026 11/15/2026 12/09/2026 12/15/2026 Number of SO granted 110,000 10,000 9,300 16,500 8,300 74,960 1,100 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price 53.96 62.24 62.8 64.39 68.33 69.75 69.35 Valuation method used Black—Scholes Grant date share fair value 52.97 62.24 62.8 64.39 68.33 69.75 69.35 Expected volatility 49.1%-50.3 % 48.8%-49.8 % 48.6%-49.4 % 48.0%-48.9 % 47.8%-48.8 % 47.7%-48.5 % 40.44 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate(1) -0.01 % -0.25 % -0.18 % -0.32%-0.15 % -0.11%+0.16 % -0.2%+0.18 % -0.18%+0.16 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA Fair value per SO 23.4-25.5 27.3-29.9 27.4-30.1 27.6-30.6 29.4-32.7 29.7-33.4 25.2-28.7 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of grant 01/16/2017 03/15/2017 04/18/2017 06/15/2017 06/15/2017 07/17/2017 09/15/2017 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 01/16/2027 03/15/2027 04/18/2027 06/15/2027 06/15/2027 07/17/2027 09/15/2027 Number of SO grant |
Financial Revenue and Expenses
Financial Revenue and Expenses | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Financial Revenue and Expenses | Note 18: Financial Revenue and Expenses The financial income and expenses are broken down as follows: Year ended December 31, 2016 2017 2018 (Amounts in thousands of Euros) Financial revenues 1,646 616 493 Financial expenses (145 ) (3,325 ) (351 ) Total 1,500 (2,709 ) 141 The financial income mainly includes unrealized exchange effect of U.S.-dollar-denominated intercompany advances and capital gains on the disposals of investment securities. The foreign exchange losses and the expenses related to the accretion of the OSEO and BpiFrance advances are classified as financial expenses in the Consolidated Statements of (Loss). |
Income Tax Expense
Income Tax Expense | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Income Tax Expense | Note 19: Income Tax Expense As mentioned in Note 3.13—Accounting Principles—Other Income, the French Research Tax Credit is not included in the line item “Income taxes” but included in the line item “Other Income.” Reconciliation between the Effective and Nominal Income Tax Expense The following table shows the reconciliation between the effective and nominal tax expense at the nominal standard French rate of 33.33% as of December 31, 2016 and 2017 and 28.0% as of December 31, 2018 (excluding additional contributions): Year ended December 31, 2016 2017 2018 (Amounts in thousands of Euros) (Loss) before taxes (114,531 ) (147,692 ) (166,061 ) Theoretical group tax rate 33,33 % 33,33 % 28,00 % Nominal tax expense 38,173 49,226 46,497 Increase/decrease in tax expense arising from: Permanent differences — — — Research tax credit 2,409 3,110 3,089 Share-based compensation (11,451 ) (10,260 ) (7,253 ) Non recognition of deferred tax assets related to tax losses and temporary differences (29,195 ) (41,453 ) (54,205 ) Other differences 64 622 11,887 Effective tax expenses — — (15 ) Effective tax rate 0 % 0 % 0,01 % Deferred Tax Assets and Liabilities As mentioned in Note 3.15, the Company has not recognized deferred tax assets in the Consolidated Statements of Financial Position. The amount of the losses carried forward at the end of December 2018 is €531 million including €527 million for DBV Technologies S.A. |
Commitments
Commitments | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Commitments | Note 20: Commitments Obligations Under the Terms of the Ordinary Rental Agreements The principal offices of the Company occupy a 4,770 square meter facility consisting of office and laboratory space, pursuant to a lease agreement dated March 3, 2015, which expires on March 8, 2024. The Company also has a second facility in Bagneux, France, which was its former corporate headquarters. This facility consists of 1,479 square meters of office and laboratory space and is used primarily by the Company’s industrial and production teams. This lease expires on May 31, 2020. A new addendum for the period 2020 to 2029 was signed on April 13, 2018. An additional lease for offices in Montrouge (France) was signed on June 4, 2018. The Company has an office in North America to support the U.S. subsidiary as well as future commercialization needs. The Company subleased 3,913 square feet of office space in New York, New York. This sublease expired on June 30, 2017. The Company entered into a similar lease agreement on November 2017. The Company subleases 3,780 square feet of office space in New York, New York. The sublease was signed for an initial period of 5 years. The Company also leases a commercial facility of 8,919 square feet in Summit, New Jersey, which is intended to support the manufacturing needs through the launch and commercialization of Viaskin ® The amount of future rents and charges in that capacity breaks down as follows at December 31, 2018: 12/31/2018 2019 3,965 2020 4,047 2021 4,064 2022 4,058 2023 3,785 2024 3,211 2025 1,998 2026 2,014 2027 1,700 2028 1,031 2029 393 Total 30,267 The Company has signed various ordinary rental agreements for office equipment and vehicles. The future rental payments as at December 31, 2018 are as follows: • 2019: €77 thousands; • 2020: €70 thousands; • 2021: €16 thousands. Obligations Under the Terms of Other Agreements The Company signed with its bank CIC an acquisition contract of monetary market fund “SICAV CM-CIC” The Company also signed a letter of credit to ensure the sub-lease A letter of credit has also been signed by the Company in April 2016 for $143 thousand to ensure the lease of its premises of its Summit (NJ) subsidiary. This credit note has been extended for an additional year. A letter of credit has also been signed by the Company in May 2017 for $300 thousands to ensure the lease of its premises of its New York subsidiary. The Company took in 2015 a term deposit for a sum of €227 thousand over 3 years. In addition, the Company has subscribed a €3,500 thousand term deposit with the CIC banking institution as collateral for a foreign exchange pledged security up to €50 million. As it has sub-contracted sub-contracting Within the context of launching its clinical studies for Viaskin ® ® The ongoing studies amount globally to €101.3 million. As of December 31, 2018, the amount remaining to pay as part of these contracts until year ended 2021 is €34.9 million. On January 7, 2009, the Company entered into an assignment, development and co-ownership AP-HP, co- AP-HP AP-HP ® AP-HP AP-HP AP-HP non-exclusive |
Relationships with Related Part
Relationships with Related Parties | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Relationships with Related Parties | Note 21: Relationships with Related Parties The compensation amounts for 2018 presented below, which were awarded to the Corporate Officers and the members of the Executive Committee of the Company totals 17.4 million euros. Following the reorganization of the Company at the beginning of 2015, the Company henceforth considered the members of the Executive Committee to be related parties. December 31, 2016 2017 2018 (Amounts in thousands of Euros) Corporate officers 714 745 1,496 Executive committee 2,268 2,184 3,325 Directors’ fees 195 407 469 Share-based payments to members of the Board of Directors 13,714 12,018 12,189 Total 16,891 15,353 17,478 In accordance with the decisions of the Board of Directors of September 25, 2012 and April 6, 2016, following the termination of the Chief Executive Officer, Mr. Pierre-Henri Benhamou, and after having noted that the payment conditions were fulfilled, the Board of Directors during its meeting held on November 28, 2018 decided the payment of the severance amounting a total of 876 thousand euros. The methods for the valuation of the benefit related to share-based payments are presented in Note 17. The company has entered into agreements with some of its directors, particularly in the context of its commercial deployment in the United States. The expense recognized for these contracts amounted to 49 thousand euros at December 31, 2018 compared to 45 thousand euros at December 31, 2017. As part of its commercial rollout in the United States, the Company entered into an agreement in December 2016 with one of its Directors for Commercial strategy consulting works. The expenses recorded in 2018 and in 2017 as part of this agreement amounts respectively €45 thousands. A schedule of amounts payable to related parties: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Compensation 767 689 66 Directors’ fees 195 432 469 Pension obligations 342 402 419 Total 1,304 1,523 954 |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Earnings Per Share | Note 22: Earnings Per Share Taking into account the division of the nominal value of shares of the Company by 15, which was decided by the annual general meeting on December 9, 2011 the amount of shares is adjusted, and multiplying it by 15, for all the outstanding shares presented. The basic earnings per share is calculated by dividing the net income going to the shareholders of the Company by the weighted average number of common shares outstanding during the course of the fiscal year. The weighted average number of shares was 24,454,850 in 2016. The weighted average number of shares was 24,757,176 in 2017. The weighted average number of shares was 28,924,976 in 2018. The instruments that entitle their holders to a portion of the share capital on a deferred basis (BSAs, BSPCEs) are considered to be anti-dilutive (2,360,945 instruments in 2016, 3,309,539 instruments in 2017 and 3,366,296 instruments in 2018). These instruments are presented in detail in Note 17. Therefore, the diluted earnings per share are identical to the basic earnings per share. December 31, 2016 2017 2018 (Amounts in thousands of Euros) Net income of the reporting period (114,531 ) (147,693 ) (166,076 ) Adjusted weighted average number of outstanding shares 24,454,850 24,757,176 28,924,976 Basic / Diluted earnings per share (€/share) (4.68 ) (5.97 ) (5.74 ) |
Management of Financial Risks
Management of Financial Risks | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Management of Financial Risks | Note 23: Management of Financial Risks The principal financial instruments of the Company are comprised of financial assets, cash, and investment securities. The purpose of managing these instruments is to allow the business activities of the Company to be financed. It is not the Company’s policy to subscribe to financial instruments for speculative purposes. The Company does not utilize derivatives. The principal risks to which the Company is exposed are liquidity risk, interest rate risk and credit risk. Liquidity Risk As of December 31, 2018, the Company had €122.8 million in cash and cash equivalents compared to €137.9 million of cash and cash equivalents as of December 31, 2017. The Company has incurred operating losses and negative cash flows from operations since inception, incurred a net loss of €166.1 million during the year ended December 31, 2018, and has an accumulated deficit and reserves of €254.9 million as of December 31, 2018. Net cash used in operating activities was €136.6 million for the year ended December 31, 2018 and €114.3 million for the year ended December 31, 2017. The Company has primarily funded these losses through equity financings, and by obtaining public assistance in support of innovation and reimbursements of research tax credit. To date, the Company has not generated any product revenue and the Company continues to prepare for the potential launch of its Viaskin ® cash-on-hand The Company expects to seek additional funds, most likely from equity and/or debt financings. However, no assurance can be given at this time as to whether the Company will be able to achieve these financing objectives. Company’s financial statements have been prepared on a going concern basis assuming that the Company will be successful in our financing objectives. As such, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Company not be able to continue as a going concern. Interest Rate Risk The Company’s exposure to interest-rate risk primarily involves investment securities. These are composed of money market funds and time deposit accounts. Changes in interest rates have a direct impact on the rate of return on these investments and the cash flows generated. The Company has no variable rate debt. The repayment flows of its debts are not subject to interest rate risk. The repayment of the conditional advances may vary depending on whether or not objectives are attained. The change in the flows of the anticipated repayments is treated in the income statement (Note 3.10). As of this date, the Company has not contracted borrowings from credit institutions and, therefore, has only very low exposure to interest rate risk. Credit Risk The credit risk related to the cash, the cash equivalents, and the current financial instruments is not significant in light of the quality of the co-contracting Fair Value The fair value of financial instruments traded on an active market, such as the securities available for sale, is based on the market rate as of the closing date. The market prices used for the financial assets owned by the Company are the bid prices in effect on the market as of the valuation date. The nominal value, less the provisions for depreciation, of the accounts receivable and current debts, is presumed to approximate the fair value of those items. Foreign Exchange Risk The Company is exposed to a very insignificant foreign exchange risk inherent in some of its supplies obtained in the United States, which have been invoiced in US dollars. As of this date, the company does not make sales revenue in dollars or in any other currency other than the euro; the Company does not receive any full or partial mechanical endorsement. The exposure to currencies other than the U.S. dollar is negligible. For 2018, approximately 34% of our purchases and other external expenses have been made in U.S. dollars compared with less than 12% in 2017 and 2016. Exchange rate effects have a non-significant In light of these insignificant amounts, the Company has not adopted, at this stage, a hedging mechanism in order to protect its business activity against fluctuations in exchange rates. The Company cannot rule out the possibility that a significant increase in its business, particularly in the United States, may result in greater exposure to exchange rate risk and should thus consider adopting an appropriate policy for hedging against these risks. |
Events After the Close of the F
Events After the Close of the Fiscal Year | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Events After the Close of the Fiscal Year | Note 24: Events After the Close of the Fiscal Year On January 3, 2019, the Company announced the following changes to its leadership team as the Company strengthens its organizational competencies in the development of the Viaskin ® • DBV’s Chief Scientific Officer (CSO), Dr. Hugh Sampson, assumed the role of interim Chief Medical Officer (CMO) effective on January 3, 2019. Dr. Sampson succeeded Dr. Lucia Septien-Velez, who decided to leave the Company to pursue other opportunities. As CSO and interim CMO, Dr. Sampson leads both the scientific and medical teams at the Company and reports to Daniel Tassé, Chief Executive Officer of DBV Technologies. • Following recent interactions with the U.S. Food and Drug Administration (FDA), Julie O’Neill, a member of DBV’s Board of Directors, was engaged to direct all product development, manufacturing, supply chain, quality assurance, and end-to-end ® A class action complaint was filed on January 15, 2019 in the United States District Court for the District of New Jersey, entitled Travis Ito-Stone 2:19-cv-00525. 10b-5 The Company may be the target of similar litigation in the future. Any future litigation could result in substantial costs and divert management’s attention and resources, which could cause serious harm to the Company’s business, operating results and financial condition. The company maintains liability insurance; however, if any costs or expenses associated with this or any other litigation exceed its insurance coverage, the Company may be forced to bear some or all of these costs and expenses directly, which could be substantial. On February 13, 2019, the Company announced that expects to resubmit its BLA for Viaskin ® On March 4, 2019, the board of directors appointed existing board member, Michel de Rosen, as Non-Executive co-founder, Non-Executive On March 5, 2019, the Company also provided an update on leadership and operational changes: • Charles Ruban, former Chief Operating Officer, who oversaw regulatory, product development and commercial operations, resigned from the Company to pursue new opportunities, effective March 15, 2019. • Laurent Martin, former Chief Development Officer, resigned from his regulatory and product development role, effective March 15, 2019. Mr. Martin continues to serve as DBV’s Pharmacien Responsable (Responsible Pharmacist) in accordance with applicable regulations in France while a search for a replacement is planned. • Kevin Trapp, Chief Commercial Officer, currently reports to Mr. Tassé. In addition, Mr. Martin’s primary responsibilities were assumed by Julie O’Neill, DBV’s manufacturing and operations leader, who oversees product development, manufacturing, supply chain, quality assurance, and end-to-end The company believes these changes in leadership will flatten the organizational structure to support its evolution from a late-stage research and development company into a potentially commercial-stage company. The Company may be the target of similar litigation in the future. Any future litigation could result in substantial costs and divert management’s attention and resources, which could cause serious harm to the Company’s business, operating results and financial condition. The company maintains liability insurance; however, if any costs or expenses associated with this or any other litigation exceed its insurance coverage, the Company may be forced to bear some or all of these costs and expenses directly, which could be substantial. The Company evaluated all other subsequent events that occurred after December 31, 2018 through the date of issuance of the consolidated financial statements and determined there are no other significant events that require adjustments or disclosure. |
Accounting Principles (Policies
Accounting Principles (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Going concern | Going concern To date, we have not generated any product revenue and we continue to prepare the potential launch of our Viaskin ® cash-on-hand We expect to seek additional funds, most likely from equity and/or debt financings. However, no assurance can be given at this time as to whether we will be able to achieve these financing objectives. Our financial statements have been prepared on a going concern basis assuming that we will be successful in our financing objectives. As such, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should we not be able to continue as a going concern. Refer to the liquidity risk disclosed in Note 23. |
Intangible Assets | 3.1 Intangible Assets In application of the provisions in IAS 38 Intangible Assets Research and Development Expenses Research expenses are recorded in the Financial Statements as expenses. In accordance with IAS 38, development expenses are recorded in the Financial Statements as intangible assets only if all the following criteria are met: (a) technical feasibility necessary for the completion of the development project; (b) intention on the part of the Company to complete the project and to utilize it; (c) capacity to utilize the intangible asset; (d) proof of the probability of future economic benefits associated with the asset; (e) availability of the technical, financial, and other resources for completing the project; and (f) reliable evaluation of the development expenses. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process, the Company believes that the six criteria stipulated by IAS 38 are only fulfilled once the Market Access Authorization has been obtained from the competent authorities. The application of this principle has resulted in all development costs being expensed as incurred. Software The costs related to the acquisition of licenses to software are posted to assets on the basis of the costs incurred to acquire and to implement the software in question. They are amortized using the straight-line method over a period of one to three years depending on the anticipated period of use. |
Property, Plant, and Equipment | 3.2 Property, Plant, and Equipment Property, plant, and equipment are recorded at their acquisition cost or, if applicable, at their production cost. Property, plant, and equipment are depreciated on the basis of the straight-line method over the estimated use period of the property. The fixtures of property rented are depreciated over the term of their own lifetime or of the term of the rental agreement, whichever is shorter. The depreciation periods used are the following: PROPERTY, PLANT, AND EQUIPMENT ITEM PERIOD DEPRECIATION Fixtures and improvements in structures 9 years Research and development / production tools 5 years Research equipment and technical facilities 5 years Computer equipment 3 years Office equipment and furniture 5 years |
Financial Assets | 3.3 Financial Assets IFRS 9 replaces IAS 39—Financial Instruments: Recognition and Measurement. IFRS 9 defines the rules applicable to the classification and recognition of financial instruments, the impairment of financial assets (using a model of expected losses to replace the model of losses incurred) as well as hedge accounting. This new standard is mandatorily effective for annual periods beginning on or after January 1 st As part of the application of IFRS 9, the Company reviewed the method of accounting for financial instruments that were previously classified as “Available-for-sale profit or loss The Company do not hold any hedging instrument as of January 1, 2018 and as of December 31, 2018. As of December 31, 2018, financial assets can be classified into three categories: Financial assets at amortized cost Financial assets at amortized cost are mainly cash and cash equivalent, loans and receivables, measured at amortized cost using the effective interest rate method, adjusted for expected credit losses and at initial recognition at their fair value (acquisition cost and transaction costs). Interest recognized at the effective interest rate is recognized under “Other financial income and expenses” in the statement of profit and loss. Financial assets at fair value through profit or loss: Financial assets at fair value through profit or loss is comprised of: • instruments whose contractual cash flows represent payments of interest or repayments of principal, but which are managed other than with a view to collecting cash flows and/or selling the asset; • instruments that management has designated as ‘fair value through profit or loss” on initial recognition. Gains and losses arising from changes in fair value are recognized in profit or loss within the line items Financial income or Financial expenses. Financial assets at fair value through other comprehensive income mainly comprise: Financial assets at fair value through other comprehensive income is mainly comprised is composed of debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items Financial income or Financial expenses. The Company does not hold this type of instrument as of January 1, 2018 and as of December 31, 2018. Impairment of financial assets measured at amortized cost The Company considers that a financial asset is impaired according to the expected loss method in order to take into account any defaults during the asset holding period. The amount of the expected loss is recognized in the balance sheet. Impairment losses are recognized in profit or loss. |
Recoverable Amount of the Intangible Assets and Property, Plant, and Equipment | 3.4 Recoverable Amount of the Intangible Assets and Property, Plant, and Equipment The property, plant, and equipment and intangible assets that have an established lifetime are subjected to an impairment test when the recoverability of their book value is called into question by the existence of indications of impairment. An impairment is posted to the accounts up to the amount of the excess of the book value over the recoverable value of the asset. The recoverable value of an asset corresponds to its fair value minus the costs of sale or its use value, whichever is higher. |
Inventories and Work in Progress | 3.5 Inventories and Work in Progress Inventories are measured at production costs calculated using the first-in, first-out Depreciation may be recorded on finished goods and work in progress (i) if their production value is greater than their net realizable value, we estimate that the estimated costs for finalization and the estimated costs for the sale, or (ii) if certain products are no longer used by the company, otherwise they are perishable. At December 31, 2018, inventories were exclusively composed of work in progress relating to the production of the first batches that may be used for the commercialization and secondly to requalified batches that are not intended to be commercialized, which were fully depreciated. |
Share Capital | 3.6 Share Capital Common shares are classified under Shareholders’ Equity. The costs of share capital transactions that are directly attributable to the issue of new shares or options are recorded in the Financial Statements in Shareholders’ Equity as a deduction from the revenue from the issue, net of tax. |
Payments in Shares | 3.7 Payments in Shares Since its incorporation, the Company has established several plans for compensation paid in equity instruments in the form of employee warrants ( bons de souscription de parts de créateur d’entreprise “ bons de souscription d’actions non-employee Pursuant to IFRS 2 Share-based payment The Company has applied IFRS 2 to all equity instruments granted since 2002 to corporate officers, members of the Scientific Committee and employees of the Company, as well as to certain persons bound by a service or investment contract. consultant to the Company. The options are not subject to any market conditions. The characteristics of the options are presented in Note 17. |
Recognition and measurement of Financial Liabilities | 3.9 Recognition and measurement of Financial Liabilities Non-derivative Other non-derivative Borrowings and debt Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within Financial expenses in the income statement over the term of the debt using the effective interest method. |
Subsidies and Conditional Advances | 3.10 Subsidies and Conditional Advances Subsidies The Company receives assistance in the form of subsidies, which are grants that are not repayable by the Company. The subsidies are recognized when there is reasonable assurance that: • the Company will comply with the conditions attached to the subsidies, and • the subsidies will be received. Subsidies that are upfront non-refundable A public subsidy that is to be received (e.g. from OSEO, the French Agency for Innovation) either as compensation for expenses or for losses already incurred, or for immediate financial support of the Company without associated expenses or losses, is recognized as other income ratably over the duration of the funded project. Conditional advances The Company also receives from time to time assistance in the form of conditional advances, which are advances repayable in whole or in part based upon acknowledgment by the funder of a technical or commercial success of the related project by the funding entity. The details concerning the conditional advances are provided in Note 11. The amount resulting from the deemed benefit of the interest-free nature of the award is considered a subsidy for accounting purposes. This deemed benefit is determined by applying a discount rate equal to the rate of fungible treasury bonds over the time period that corresponds to the time period of the repayment of the advances. In the event of a change in payment schedule of the stipulated repayments of the conditional advances, the Company makes a new calculation of the net book value of the debt resulting from the discounting of the expected new future cash flows. The adjustment that results therefrom is recognized in the income statement for the fiscal year during which the modification is recognized. The conditional advances that can be subject to this type of modification are the with Compagnie Française d’Assurance pour le Commerce Extérieur (“COFACE”) advances presented in Note 11. The agreement with COFACE terminated on December 31, 2016. |
Provisions | 3.11 Provisions Provisions for Risks and Expenses The provisions for risks and lawsuits correspond to the commitments resulting from lawsuits and various risks whose due dates and amounts are uncertain. A provision is posted to the accounts when the Company has a legal or implicit obligation to a third party resulting from a past event, concerning which it is likely or certain that it will cause an outflow of resources to that third party, without consideration that is anticipated to be at least equivalent to the latter, and that the future outflows of liquid assets can be estimated reliably. The amount recorded in the accounts as a provision is the best estimation of the expenses necessary to extinguish the obligation. Pension Retirement Obligations The employees of the Company receive the retirement benefits stipulated by law in France: • obtaining a compensation paid by the Company to employees upon their retirement (defined-benefit plan); • payment of retirement pensions by the Social Security agencies, which are financed by the contributions made by companies and employees (defined-contribution plans). For the defined-benefit plans, the costs of the retirement benefits are estimated by using the projected credit unit method. According to this method, the cost of the retirement pensions is recognized in the Consolidated Statement of (Loss) so that it is distributed uniformly over the term of the services of the employees. The retirement benefit commitments are valued at the current value of the future payments estimated using, for the discounting, the market rate based on the long-term obligations of the first-category companies with a term that corresponds to that estimated for the payment of the services provided. The Company relies on external actuaries to conduct an annual review of the valuation of these plans. The difference between the amount of the provision at the beginning of a fiscal year and at the close of that year is recognized through profit or loss for the portion representing the costs of services rendered and through other comprehensive income for the portion representing the actual gains and losses. The Company’s payments for the defined-contribution plans are recognized as expenses on the income statement of the period with which they are associated. |
Revenue | 3.12 Revenue IFRS 15 became applicable on January 1, 2018, requiring the Company to update its accounting policies on revenue. The concepts of “transfer of control,” which is used primarily to determine the date of revenue recognition, and “performance obligations” do not call for any change in the accounting treatment of the Company’s contracts. The concept of “variable consideration” does not materially alter the principles and methods used to measure net sales. |
Other Income | 3.13 Other Income Subsidies Since it was formed, because of its innovative character, the Company has received a certain number of sources of assistance or subsidies from the central government or from local public authorities such as OSEO or the Banque Publique d’Investissement, intended to finance its operations or the recruitment of specific personnel. When the obtention of the subsidy is reasonably certain, these subsidies are recognized as “Other income” during the calendar year over which the corresponding expenses or expenditures were recorded. Research Tax Credit The Research Tax Credit ( Crédit d’Impôt Recherche, The Company has received the Research Tax Credit annually since it was formed. The Company received the reimbursement of the 2015 Research Tax Credit for an amount of €5.7 million during the year 2016. The Company received the reimbursement of the 2016 Research Tax Credit for an amount of €7.3 million during the year 2017. The Company received the reimbursement of the 2017 Research Tax Credit for an amount of €9.5 million during the year 2018. The Company will request the reimbursement of the 2018 Research Tax Credit for an amount of €10.8 million during the year 2019, under the community tax rules for small and medium firms in compliance with the regulatory texts applicable. Collaboration agreement with Nestlé Health Science On May 31, 2016, the Company announced its entry into an exclusive global collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use non-refundable Regarding the first application of IFRS 15 on January 1, 2018, an analysis has been completed on performance conditions, revenue recognition method for milestones payment and on the sale price allocation for the collaboration contract signed with Nestlé in 2016. It has been determined that the license and developments to be made by the Company are a unique performance obligation. As a result, the Company has concluded that under IFRS 15, revenue related to the contract will be recognized progressively, up to the costs incurred by the Company at the end of 2018. No margin is recognized at this stage of the development. Deferred revenue is recognized and reversed over the period in which there is a contractual obligation. This this agreement is not considered an onerous contract for the year-ended December 31,2018. As a result, the application of IFRS 15 had no impact on the financial statements as at December 31, 2018, and retrospectively as at December 31, 2017. |
Rental Agreements | 3.14 Rental Agreements The rental agreements involving property, plant, and equipment are classified as finance lease agreements when the Company bears a substantial portion of all the benefits and risks inherent in the ownership of the property. The assets that are covered under financing lease agreements are capitalized as of the beginning date of the rental agreement on the basis of the fair value of the rented asset or the discounted values of the future minimum payments, whichever is lower. Each rental payment is distributed between the debt and the financial cost in such a manner as to determine a constant interest rate on the principal that remains due. The corresponding rental obligations, net of the financial expenses, are classified as financial liabilities. The portion of the financial expense that corresponds to the interest is recognized as an expense over the term of the agreement. The property, plant, or equipment acquired within the framework of a finance lease agreement is amortized over the use period or the term of the lease agreement, whichever is shorter. The rental agreements for which a significant portion of the risks and advantages is preserved by the lessor are classified as ordinary rental agreements. The payments made for these ordinary rental agreements, net of any incentive measures, are recognized as expenses on the income statement in a linear manner over the term of the agreement. |
Taxes | 3.15 Taxes Income Tax Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of the assets and liabilities that appear in the financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward. The tax rates that have been ratified by a legal text as of the closing date are utilized to determine the deferred taxes. The deferred tax assets are recorded in the accounts only to the extent that it is likely that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforward in the Consolidated Statements of Financial Position. |
Segment Information | 3.16 Segment Information The Company operates in a single operating segment: the conducting of research and development of epicutaneous immunotherapy products in order to market them in the future. The assets, liabilities, and operating losses recognized are primarily located in France. |
Other Items in the Comprehensive (or Loss) | 3.17 Other Items in the Comprehensive (or Loss) The revenue and expense items for the period that are not posted in the Consolidated Statements of (Loss) as stipulated by the applicable standards are presented, as necessary, under the rubric “Other items in the comprehensive (or loss).” |
Use of Estimates | 3.18 Use of Estimates The preparation of our Financial Statements requires the management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. Estimates and assumptions are based on historical experience and other factors that management believes to be reasonable under the circumstances. Estimates and assumptions are measured on an ongoing basis. Actual results may differ from these estimates. These estimates and judgments mainly involve: • an estimate of time and costs required to complete the collaboration agreement with Nestlé Health Science; • a valuation of the fair value of the employee warrants (BSPCEs) granted to employees and/or executives and share warrants (BSAs) granted to non-employee • an estimate of the expected dates of achievement of the performance conditions for the duration of the spillover from the granting of stock options and free shares; • an estimate of the Research Tax Credit based on internal and external expenses incurred by the Company during the year. Only eligible research expenses are included in the calculation of the research tax credit; • an estimate of provisions. |
Presentation of Financial Assets and Financial Liabilities Measured at Fair Value | 3.19 Presentation of Financial Assets and Financial Liabilities Measured at Fair Value In accordance with the amendments to IFRS 7, financial instruments are presented in three categories based on a hierarchical method used to determine their fair value: • level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; • level 2: fair value calculated using valuation techniques based on observable market data such as prices of similar assets and liabilities or parameters quoted in an active market; • level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as prices in an inactive market or a valuation based on multiples for unlisted securities. |
Subsequent events | 3.20 Subsequent events The Consolidated Statements of Financial Position and the Consolidated Statements of (Loss) of the Company are adjusted to reflect the subsequent events that alter the amounts related to the situations that exist as of the closing date. The adjustments are made until the date the financial statements are approved and authorized for issuance by the Board of Directors. |
Accounting Principles (Tables)
Accounting Principles (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Depreciation Periods | The depreciation periods used are the following: PROPERTY, PLANT, AND EQUIPMENT ITEM PERIOD DEPRECIATION Fixtures and improvements in structures 9 years Research and development / production tools 5 years Research equipment and technical facilities 5 years Computer equipment 3 years Office equipment and furniture 5 years |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Intangible Assets | The intangible assets are broken down as follows: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Patents, licenses, trademarks 196 414 201 Software 376 450 703 Total historical cost 572 864 905 Accumulated amort. of patents, licenses, and trademarks (125 ) (340 ) (200 ) Accumulated depreciation of software packages (351 ) (401 ) (675 ) Accumulated amortization and depreciation (476 ) (741 ) (875 ) Net total 96 123 29 |
Property, Plant, and Equipment
Property, Plant, and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Property, Plant, and Equipment | 1/1/2016 Increase Decrease 12/31/2016 (Amounts in thousands of Euros) Laboratory equipment 2,357 740 — 3,097 Building fixtures 938 3,672 — 4,610 Office equipment 209 398 — 607 Computer equipment 470 516 — 986 Property, plant, and equipment in progress 3,672 2,713 — 6,385 Total, gross 7,646 8,039 — 15,685 Accumulated depreciation of laboratory equipment 948 557 — 1,505 Accumulated depreciation of the building fixtures 782 327 — 1,109 Accumulated depreciation of office equipment 131 81 — 212 Accumulated depreciation of computer equipment 205 172 — 377 Total accumulated amortization and depreciation 2,065 1,137 — 3,203 Total, net 5,581 6,901 — 12,482 1/1/2017 Increase Decrease 12/31/2017 (Amounts in thousands of Euros) Laboratory equipment 3,097 2,806 (83 ) 5,820 Building fixtures 4,610 534 (46 ) 5,098 Office equipment 607 275 (116 ) 766 Computer equipment 986 116 (30 ) 1,073 Property, plant, and equipment in progress 6,385 3,384 (55 ) 9,714 Total, gross 15,685 7,114 (329 ) 22,470 Accumulated depreciation of laboratory equipment 1,505 802 (63 ) 2,244 Accumulated depreciation of the building fixtures 1,109 484 (14 ) 1,580 Accumulated depreciation of office equipment 212 213 (105 ) 320 Accumulated depreciation of computer equipment 377 172 (30 ) 520 Total accumulated amortization and depreciation 3,202 1,671 (211 ) 4,663 Total, net 12,482 5,443 (118 ) 17,808 1/1/2018 Increase Decrease 12/31/2018 (Amounts in thousands of Euros) Laboratory equipment 5,820 6,305 (12 ) 12,113 Building fixtures 5,098 133 — 5,231 Office equipment 766 25 — 790 Computer equipment 1,073 434 — 1,507 Property, plant, and equipment in progress 9,714 7,623 (9,750 ) 7,587 Total, gross 22,470 14,520 (9,762 ) 27,228 Accumulated depreciation of laboratory equipment 2,244 1,567 — 3,811 Accumulated depreciation of the building fixtures 1,580 352 (12 ) 1,919 Accumulated depreciation of office equipment 320 129 — 449 Accumulated depreciation of computer equipment 520 310 — 830 Total accumulated amortization and depreciation 4,663 2,358 (12 ) 7,009 Total, net 17,808 12,162 (9,750 ) 20,219 |
Non-Current Financial Assets (T
Non-Current Financial Assets (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Non-Current Financial Assets | December 31, 2016 2017 2018 (Amounts in thousands of Euros) Deposits 824 577 1,374 Pledged securities and other non-current 611 1,102 4,226 Liquidity contract 1,310 1,333 432 Total non-current 2,745 3,012 6,033 |
Inventories and Work in Progr_2
Inventories and Work in Progress (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Inventories | December 31, 2016 2017 2018 (Amounts in thousands of Euros) Inventories of raw materials 69 — — Work in progress — — 2,338 Allowance for inventory write-down (charged to income statement) (69 ) — (772 ) Total net value of the inventories — — 1,566 |
Customer Accounts Receivable _2
Customer Accounts Receivable and Other Current Assets (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Customer Accounts Receivable and Related Receivables | Customer Accounts Receivable and Related Receivables December 31, 2016 2017 2018 (Amounts in thousands of Euros) Accounts receivable 1,263 1,265 — Valuation allowance (charged to income statement) (13 ) — — Total net value of accounts receivable 1,250 1,265 — |
Summary of Other Current Assets | The other current assets are broken down as follows: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Research tax credit 7,228 9,217 10,829 Other tax claims 2,618 5,258 4,292 Other receivables 1,883 1,192 1,745 Prepaid expenses 2,725 2,054 4,265 Total 14,454 17,721 21,131 |
Reconcilliation of Research Tax Credit | The changes in this Research Tax Credit over the last three years are presented as follows: Amount in Opening Balance Sheet Receivable as of January 1, 2016 5,702 + Other income 7,228 - Payment received (5,702 ) - Adjustment — Closing Balance Sheet Receivable as of December 31, 2016 7,228 Amount in Opening balance sheet receivable as of January 1, 2017 7,228 + Operating revenue 9,217 - Payment received (7,341 ) - Adjustement 113 Closing balance sheet receivable as of December 31, 2017 9,217 Amount in thousands of Euros Opening balance sheet receivable as of January 1, 2018 9,217 + Operating revenue 10,829 - Payment received (9,479 ) - Adjustement 262 Closing balance sheet receivable as of December 31, 2018 10,829 |
Cash and Cash Equivalents (Tabl
Cash and Cash Equivalents (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Cash and Cash Equivalents | The cash and cash equivalents item is broken down as follows (in thousands of Euros): December 31, 2016 2017 2018 (Amounts in thousands of Euros) Cash 146,374 32,054 77,236 Cash equivalent term deposits 110,100 105,826 45,534 Total cash and cash equivalent as reported in statement of financial position 256,473 137,880 122,770 Bank overdrafts — — — Total net cash and cash equivalents as reported in the statement of cash flow 256,473 137,880 122,770 |
Capital (Tables)
Capital (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Historical Changes in the Share Capital of the Company | The table below presents the historical changes in the share capital of the Company as of December 31, 2016 , 2017 and 2018: Date Nature of the Transactions Share Capital Share premium Number of Nominal Balance as of January 1, 2016 K€ 2,420.5 K€ 403,910.4 24,205,129 € 0.10 01/05/16 Capital increase by issuance of common shares K€ 0.6 K€ 32.7 6,495 02/16/16 Issue of share subscription warrants K€ K€ 471.1 € 0.10 04/06/16 Capital increase by incorporation of reserve K€ 10.2 K€ (10.2 ) 101,829 € 0.10 05/27/16 Capital increase by issuance of common shares K€ 0.2 K€ 7.5 1,500 € 0.10 06/03/16 Capital increase by issuance of common shares K€ 15.6 K€ (15.6 ) 156,000 € 0.10 06/06/16 Capital increase by issuance of common shares K€ 6.0 K€ 301.2 59,890 € 0.10 06/10/16 Capital increase by issuance of common shares K€ 3.5 K€ 176.0 34,985 € 0.10 07/18/16 Capital increase by issuance of common shares K€ 2.0 K€ 100.7 20,010 € 0.10 08/21/16 Issue of share subscription warrants K€ K€ 106 € 08/04/16 Capital increase by issuance of common shares K€ 1.0 K€ 50.4 10,020 € 0.10 08/24/16 Capital increase by issuance of common shares K€ 0.7 K€ 37.1 7,380 € 0.10 08/30/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 08/31/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/01/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/02/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/05/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/06/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/06/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/08/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/09/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/12/16 Capital increase by issuance of common shares K€ 0.4 K€ 66.2 3,500 € 0.10 09/12/16 Capital increase by issuance of common shares K€ 0.5 K€ 23.1 4,590 € 0.10 11/25/16 Capital increase by issuance of common shares K€ 0.6 K€ 30.2 6,000 € 0.10 Balance as of December 31, 2016 K€ 2,464.9 K€ 405,882.5 24,648,828 € 0.10 Date Nature of the Transactions Share Capital Share premium Number of Nominal Balance as of January 1, 2017 K€ 2,464.9 K 405,882.5 24,648,828 € 0.10 02/03/17 Capital increase by issuance of common shares K€ 2.0 K€ 100.7 20,010 € 0.10 02/09/17 Issue of share subscription warrants K€ K€ 237.4 € 05/16/17 Capital increase by issuance of common shares K€ 4.0 K€ 170.7 40,365 € 0.10 07/12/17 Capital increase by issuance of common shares K€ 0.2 K€ 8.3 1,650 € 0.10 08/04/17 Capital increase by issuance of common shares K€ 0.1 K€ 64.6 1,200 € 0.10 09/14/17 Capital increase by issuance of common shares K€ 3.6 K€ 208.2 35,925 € 0.10 09/14/17 Issue of share subscription warrants K€ K€ 53.1 € 09/29/17 Capital increase by issuance of common shares K€ 0.1 K€ 4.0 500 € 0.10 09/30/17 Capital increase by incorporation of reserve K€ 23.1 K€ (23.1 ) 230,843 € 0.10 10/02/17 Capital increase by issuance of common shares K€ 0.1 K€ 4.0 500 € 0.10 12/15/17 Capital increase by incorporation of reserve K€ 1.1 K€ (1.1 ) 11,001 € 0.10 Balance as of December 31, 2017 K€ 2,499.1 K€ 406,709.3 24,990,822 € 0.10 Date Nature of the Transactions Share Capital Share premium Number of Nominal Balance as of January 1, 2018 K€ 2,499.1 K€ 406,709.3 24,990,822 € 0.10 01/08/18 Capital increase by issuance of common shares K€ 0.7 K€ 52.3 7,000 € 0.10 01/09/18 Capital increase by issuance of common shares K€ 0.5 K€ 25.2 5,010 € 0.10 01/16/18 Capital increase by issuance of common shares K€ 2.0 K€ 100.4 19,950 € 0.10 01/18/18 Capital increase by issuance of common shares K€ 12.9 K€ 963.6 129,000 € 0.10 01/30/18 Capital increase by issuance of common shares K€ 1.3 K€ 97.1 13,000 € 0.10 01/31/18 Capital increase by issuance of common shares K€ 2.0 K€ 149.4 20,000 € 0.10 02/16/18 Capital increase by incorporation of reserve K€ 23.8 K€ (23.8 ) 238,337 € 0.10 03/13/18 Capital increase by incorporation of reserve K€ 23.8 K€ (23.8 ) 238,319 € 0.10 03/23/18 Capital increase by issuance of common shares K€ 352.8 K€ 122,095.5 3,527,752 € 0.10 03/26/18 Capital increase by issuance of common shares K€ 52.9 K€ 18,314.3 529,162 € 0.10 04/05/18 Capital increase by issuance of common shares K€ 1.2 K€ 91.9 12,302 € 0.10 04/06/18 Capital increase by incorporation of reserve K€ 5.8 K€ (5.8 ) 57,500 € 0.10 04/06/18 Capital increase by issuance of common shares K€ 1.4 K€ 105.6 14,138 € 0.10 04/09/18 Capital increase by issuance of common shares K€ 0.4 K€ 26.6 3,560 € 0.10 04/16/18 Capital increase by issuance of common shares K€ 0.8 K€ 88.0 7,500 € 0.10 07/02/18 Capital increase by incorporation of reserve K€ 19.3 K€ (19.3 ) 193,000 € 0.10 08/21/18 Issue of share subscription warrants K€ K€ 163.7 € 07/05/18 Capital increase by issuance of common shares K€ 3.3 K€ 164.1 32,625 € 0.10 07/11/18 Capital increase by issuance of common shares K€ 6.4 K€ 478.1 64,000 € 0.10 08/16/18 Capital increase by incorporation of reserve K€ 1.0 K€ (1.0 ) 10,000 € 0.10 09/01/18 Capital increase by incorporation of reserve K€ 0.5 K€ (0.5 ) 5,000 € 0.10 09/21/18 Capital increase by issuance of common shares K€ 0.5 K€ 37.4 5,000 € 0.10 10/27/18 Capital increase by incorporation of reserve K€ 1.5 K€ (1.5 ) 15,000 € 0.10 12/09/18 Capital increase by incorporation of reserve K€ 2.0 K€ (2.0 ) 19,800 € 0.10 12/31/18 Fees charged to share premium K€ K€ (10,292.6 ) € Balance as of December 31, 2018 K€ 3,015.8 K€ 539,292.0 30,157,777 € 0.10 |
Summary of Share Warrants and Employee Warrants | The Company has issued share warrants (BSAs), employee warrants (BSPCEs), performance shares (AGAs) and stock-options (SO) as follows: Date Type Number of Number of Number of Maximum Strike price 12/07/2007 BSA 1,717 572 859 12,885 € 4.33 01/21/2009 BSA/BSPCE 16,380 — 2,997 44,955 € 4.33 01/21/2009 BSPCE 2,296 — — — € 4.33 06/25/2010 BSA 1,825 — 730 10,950 € 4.33 01/28/2011 BSA 10,039 7,529 — — € 5.13 06/24/2011 BSA/BSPCE 32,000 — 10,440 156,600 € 5.13 11/22/2011 BSA/BSPCE 11,377 — 2,509 37,635 € 5.13 01/17/2012 BSA 89,835 — — — € 5.13 04/02/2012 AGA 669,796 1,860 — — € — 07/25/2012 AGA 134,081 — — — € — 09/25/2012 BSA 30,000 — 10,000 10,000 € 8.59 11/28/2012 AGA 35,360 — — — € — 07/25/2013 BSA 73,000 — 13,000 13,000 € 8.10 09/12/2013 AGA 501,500 113,333 — — € — 09/18/2013 SO 518,000 47,000 471,000 471,000 € 7.57 06/03/2014 BSA 10,000 — 5,000 5,000 € 18.79 06/03/2014 AGA 186,000 30,000 — — € — Date Type Number of Number of Number of Maximum Strike price 06/03/2014 SO 75,000 — 40,000 40,000 € 19.01 03/24/2015 BSA 10,000 — 10,000 10,000 € 43.00 06/23/2015 SO 120,000 — 120,000 120,000 € 48.90 09/30/2015 AGA 708,500 13,000 695,500 695,500 € — 11/19/2015 SO 195,000 25,000 170,000 170,000 € 66.06 11/19/2015 BSA 22,500 7,500 15,000 15,000 € 66.06 12/15/2015 AGA 42,000 6,000 36,000 36,000 € — 12/15/2015 BSA 90,000 16,500 73,500 73,500 € 64.14 01/04/2016 SO 75,000 — 75,000 75,000 € 65.68 04/06/2016 AGA 63,750 5,000 58,750 58,750 € — 04/21/2016 SO 33,000 — 33,000 33,000 € 62.82 05/02/2016 SO 22,000 — 22,000 22,000 € 59.04 06/21/2016 SO 110,000 — 110,000 110,000 € 53.96 06/21/2016 BSA 20,000 — 20,000 20,000 € 52.97 06/21/2016 AGA 208,000 — 208,000 208,000 € — 08/01/2016 SO 10,000 — 10,000 10,000 € 62.24 09/15/2016 SO 9,300 — 9,300 9,300 € 62.80 10/17/2016 SO 16,500 — 16,500 16,500 € 64.39 10/27/2016 AGA 15,000 — 15,000 15,000 € — 11/15/2016 SO 8,300 — 8,300 8,300 € 68.33 12/09/2016 SO 74,960 — 74,960 74,960 € 69.75 12/09/2016 AGA 23,600 — 23,600 23,600 € — Total 4,275,616 273,294 2,360,945 2,606,435 Date Type Number of Number of Number of Maximum Strike price 12/07/2007 BSA 1,717 572 — — € 4.33 01/21/2009 BSA/BSPCE 16,380 — — — € 4.33 01/21/2009 BSPCE 2,296 — — — € 4.33 06/25/2010 BSA 1,825 — — — € 4.33 01/28/2011 BSA 10,039 7,529 — — € 5.13 06/24/2011 BSA/BSPCE 32,000 — 8,996 134,940 € 5.13 11/22/2011 BSA/BSPCE 11,377 — 2,509 37,635 € 5.13 01/17/2012 BSA 89,835 — — — € 5.13 04/02/2012 AGA 669,796 1,860 — — € — 07/25/2012 AGA 134,081 — — — € — 09/25/2012 BSA 30,000 — 7,500 7,500 € 8.59 11/28/2012 AGA 35,360 — — — € — 07/25/2013 BSA 73,000 — 9,500 9,500 € 8.10 09/12/2013 AGA 501,500 113,333 — — € — 09/18/2013 SO 518,000 47,000 471,000 471,000 € 7.57 06/03/2014 BSA 10,000 — 2,500 2,500 € 18.79 Date Type Number of Number of Number of Maximum Strike price 06/03/2014 AGA 186,000 30,000 — — € — 06/03/2014 SO 75,000 — 40,000 40,000 € 19.01 03/24/2015 BSA 10,000 — 10,000 10,000 € 43.00 06/23/2015 SO 120,000 — 120,000 120,000 € 48.90 09/30/2015 AGA 708,500 23,000 454,657 454,657 € — 11/19/2015 SO 195,000 25,000 170,000 170,000 € 66.06 11/19/2015 BSA 22,500 7,500 15,000 15,000 € 66.06 12/15/2015 AGA 42,000 9,000 21,999 21,999 € — 12/15/2015 BSA 90,000 16,500 73,500 73,500 € 64.14 01/04/2016 SO 75,000 — 75,000 75,000 € 65.68 04/06/2016 AGA 63,750 6,250 57,500 57,500 € — 04/21/2016 SO 33,000 — 33,000 33,000 € 62.82 05/02/2016 SO 22,000 — 22,000 22,000 € 59.04 06/21/2016 SO 110,000 7,500 101,300 101,300 € 53.96 06/21/2016 BSA 20,000 — 20,000 20,000 € 52.97 06/21/2016 AGA 208,000 — 208,000 208,000 € — 08/01/2016 SO 10,000 — 10,000 10,000 € 62.24 09/15/2016 SO 9,300 — 9,300 9,300 € 62.80 10/17/2016 SO 16,500 7,200 9,300 9,300 € 64.39 10/27/2016 AGA 15,000 — 15,000 15,000 € — 11/15/2016 SO 8,300 — 8,300 8,300 € 68.33 12/09/2016 SO 74,960 2,000 72,000 72,000 € 69.75 12/09/2016 AGA 23,600 1,900 21,700 21,700 € — 12/09/2016 BSA 59,000 24,992 34,008 34,008 € 69.75 12/15/2016 SO 1,100 — 1,100 1,100 € 69.35 01/16/2017 SO 19,100 — 19,100 19,100 € 66.11 03/14/2017 AGA 22,500 2,500 20,000 20,000 € — 03/15/2017 SO 7,200 — 7,200 7,200 € 66.25 04/18/2017 SO 16,500 — 16,500 16,500 € 60.77 04/20/2017 AGA 24,000 — 24,000 24,000 € — 06/15/2017 SO 126,000 7,500 118,500 118,500 € 59.05 06/15/2017 SO 111,600 — 111,600 111,600 € 60.54 06/15/2017 BSA 9,000 — 9,000 9,000 € 59.05 07/17/2017 SO 30,900 — 30,900 30,900 € 71.61 09/15/2017 SO 52,600 — 52,600 52,600 € 74.22 12/05/2017 SO 625,200 — 625,200 625,200 € 39.00 12/15/2017 SO 8,300 — 8,300 8,300 € 38.08 Total 5,388,616 341,196 3,148,469 3,309,539 Date Type Number of Number of Number of Maximum Strike price 12/07/2007 BSA 1,717 572 — — € 4.33 01/21/2009 BSA/BSPCE 16,380 — — — € 4.33 01/21/2009 BSPCE 2,296 — — — € 4.33 06/25/2010 BSA 1,825 — — — € 4.33 01/28/2011 BSA 10,039 7,529 — — € 5.13 06/24/2011 BSA/BSPCE 32,000 — 7,666 114,990 € 5.13 11/22/2011 BSA/BSPCE 11,377 — — — € 5.13 01/17/2012 BSA 89,835 — — — € 5.13 04/02/2012 AGA 669,796 1,860 — — € — 07/25/2012 AGA 134,081 — — — € — 09/25/2012 BSA 30,000 — 5,000 5,000 € 8.59 Date Type Number of Number of Number of Maximum Strike price 11/28/2012 AGA 35,360 — — — € — 07/25/2013 BSA 73,000 — 7,000 7,000 € 8.10 09/12/2013 AGA 501,500 113,333 — — € — 09/18/2013 SO 518,000 47,000 203,000 203,000 € 7.57 06/03/2014 BSA 10,000 — — — € 18.79 06/03/2014 AGA 186,000 30,000 — — € — 06/03/2014 SO 75,000 — 40,000 40,000 € 19.01 03/24/2015 BSA 10,000 — 10,000 10,000 € 43.00 06/23/2015 SO 120,000 — 120,000 120,000 € 48.90 09/30/2015 AGA 708,500 23,000 — — € — 11/19/2015 SO 195,000 25,000 170,000 170,000 € 66.06 11/19/2015 BSA 22,500 7,500 15,000 15,000 € 66.06 12/15/2015 AGA 42,000 9,000 — — € — Date Type Number of Number of Number of Maximum Strike price 12/15/2015 BSA 90,000 16,500 73,500 73,500 € 64.14 01/04/2016 SO 75,000 — 75,000 75,000 € 65.68 04/06/2016 AGA 63,750 6,250 — — € — 04/21/2016 SO 33,000 11,000 22,000 22,000 € 62.82 05/02/2016 SO 22,000 22,000 — — € 59.04 06/21/2016 SO 110,000 21,300 87,500 87,500 € 53.96 06/21/2016 BSA 20,000 — 20,000 20,000 € 52.97 06/21/2016 AGA 208,000 — — — € — 08/01/2016 SO 10,000 — 10,000 10,000 € 62.24 09/15/2016 SO 9,300 — 9,300 9,300 € 62.80 10/17/2016 SO 16,500 7,200 9,300 9,300 € 64.39 10/27/2016 AGA 15,000 — — — € — 11/15/2016 SO 8,300 — 8,300 8,300 € 68.33 Date Type Number of warrants issued as of 12/31/2018 Number of warrants null and void as of 12/31/2018 Number of warrants null and outstanding as of 12/31/2018 Maximum number of shares to be issued Strike price per share 12/09/2016 SO 74,960 22,965 51,995 51,995 € 69.75 12/09/2016 AGA 23,600 3,800 — — € — 12/09/2016 BSA 59,000 24,992 34,008 34,008 € 69.75 12/15/2016 SO 1,100 — 1,100 1,100 € 69.35 01/16/2017 SO 19,100 — 19,100 19,100 € 66.11 03/14/2017 AGA 22,500 5,500 17,000 17,000 € — 03/17/2017 SO 7,200 — 7,200 7,200 € 66.25 04/18/2017 SO 16,500 9,300 7,200 7,200 € 60.77 04/20/2017 AGA 24,000 — 24,000 24,000 € — 06/15/2017 SO 126,000 35,000 91,000 91,000 € 59.05 06/15/2017 SO 111,600 — 111,600 111,600 € 60.54 06/15/2017 BSA 9,000 — 9,000 9,000 € 59.05 07/17/2017 SO 30,900 23,700 7,200 7,200 € 71.61 Date Type Number of warrants issued as of 12/31/2018 Number of warrants null and void as of 12/31/2018 Number of warrants null and outstanding as of 12/31/2018 Maximum number of shares to be issued Strike price per share 09/15/2017 SO 52,600 7,200 45,400 45,400 € 74.22 12/05/2017 SO 625,200 85,125 540,075 540,075 € 39.00 12/15/2017 SO 8,300 — 8,300 8,300 € 38.18 01/15/2018 SO 15,500 7,200 8,300 8,300 € 43.60 04/16/2018 SO 16,500 — 16,500 16,500 € 38.64 05/16/2018 SO 16,500 — 16,500 16,500 € 40.84 06/15/2018 SO 23,600 — 23,600 23,600 € 38.92 06/22/2018 SO 50,000 — 50,000 50,000 € 37.22 06/22/2018 AGA 486,153 21,125 465,028 465,028 € — 07/02/2018 BSA 44,000 — 44,000 44,000 € 37.24 07/16/2018 SO 28,800 — 28,800 28,800 € 33.81 08/15/2018 SO 33,500 — 33,500 33,500 € 32.90 09/06/2018 SO 65,000 — 65,000 65,000 € 36.96 Date Type Number of warrants issued as of 12/31/2018 Number of warrants null and void as of 12/31/2018 Number of warrants null and outstanding as of 12/31/2018 Maximum number of shares to be issued Strike price per share 06/09/2018 AGA 450 — 450 450 € — 09/17/2018 SO 80,900 — 80,900 80,900 € 40.94 10/15/2018 SO 76,700 — 76,700 76,700 € 37.28 11/01/2018 AGA 57,000 10,500 46,500 46,500 € — 11/15/2018 SO 26,000 — 26,000 26,000 € 32.57 11/29/2018 SO 350,000 — 350,000 350,000 € 30.02 12/12/2018 SO 34,000 — 34,000 34,000 € 27.96 12/12/2018 AGA 19,250 — 19,250 19,250 € — 12/17/2018 SO 7,200 — 7,200 7,200 € 26.76 Total 6,819,669 605,451 3,258,972 3,366,296 |
Financial and Other Non-Curre_2
Financial and Other Non-Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Debt Recorded on Statement of Financial Position | The table below presents the details of the debts recorded on the statement of financial position by the type of conditional advance: 3rd OSEO 4th OSEO BPI COFACE Total Balance sheet debt at start of period 01/01/2016 318 1,669 2,666 156 4,809 Receipts — — — — — Repayments (128 ) — — (147 ) (275 ) Other transactions 2 16 85 (9 ) 95 Balance sheet debt as at 12/31/2016 192 1,684 2,751 — 4,628 Of which—Non-current 4,049 Of which—Current portion 578 Stated interest rate No 2.05 % No No Discount rate 0.4%-1.9 % 1.5%-1.8 % 3.20 % 4.25 % Maturity (in years) 0-3 7-9 2-7 0 3rd OSEO 4th OSEO BPI Total Balance sheet debt at start of period 01/01/2017 192 1,684 2,751 4,627 Receipts — — — — Repayments (128 ) — (450 ) (578 ) Other transactions 1 16 84 101 Balance sheet debt as at 12/31/2017 64 1,700 2,386 4,150 Of which—Non-current 1,825 Of which—Current portion 2,325 Stated interest rate No 2.05 % No Discount rate 0.4%-1.9 % 1.5%-1.8 % 3.2 % Maturity (in years) 0-3 7-9 2-7 3rd OSEO 4th OSEO BPI Total Balance sheet debt at start of period 01/01/2018 64 1,700 2,386 4,150 Receipts — — — — Repayments (64 ) (1,136 ) (600 ) (1,800 ) Other transactions — 60 69 129 Balance sheet debt as at 12/31/2018 — 624 1,854 2,479 Of which—Non-current 1,278 Of which—Current portion 1,201 Stated interest rate No 2.05 % No Discount rate 0.4%-1.9 % 1.5%-1.8 % 3.2 % Maturity (in years) 0-3 7-9 2-7 |
Summary of Due Dates of the Financial Liabilities | Due dates of the financial liabilities recognized as of December 31, 2016: Gross Less than One One to Five More than (Amounts in thousands of Euros) Non-current 4,049 — 2,531 1,518 Non-current — — — — Other non-current 10,746 — 10,370 377 Current conditional advances 578 578 — — Current financial rent debts 12 12 — — Other current liabilities 14,692 14,692 — — Supplier accounts payable and related payables 13,720 13,720 — — Total financial liabilities 43,798 29,003 12,900 1,895 Due dates of the financial liabilities recognized as of December 31, 2017: Gross Less than One One to Five More than (Amounts in thousands of Euros) Non-current 1,825 — 1,825 — Non-current — — — — Other non-current 8,869 — 8,421 448 Current conditional advances 2,325 2,325 — — Current financial rent debts — — — — Other current liabilities 15,751 15,751 — — Supplier accounts payable and related payables 16,941 16,941 — — Total financial, current and non-current 45,711 35,017 10,246 448 Due dates of the financial liabilities recognized as of December 31, 2018: Gross Less than One One to Five More than Five Years (Amounts in thousands of Euros) Non-current 1,278 — 1,278 — Non-current — — — — Other non-current 4,105 — 3,991 114 Current conditional advances 1,201 1,201 — — Current financial rent debts — — — — Other current liabilities 12,506 12,506 — — Supplier accounts payable and related payables 28,567 28,567 — — Total financial, current and non-current 47,657 42,273 5,269 114 |
Non-Current Provisions (Tables)
Non-Current Provisions (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Schedule of Non-Current Provisions | December 31, 2016 2017 2018 Pension retirement obligations 853 1,260 1,536 Total 853 1,260 1,536 |
Schedule of Commitments for Compensation Payable to Employees Upon Their Retirement | Commitments for Compensation Payable to Employees Upon Their Retirement Amounts in As of January 1, 2016 (490 ) Costs of services rendered (operating expense) (104 ) Interest expense (financial expense) (10 ) Benefit paid — Actuarial losses (249 ) As of December 31, 2016 (853 ) Costs of services rendered (operating expense) (219 ) Interest expense (financial expense) (11 ) Benefit paid — Actuarial losses (177 ) As of December 31, 2017 (1,260 ) |
Schedule of Retirement Commitments | As part of the estimation of the retirement commitments, the following assumptions were used for all categories of employees: December 31, 2016 2017 2018 % social security contributions 50.0 % 50.0 % 50.0 % Salary increases 2.0 % 2.0 % 2.0 % Discount rate 1.31 % 1.30 % 1.57 % |
Supplier Accounts Receivable _2
Supplier Accounts Receivable and Other Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Schedule of Other Current Liabilities | Other Current Liabilities 2016 2017 2018 (Amounts in thousands of Euros) Social security 10,794 12,094 6,343 Tax liabilities 504 428 448 Other debts 146 440 1,354 Deferred revenues 3,248 2,789 4,360 Total 14,692 15,751 12,506 |
Financial Instruments Recogni_2
Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Schedule of Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) | 2016 Book value in Fair value Loans and Debt At Fair value Financial assets Long-term financial assets 2,745 1,310 1,435 — 2,745 Customer accounts receivables and related receivables 1,250 — 1,250 — 1,250 Other current financial assets 516 — 516 — 516 Cash and cash equivalents 256,473 256,473 — — 256,473 Total financial assets 260,985 257,783 3,202 — 260,985 Financial liabilities Long-term conditional advances 4,049 — — 4,049 4,049 Long term financial rent debt — — — — — Other long-term liabilities 10,746 — — 10,746 10,746 Short-term conditional advances 578 — — 578 578 Short term financial rent debt 12 — — 12 12 Other short-term liabilities 14,692 — — 14,692 14,692 Account payable and other liabilities 13,720 — — 13,720 13,720 Total financial liabilities 43,798 — — 43,798 43,798 2017 Book value in Fair value Loans and Debt At Fair value Financial assets Long-term financial assets 3,012 1,333 1,679 — 3,012 Customer accounts receivables and related receivables 1,265 — 1,265 — 1,265 Other current financial assets 378 — 378 — 378 Cash and cash equivalents 137,880 137,880 — — 137,880 Total financial assets 142,534 139,213 3,321 — 142,534 Financial liabilities Long-term conditional advances 1,825 — — 1,825 1,825 Long term financial rent debt — — — — — Other long-term liabilities 8,869 — — 8,869 8,869 Short-term conditional advances 2,325 — — 2,325 2,325 Short term financial rent debt — — — — — Other short-term liabilities 15,751 — — 15,751 15,751 Account payable and other liabilities 16,941 — — 16,941 16,941 Total financial liabilities 45,711 — — 45,711 45,711 2018 Book value in Fair value Financial assets Non-derivative Fair value (2) Financial assets Long-term financial assets 6,033 432 5,601 — 6,033 Customer accounts receivables and related receivables — — — — — Other current financial assets 912 — 912 — 912 Cash and cash equivalents 122,770 — 122,770 — 122,770 Total financial assets 129,715 432 129,283 — 129,715 Financial liabilities Long-term conditional advances 1,278 — — 1,278 1,278 Long term financial rent debt — — — — — Other long-term liabilities 4,105 — — 4,105 4,105 Short-term conditional advances 1,201 — — 1,201 1,201 Short term financial rent debt — — — — — Other short-term liabilities 12,506 — — 12,506 12,506 Account payable and other liabilities 28,567 — — 28,567 28,567 Total financial liabilities 47,656 — — 47,656 47,656 (1) The fair value of financial assets as fair value through Consolidated Statements of (Loss) is determined based on Level 1 fair value measurements and corresponds to the market value of the assets. (2) The fair value of “financial assets at amortized cost” as per IFRS 9 or “loans and receivables” as per IAS 39 corresponds to the value reported in the Consolidated Statements of Financial Position. (3) The book amount of “Non-derivative |
Operating Income (Tables)
Operating Income (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Operating Income | The operating income is broken down in the following manner: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Revenues — — — Research tax credit 7,228 9,330 11,034 Subsidies 303 271 152 Other operating income 1,554 2,308 3,351 Total 9,084 11,909 14,537 |
Operating Expenses (Tables)
Operating Expenses (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Research and Development Expense | The research and development expenses are broken down as follows: December 31, 2016 2017 2018 Research and development expenses (Amounts in thousands of Euros) Personnel expenses 32,777 37,112 37,912 Sub-contracting, 34,413 54,397 52,927 Small equipments and other supplies 3,909 4,110 4,771 Rental 1,903 2,018 2,703 Conferences, travel expenses 2,387 2,807 2,591 Depreciation and amortization 1,141 2,424 2,492 Others 2,298 2,364 3,776 Total research and development expenses 78,828 105,232 107,171 |
Summary of Sales And Marketing Expense | The sales and marketing expenses are broken down as follows: December 31, 2016 2017 2018 Sales and marketing expenses (Amounts in thousands of Euros) Personnel expenses 4,954 6,976 12,553 Fees 4,447 2,480 5,148 Communication and travel expenses 1,393 5,984 14,021 Others 487 384 446 Total sales and marketing expenses 11,282 15,824 32,169 |
Summary of General and Administrative Expense | By nature, the breakdown of general and administrative expenses is as follows: December 31, 2016 2017 2018 General and administrative expenses (Amounts in thousands of Euros) Personnel expenses 22,613 19,742 19,101 Fees 7,701 10,347 12,718 Rental 501 584 911 Insurance policies 1,853 1,367 1,930 Communication and travel expenses 1,136 1,599 1,576 Depreciation and amortization 181 422 1,720 Others 1,020 1,776 3,442 Total general and administrative expenses 35,005 35,837 41,399 |
Summary of Personnel Expense | The personnel expenses are broken down as follows: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Wages and salaries 14,651 22,451 31,684 Social security contributions 3,903 7,157 8,858 Expenses for pension commitments 982 1,583 2,095 Employer contribution to bonus shares 6,456 1,857 1,026 Share-based payments 34,353 30,781 25,904 Total 60,345 63,830 69,567 |
Share-Based Payments (Tables)
Share-Based Payments (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Statement [LineItems] | |
Summary Of Breakdown of the Closing Balance | Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BSA2010 Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BSA2010 with exercise price of €77 610 610 500 500 500 500 Total 610 610 500 500 500 500 |
Summary Of Breakdown of the Closing Balance | Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BSAX Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BSAX with exercise price of €65 1,036 1,036 — — — — Total 1,036 1,036 — — — — |
BCE 4 [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of BCE4 Date of grant (Board of Directors) 01/21/2009 01/21/2009 01/21/2009 01/21/2009 01/21/2009 Vesting period (years) 0 1 2 3 4 Plan expiration date 01/20/2019 01/20/2019 01/20/2019 01/20/2019 01/20/2019 Number of BCE4 granted 2,411 1,340 536 536 535 Share entitlement per BCE4(1) 15 15 15 15 15 Exercise price 65 65 65 65 65 Valuation method used Black—Scholes Grant date share fair value 70 70 70 70 70 Expected volatility 40 % 40 % 40 % 40 % 40 % Average life of BCE4 5.0 5.5 6.0 6.5 7.0 Discount rate(2) 2.71 % 2.71 % 2.98 % 2.98 % 3.11 % Expected dividends 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA Fair value per BCE4 29.06 30.33 31.90 33.06 34.35 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE4 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE4 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BCE4. |
Summary Of Change in Number of BCE4 Outstanding | Change in Number of BCE4 Outstanding Year ended December 31, Number of BCE4 2016 2017 2018 Balance at beginning of period 2,691 2,691 — Granted during the period — — — Forfeited during the period — — — Exercised during the period — 2,691 — Expired during the period — — — Balance at end of period 2,691 — — |
Summary of Number of Share Options Oustanding and Exercisable | Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BCE4 Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BCE4 with exercise price of €65 2,691 2,691 — — — — Total 2,691 2,691 — — — — |
BCE2010 [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of BCE2010 Date of grant (Board of Directors) 06/24/2011 06/24/2011 06/24/2011 06/24/2011 11/22/2011 11/22/2011 11/22/2011 11/22/2011 Vesting period (years) 0.5 1.5 2.5 3.5 1 2 3 4 Plan expiration date 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BCE2010 granted 6,000 6,000 6,000 6,000 2,510 2,510 2,510 2,509 Share entitlement per BCE2010(1) 15 15 15 15 15 15 15 15 Exercise price 77 77 77 77 77 77 77 77 Valuation method used Black and Scholes Grant date share fair value 77 77 77 77 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BCE2010 5.5 6.0 6.5 7.0 5.4 5.9 6.4 6.9 Discount rate(2) 2.55 % 2.68 % 2.68 % 2.87 % 2.05 % 2.42 % 2.42 % 2.66 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BCE2010 31.16 32.71 34.03 35.58 30.42 32.29 33.58 35.2 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BCE2010. |
Summary Of Change in Number of Outstanding shares | Change in Number of BSA Outstanding Year ended December 31, Number of BSA 2016 2017 2018 Balance at beginning of period 143,694 147,359 181,008 Granted during the period 93,500 68,000 44,000 Forfeited during the period — 24,902 — Exercised during the period 89,835 9,359 7,500 Expired during the period — — — Balance at end of period 147,359 181,008 217,508 |
Summary Breakdown of the Closing Balance | Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BCE2010 Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BCE2010 with exercise price of €77.00 12,339 12,339 11,005 11,005 7,166 7,166 Total 12,339 12,339 11,005 11,005 7,166 7,166 |
BSA [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of BSA Date of grant (Board of 12/07/2007 12/07/2007 12/07/2007 12/07/2007 01/17/2012 01/17/2012 01/17/2012 01/17/2012 Vesting period (years) 1 2 3 4 1 2 3 4 Plan expiration date 12/08/2017 12/08/2017 12/08/2017 12/08/2017 01/17/2022 01/17/2022 01/17/2022 01/17/2022 Number of BSA granted 431 431 428 427 22,459 22,459 22,459 22,458 Share entitlement per BSA(1) 15 15 15 15 1 1 1 1 Exercise price 65 65 65 65 5.13 5.13 5.13 5.13 Valuation method used Black—Scholes Grant date share fair value 65 65 65 65 5.13 5.13 5.13 5.13 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSA 4.5 5.0 5.5 6.0 5.5 6.0 6.5 7.0 Discount rate(2) 4.06 % 4.09 % 4.09 % 4.10 % 2.33 % 2.33 % 2.61 % 2.61 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BSA 22.18 23.62 24.95 26.22 2.05 2.14 2.26 2.34 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA. Date of grant (Board of Directors) 09/25/2012 09/25/2012 09/25/2012 09/25/2012 07/25/2013 06/03/2014 Vesting period (years) 1 2 3 4 0 0 Plan expiration date 09/25/2022 09/25/2022 09/25/2022 09/25/2022 07/25/2023 06/03/2024 Number of BSA granted 7,500 7,500 7,500 7,500 73,000 10,000 Share entitlement per BSA 1 1 1 1 1 1 Exercise price 8.59 8.59 8.59 8.59 8.1 18.79 Valuation method used Black—Scholes Grant date share fair value 8.4 8.4 8.4 8.4 8.15 19.01 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSA 5.5 6.0 6.5 7.0 5.0 5.0 Discount rate(1) 1.21 % 1.21 % 1.53 % 1.53 % 1.16 % 0.71 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA Fair value per BSA 2.29 2.43 2.61 2.74 2.18 4.98 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA. Date of grant (Board of Directors) 03/24/2015 11/19/2015 12/15/2015 06/21/2016 Vesting period (years) Plan expiration date 03/24/2025 11/19/2025 12/15/2015 06/21/2016 Number of BSA granted 10,000 15,000 90,000 (1) 20,000 Share entitlement per BSA 1 1 1 1 Exercise price 43.00 66.06 64.14 52.97 Valuation method used Black—Scholes Grant date share fair value 43 66.06 42.61 61.25 Expected volatility 36 % 50.91 % 51 % 47 % Average life of BSA 5.0 5.0 5.0 5.0 Discount rate(1) 0.68 % 0.81 % -0.09 % -0.41 % Expected dividends 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA Fair value per BSA 9.90 22.60 7.28 21.59 Date of grant (Board of Directors) 12/09/2016 06/15/2017 05/02/2018 Vesting period (years) 0 0 0 Plan expiration date 12/09/2026 06/15/2027 05/02/2028 Number of BSA granted 59,000 9,000 44,000 Share entitlement per BSA 1 1 1 Exercise price 69.75 59.05 37.24 Valuation method used Black—Scholes Grant date share fair value 63.18 73.32 37.74 Expected volatility 40 % 39 % 50 % Average life of BSA 5.0 5.0 5.0 Discount rate(1) -0.04 % -0.12 % -0.15 % Expected dividends 0 % 0 % 0 % Performance conditions NA NA NA Fair value per BSA 12.94 24.02 9.02 |
Summary Of Change in Number of Outstanding shares | Change in Number of BSA Outstanding Year ended December 31, Number of BSA 2016 2017 2018 Balance at beginning of period 143,694 147,359 181 008 Granted during the period 93,500 68,000 44,000 Forfeited during the period — 24,902 — Exercised during the period 89,835 9,359 7,500 Expired during the period — — — Balance at end of period 147,359 181,008 217,508 |
Summary Breakdown of the Closing Balance | Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of BSA Outstanding Outstanding Outstanding Exercisable Outstanding Exercisable BSA2010 with exercise price of €65 859 859 — — — — BSA2010 with exercise price of €5.13 — — — — — — BSA2010 with exercise price of €8.59 10,000 10,000 7,500 7,500 5,000 5,000 BSA2010 with exercise price of €8.10 13,000 13,000 9,500 9,500 7,000 7,000 BSA2010 with exercise price of €18.79 5,000 5,000 2,500 2,500 — — BSA with exercise price of €43.00 10,000 10,000 10,000 10,000 10,000 10,000 BSA with exercise price of €66.06 15,000 15,000 15,000 15,000 15,000 15,000 BSA with exercise price of €64.14 73,500 73,500 73,500 73,500 73,500 73,500 BSA with exercise price of €52.97 20,000 20,000 20,000 20,000 20,000 20,000 BSA with exercise price of €69.75 — — 34,008 34,008 34,008 34,008 BSA with exercise price of €59.05 — — 9,000 9,000 9,000 9,000 BSA with exercise price of €37.24 — — — — 44,000 44,000 Total 147,359 147,359 181,008 181,008 217,508 217,508 |
Share Option [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of SO Date of grant (Board of Directors) 09/18/2013 06/03/2014 06/23/2015 11/19/2015 01/04/2016 04/21/2016 05/02/2016 Vesting period (years) 4 2 1-4 1-4 1-4 1-4 1-4 Plan expiration date 09/18/2023 06/03/2024 06/23/2025 11/19/2025 01/04/2026 04/21/2026 05/02/2026 Number of SO granted 518,000 75,000 120,000 195,000 75,000 33,000 22,000 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price 7.57 19.01 48.9 66.06 65.68 62.82 59.04 Valuation method used Black—Scholes Grant date share fair value 7.9 19.01 48.9 66.06 65.68 62.82 58.62 Expected volatility 40 % 40 % 51 % 51 % 49.3%-49.8 % 49.4%-50.7 % 49.3%-50.6 % Average life of SO 7 6 7 7 5-7 5-7 5-7 Discount rate(1) 1.72 % 0.89 % 0.89 % 0.81 % 0.39 % 0.04 % 0.10 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA Fair value per SO 3.57 7.46 25.28 34.05 29.5-32.6 28.3-30.9 26.4-28.8 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of grant 06/21/2016 08/01/2016 09/15/2016 10/17/2016 11/15/2016 12/09/2016 12/15/2016 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 06/21/2026 08/01/2026 09/15/2016 10/17/2026 11/15/2026 12/09/2026 12/15/2026 Number of SO granted 110,000 10,000 9,300 16,500 8,300 74,960 1,100 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price 53.96 62.24 62.8 64.39 68.33 69.75 69.35 Valuation method used Black—Scholes Grant date share fair value 52.97 62.24 62.8 64.39 68.33 69.75 69.35 Expected volatility 49.1%-50.3 % 48.8%-49.8 % 48.6%-49.4 % 48.0%-48.9 % 47.8%-48.8 % 47.7%-48.5 % 40.44 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate(1) -0.01 % -0.25 % -0.18 % -0.32%-0.15 % -0.11%+0.16 % -0.2%+0.18 % -0.18%+0.16 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA Fair value per SO 23.4-25.5 27.3-29.9 27.4-30.1 27.6-30.6 29.4-32.7 29.7-33.4 25.2-28.7 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of grant 01/16/2017 03/15/2017 04/18/2017 06/15/2017 06/15/2017 07/17/2017 09/15/2017 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 01/16/2027 03/15/2027 04/18/2027 06/15/2027 06/15/2027 07/17/2027 09/15/2027 Number of SO granted 19,100 7,200 16,500 126,000 111.600 30,900 52,600 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price 66.11 66.25 60.77 59.05 60.54 71.61 74.22 Valuation method used Grant date share fair value 66.11 65.42 59.73 59.05 59.05 71.61 71.80 Expected volatility 40.21 % 39.82 % 39.63 % 39.23 % 39.23 % 38.84 % 38.57 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate(1) -0.17%+0.19 % +0.21%+0.61 % +0.02%+0.39 % -0.21%+0.07 % -0.21%+0.07 % +0.01%+0.34 % -0.14%+0.19 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA Fair value per SO 23.9-27.2 23.6-27.1 21.2-24.2 20.8-23.6 20.4-23.22 25.3-28.2 24.3-27.8 Date of grant 12/05/2017 12/15/2017 01/15/2018 04/16/2018 05/15/2018 06/15/2018 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 12/05/2027 12/15/2027 01/15/2028 04/16/2028 05/15/2028 06/15/2028 Number of SO granted 625,200 8,300 15,500 16,500 16,500 23,600 Share entitlement per SO 1 1 1 1 1 1 Exercise price 39.00 38.18 43.60 38.64 40.84 38.92 Valuation method used Black—Scholes Grant date share fair value 35.73 36.43 43.60 38.64 40.84 35.48 Expected volatility 43.23 % 43.13 % 45.57 % 46.37 % 46.15 % 45.95 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) -0.23%+0.07 % -0.23%+0.07 % 0.32 % 0.35 % 0.41 % 0.23 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA Fair value per SO 12.9-14.7 13.5-15.4 18.1-20.2 16.3-18.2 17.2-19.2 13.8-15.6 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO. Date of grant 06/22/2018 07/16//2018 08/15/2018 09/17/2018 10/15/2018 11/15/2018 12/17/2018 Vesting period (years) 1-4 1-4 1-4 1-4 1-4 1-4 1-4 Plan expiration date 06/22/2028 07/16/2028 15/08/2028 09/17/2028 10/15/2028 11/15/2028 12/17/2028 Number of SO granted 50,000 28,800 33,500 80,900 76,700 26,000 7,200 Share entitlement per SO 1 1 1 1 1 1 1 Exercise price 37.22 33.81 32.90 40.94 37.28 32.57 26.76 Valuation method used Black and Scholes Grant date share fair value 34.32 32.16 32.90 40.94 31.74 28.66 26.76 Expected volatility 45.85 % 46.51 % 46.67 % 46.92 % 47.12 % 47.44 % 47.90 % Average life of SO 5-7 5-7 5-7 5-7 5-7 5-7 5-7 Discount rate (1) 0.19 % 0.14 % 0.17 % 0.27 % 0.37 % 0.29 % 0.26 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Yes (2) Fair value per SO 13.42-15.11 13.02-14.59 13.85-15.43 17.39-19.37 12.12-13.78 11.18-12.66 11.57-12.88 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO (2) Performance conditions: Viaskin ® Date of grant 06/09/2018 11/29/2018 12/12/2018 Vesting period (years) 1-4 1-4 1-4 Plan expiration date 09/06/2028 11/29/2028 12/12/2028 Number of SO granted 65,000 350,000 34,000 Share entitlement per SO 1 1 1 Exercise price 36.96 30.02 27.96 Valuation method used Black and Scholes Grant date share fair value 36.96 27.44 27.96 Expected volatility 46.85 % 47.51 % 47.87 % Average life of SO 5-7 5-7 5-7 Discount rate (1) 0.21 % 0.27 % 0.27 % Expected dividends 0 % 0 % 0 % Performance conditions Yes (2) Yes (2) Yes (2) Fair value per SO 15.65-17.43 11.08-12.47 12.09-13.46 (1) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of SO (2) Performance conditions: Viaskin ® |
Disclosure of Change in Number of Share Options Outstanding | Change in Number of SO Outstanding December 31, Number of SO 2016 2017 2018 Balance at beginning of period 861,000 1,160,060 2,133,100 Granted during the period 359,060 998,500 824,200 Forfeited during the period 25,000 24,260 227,730 Exercised during the period 35,000 1,200 268,000 Expired during the period — — — Balance at end of period 1,160,060 2,133,100 2,461,570 |
SO [Member] | |
Statement [LineItems] | |
Summary of Change in Number of Outstanding shares | Breakdown of the Closing Balance Year ended December 31, 2016 2017 2018 Number of SO Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable SO with exercise price of €7.57 471,000 — 471,000 471,000 203,000 203,000 SO with exercise price of €19.01 40,000 40,000 40,000 40,000 40,000 40,000 SO with exercise price of €48.90 120,000 45,000 120,000 75,000 120,000 90,000 SO with exercise price of €66.06 170,000 — 170,000 85,000 170,000 127,500 SO with exercise price of €65.68 75,000 — 75,000 18,750 75,000 37,500 SO with exercise price of €62.82 33,000 — 33,000 8,250 22,000 11,000 SO with exercise price of €59.04 22,000 — 22,000 5,500 — — SO with exercise price of €53.96 110,000 — 101,300 24,425 87,500 54,687 SO with exercise price of €62.24 10,000 — 10,000 2,500 10,000 5,000 SO with exercise price of €62.80 9,300 — 9,300 2,325 9,300 4,650 SO with exercise price of €64.39 16,500 — 9,300 2,325 9,300 4,650 SO with exercise price of €68.33 8,300 — 8,300 2,075 8,300 4,150 SO with exercise price of €69.75 74,960 — 72,900 18,225 51,995 25,997 SO with exercise price of €66.35 — — 1,100 275 1,100 550 SO with exercise price of €66.11 — — 19,100 — 19,100 7,162 SO with exercise price of €66.25 — — 7,200 — 7,200 2,700 SO with exercise price of €60.77 — — 16,500 — 7,200 2,700 SO with exercise price of €59.05 — — 118,500 — 91,000 34,125 SO with exercise price of €60.54 — — 111,600 — 111,600 41,850 SO with exercise price of €71.61 — — 30,900 — 7,200 1,800 SO with exercise price of €74.22 — — 52,600 — 45,400 11,350 SO with exercise price of €39.00 — — 625,200 — 540,075 135,018 SO with exercise price of €38.18 — — 8,300 — 8,300 2,075 SO with exercise price of €43.60 — — — — 8,300 — SO with exercise price of €38.64 — — — — 16,500 — SO with exercise price of €40.84 — — — — 16,500 — SO with exercise price of €38.92 — — — — 23,600 — SO with exercise price of €37.22 — — — — 50,000 — SO with exercise price of €33.81 — — — — 28,800 — SO with exercise price of €32.90 — — — — 33,500 — SO with exercise price of €36.96 — — — — 65,000 — SO with exercise price of €40.94 — — — — 80,900 — SO with exercise price of €37.28 — — — — 76,700 — SO with exercise price of €32.57 — — — — 26,000 — SO with exercise price of €30.02 — — — — 350,000 — SO with exercise price of €27.96 — — — — 34,000 — SO with exercise price of €37.24 — — — — 7,200 — Total 1,160,000 85,000 2,133,100 755,650 2,461,570 847,464 |
Free Share [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of Free Shares Date of grant (Board of Directors) 04/02/2012 07/25/2012 11/28/2012 07/25/2013&09/12/2013 06/03/2014 Vesting period (years) 2 2 2 2 2 Number of free shares granted 669,796 134,081 35,360 501,500 186,000 Share entitlement per free share (1) 1 1 1 1 1 Grant date share fair value 8.86 8.20 8.70 7.96 19.01 Expected dividends 0 % 0 % 0 % 0 % 0 % Performance conditions Yes (1) Yes (1) No Yes (2) Yes (3) Expected turnover during the vesting period 1 % 1 % 1 % 1 % 1 % Date of grant (Board of Directors) 09/30/2015 12/15/2015 Vesting period (years) 2 2 Number of free shares granted 708,500 42,000 Share entitlement per free share (1) 1 1 Grant date share fair value 62.99 64.14 Expected dividends 0 % 0 % Performance conditions Yes (4) Yes (4) Expected turnover during the vesting period 0 % 0 % (1) The acquisition of free shares is contingent for certain individuals (the “Key Managers”), including Dr. Benhamou, upon the achievement of the three performance criteria below: • One-third th • One-third • One-third ® (2) The acquisition of free shares is contingent for the Key Managers, including Dr. Benhamou, upon the achievement of the three performance criteria below: • One-third th ® • One-third ® • One-third It is specified that in the event of a change of control of the Company (as defined in Article L. 233-3 (3) The acquisition of free shares is contingent for the Key Managers, including Dr. Benhamou, upon the achievement of the two performance criteria below: • Half of the shares allocated to Key Managers will only be acquired from the later of the two following dates (i) expiry of a period of two years from the date of allocation and (ii) inclusion of the 100 th ® • Half of the shares allocated to Key Managers will only be acquired from the later of the two following dates (i) expiry of a period of two years from the date of allocation and (ii) approval by the FDA of a protocol for the Phase III trial of Viaskin ® (4) The acquisition of free shares is contingent for all the employees, including Dr. Benhamou, upon the achievement of the three performance criteria below: • One third of the shares will only be acquired from the later of the following two dates : (i) the end of the 2 year vesting period which runs from September 30, 2015 and (ii) achievement of the primary efficacy endpoint of the Phase III ‘Pepites’ trial for Viaskin ® pre-BLA ® • One third of the shares will only be acquired from the later of the following two dates : (i) the end of the 2 year vesting period which runs from September 30, 2015 and (ii) achievement of the primary efficacy endpoint of the Phase II ‘Miles’ trial for Viaskin ® • One third of the shares will only be acquired from until the later of the following two dates: (i) the end of the 2 year vesting period which runs from September 30, 2015 and (ii) the beginning of clinical testing of another product candidate from the Viaskin ® Board of Directors 04/06/2016 06/21/2016 08/16/2016 09/01/2016 10/27/2016 12/09/2016 Vesting period (years) 2 2 2 2 2 2 Number of free shares granted 63,750 193,000 10,000 5,000 15,000 23,600 Share entitlement per free share 1 1 1 1 1 1 Grant date share fair value 62.40 52.97 60.68 61.49 67.44 69.75 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions yes (1) yes (1) yes (1) yes (1) yes (2) yes (2) Expected turnover during the vesting period 0 % 0 % 0 % 0 % 0 % 0 % (1) The acquisition of free shares is contingent for all the employees, including Dr. Benhamou, upon the achievement of the three performance criteria below: • One third of the shares will only be acquired from the later of the following two dates: (i) the end of the 2 year vesting period which runs from Grant Date and (ii) achievement of the primary efficacy endpoint of the Phase III ‘Pepites’ trial for Viaskin ® pre-BLA ® • One third of the shares will only be acquired from the later of the following two dates: (i) the end of the 2 year vesting period which runs from Grant Date and (ii) achievement of the primary efficacy endpoint of the Phase II ‘Miles’ trial for Viaskin ® • One third of the shares will only be acquired from until the later of the following two dates: (i) the end of the 2 year vesting period which runs from Grant date and (ii) the beginning of clinical testing of another product candidate from the Viaskin ® (2) The acquisition of free shares is contingent for key and new employees upon the achievement of the two performance criteria below: • Half of the shares will only be acquired from the later of the following two dates: (i) the end of the 2 year vesting period which runs from Grant Date and (ii) achievement of the primary efficacy endpoint of the Phase III ‘Pepites’ trial for Viaskin ® pre-BLA ® • Half of the shares will only be acquired from the later of the following two dates: (i) the end of the 2 year vesting period which runs from Grant Date and (ii) achievement of the primary efficacy endpoint of the Phase II ‘Miles’ trial for Viaskin ® Performance conditions other than market conditions, which are taken into account by adjusting the number of equity instruments included in the measurement of the transaction amount, but are not taken into account when estimating the fair value of the shares. Board of Directors 03/14/2017 04/20/2017 06/22/2018 06/09/2018 01/11/2018 12/12/2018 17/12/2018 Vesting period (years) 2 2 1 1 1 1 1 Lockup period 0 0 2 2 2 2 2 Number of free shares granted 22,500 24,000 486,153 450 57,000 16,250 3,000 Share entitlement per free share 1 1 1 1 1 1 1 Grant date share fair value 68.07 61.20 34.32 36.96 33.33 27.96 26.76 Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions yes (1) yes (1) yes (2) yes (2) yes (2) yes (2) yes (2) Expected turnover during the vesting period 0 % 0 % 0 % 0 % 5 % 5 % 5 % (1) The acquisition of free shares is contingent for key and new employees upon the achievement of the two performance criteria below: • Half of the Shares allocated will not be acquired until the later of the following two dates: (i) the end of the two (2)-year acquisition period which runs from today and (ii) submission of the application for market authorization from the FDA for Viaskin ® • Half of the Shares allocated will not be acquired until the later of the following two dates: (i) the end of the two (2)-year acquisition period which runs from today and (ii) the first date of sale of Viaskin ® (2) The definitive allocation of the free shares will only occur at the later of the following two dates, subject to the presence requirement: (i) expiry of the current acquisition period as from their initial allocation; and (ii) approval of Viaskin ® |
Summary Of Change in Number of BCE4 Outstanding | Change in Number of Free Shares Outstanding Year ended December 31, Number of Free shares 2016 2017 2018 Balance at beginning of period 1,008,329 1,036,850 822,856 Granted during the period 310,350 46,500 562,853 Forfeited during the period 24,000 18,650 36,525 Exercised during the period 257,829 241,844 776,956 Expired during the period — — — Balance at end of period 1,036,850 822,856 572,228 |
BSA2010 [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of BSA2010 Date of grant (Board of 01/28/2011 01/28/2011 01/28/2011 01/28/2011 06/24/2011 06/24/2011 06/24/2011 06/24/2011 Vesting period (years) 0.9 1.9 2.9 3.9 0.5 1.5 2.5 3.5 Plan expiration date 01/27/2021 01/27/2021 01/27/2021 01/27/2021 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BSA2010 granted 2,510 2,510 2,510 2,509 2,000 2,000 2,000 2,000 Share entitlement per BSA2010(1) 15 15 15 15 15 15 15 15 Exercise price 77 77 77 77 77 77 77 77 Valuation method used Black—Scholes Black—Scholes Grant date share fair value 77 77 77 77 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSA2010 5.5 6.0 6.5 7.0 5.5 6.0 6.5 7.0 Discount rate(2) 2.70 % 2.82 % 2.82 % 3.04 % 2.55 % 2.68 % 2.68 % 2.87 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BSA2010 31.33 32.90 34.23 35.84 31.15 32.70 34.02 35.57 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA2010. Date of grant (Board of Directors) 11/22/2011 11/22/2011 11/22/2011 11/22/2011 Vesting period (years) 1.0 2.0 3.0 4.0 Plan expiration date 11/22/2021 11/22/2021 11/22/2021 11/22/2021 Number of BSA2010 granted 335 335 334 334 Share entitlement per BSA(1) 15 15 15 15 Exercise price 77 77 77 77 Valuation method used Black—Scholes Grant date share fair value 77 77 77 77 Expected volatility 40 % 40 % 40 % 40 % Average life of BSA 5.5 6.0 6.5 7.0 Discount rate(2) 2.23 % 2.60 % 2.60 % 2.85 % Expected dividends 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA Fair value per BSA 30.70 32.58 33.89 35.54 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSA2010. |
Summary Of Breakdown of the Closing Balance | Change in Number of BSA2010 Outstanding Year ended December 31, Number of BSA 2016 2017 2018 Balance at beginning of period 1,044 610 500 Granted during the period — — — Forfeited during the period — — — Exercised during the period 434 110 — Expired during the period — — — Balance at end of period 610 500 500 |
BSAX [member] | |
Statement [LineItems] | |
Summary Details of Share Based Payments | Details of BSAX Date of grant (Board of 01/21/2009 01/21/2009 01/21/2009 21/01/2009 06/25/2010 06/25/2010 06/25/2010 06/25/2010 Vesting period (years) 1 2 3 4 1 2 3 4 Plan expiration date 01/20/2019 01/20/2019 01/20/2019 01/20/2019 06/24/2020 06/24/2020 06/24/2020 06/24/2020 Number of BSAX granted 77 77 77 75 457 457 456 455 Share entitlement per BSAX(1) 15 15 15 15 15 15 15 15 Exercise price 65 65 65 65 65 65 65 65 Valuation method used Black—Scholes Grant date share fair value 70 70 70 70 70 70 70 70 Expected volatility 40 % 40 % 40 % 40 % 40 % 40 % 40 % 40 % Average life of BSAX 5.5 6.0 6.5 7.0 5.5 6.0 6.5 7.0 Discount rate(2) 2.71 % 2.98 % 2.98 % 3.11 % 2.04 % 2.23 % 2.23 % 2.50 % Expected dividends 0 % 0 % 0 % 0 % 0 % 0 % 0 % 0 % Performance conditions NA NA NA NA NA NA NA NA Fair value per BSAX 30.32 31.89 33.05 33.45 29.47 30.88 31.99 33.44 (1) The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSAX warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSAX plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. (2) Based on French government bonds (GFRN) with a maturity corresponding to the maturity of BSAX. |
Summary of Change in Number of Outstanding shares | Change in Number of BSAX Outstanding Year ended December 31, Number of BSAX 2016 2017 2018 Balance at beginning of period 1,036 1,036 — Granted during the period — — — Forfeited during the period — — — Exercised during the period — 1,036 — Expired during the period — — — Balance at end of period 1,036 — — |
Financial Revenue and Expenses
Financial Revenue and Expenses (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Financial Income and Expenses | The financial income and expenses are broken down as follows: Year ended December 31, 2016 2017 2018 (Amounts in thousands of Euros) Financial revenues 1,646 616 493 Financial expenses (145 ) (3,325 ) (351 ) Total 1,500 (2,709 ) 141 |
Income Tax Expense (Tables)
Income Tax Expense (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Reconciliation of Effective and Nominal Tax Expense | The following table shows the reconciliation between the effective and nominal tax expense at the nominal standard French rate of 33.33% as of December 31, 2016 and 2017 and 28.0% as of December 31, 2018 (excluding additional contributions): Year ended December 31, 2016 2017 2018 (Amounts in thousands of Euros) (Loss) before taxes (114,531 ) (147,692 ) (166,061 ) Theoretical group tax rate 33,33 % 33,33 % 28,00 % Nominal tax expense 38,173 49,226 46,497 Increase/decrease in tax expense arising from: Permanent differences — — — Research tax credit 2,409 3,110 3,089 Share-based compensation (11,451 ) (10,260 ) (7,253 ) Non recognition of deferred tax assets related to tax losses and temporary differences (29,195 ) (41,453 ) (54,205 ) Other differences 64 622 11,887 Effective tax expenses — — (15 ) Effective tax rate 0 % 0 % 0,01 % |
Commitments (Tables)
Commitments (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Schedule of Future Rents and Charges | The amount of future rents and charges in that capacity breaks down as follows at December 31, 2018: 12/31/2018 2019 3,965 2020 4,047 2021 4,064 2022 4,058 2023 3,785 2024 3,211 2025 1,998 2026 2,014 2027 1,700 2028 1,031 2029 393 Total 30,267 |
Relationships with Related Pa_2
Relationships with Related Parties (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Summary of Relationships with Related Parties | December 31, 2016 2017 2018 (Amounts in thousands of Euros) Corporate officers 714 745 1,496 Executive committee 2,268 2,184 3,325 Directors’ fees 195 407 469 Share-based payments to members of the Board of Directors 13,714 12,018 12,189 Total 16,891 15,353 17,478 |
Schedule of Amounts Payable to Related Parties | A schedule of amounts payable to related parties: December 31, 2016 2017 2018 (Amounts in thousands of Euros) Compensation 767 689 66 Directors’ fees 195 432 469 Pension obligations 342 402 419 Total 1,304 1,523 954 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Text block [abstract] | |
Earnings Per Share | December 31, 2016 2017 2018 (Amounts in thousands of Euros) Net income of the reporting period (114,531 ) (147,693 ) (166,076 ) Adjusted weighted average number of outstanding shares 24,454,850 24,757,176 28,924,976 Basic / Diluted earnings per share (€/share) (4.68 ) (5.97 ) (5.74 ) |
The Company - Additional Inform
The Company - Additional Information (Detail) € / shares in Units, $ / shares in Units, € in Millions, $ in Millions | Mar. 26, 2018EUR (€)shares | Mar. 26, 2018USD ($)shares | Mar. 23, 2018€ / sharesshares | Mar. 23, 2018$ / sharesshares | Mar. 21, 2018€ / shares | Mar. 21, 2018$ / shares | Jun. 21, 2016Director | Sep. 30, 2016Patient | Dec. 31, 2018shares | Dec. 31, 2017shares | Dec. 31, 2016shares |
Disclosure Of Company [Line items] | |||||||||||
Shares issued | 3,366,296 | 3,309,539 | 2,606,435 | ||||||||
Proceeds from offering of shares | € 140.8 | $ 172.5 | |||||||||
Number of directors after additions | Director | 8 | ||||||||||
Common Shares [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Underwritten ordinary shares | 3,527,752 | 3,527,752 | |||||||||
Shares issued | 208,802 | 208,802 | |||||||||
Number of additional shares issued | 529,162 | 529,162 | |||||||||
American depositary receipts [member] | Common Shares [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Shares issued | 417,604 | 417,604 | |||||||||
Exchange rate | 1.2246 | 1.2246 | 1.2246 | 1.2246 | |||||||
Public offering [member] | Common Shares [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Shares issued | 1,392,015 | 1,392,015 | |||||||||
Public offering [member] | American depositary receipts [member] | Common Shares [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Shares issued | 2,784,030 | 2,784,030 | |||||||||
Share offering price | $ / shares | $ 21.26 | $ 21.26 | |||||||||
Concurrent private placement [member] | Common Shares [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Shares issued | 2,135,737 | 2,135,737 | |||||||||
Share offering price | € / shares | € 34.71 | € 34.71 | |||||||||
Viaskin Peanut [member] | Bottom of range [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Age of patients evaluated | 4 years | ||||||||||
Viaskin Peanut [member] | Top of range [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Age of patients evaluated | 11 years | ||||||||||
Viaskin Milk [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Number of patients evaluated | Patient | 198 | ||||||||||
Viaskin Milk [member] | Bottom of range [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Age of patients evaluated | 2 years | ||||||||||
Viaskin Milk [member] | Top of range [member] | |||||||||||
Disclosure Of Company [Line items] | |||||||||||
Age of patients evaluated | 17 years |
General Information and State_2
General Information and Statement of Compliance - Additional Information (Detail) - EUR (€) € in Millions | Dec. 21, 2018 | Aug. 13, 2018 | Jul. 03, 2018 | Apr. 07, 2015 | Dec. 31, 2018 |
Top of range [member] | |||||
Disclosure of subsidiaries [line items] | |||||
Increasing amount of financial liabilities | € 25 | ||||
Bottom of range [member] | |||||
Disclosure of subsidiaries [line items] | |||||
Increasing amount of financial liabilities | € 30 | ||||
US subsidiary [member] | |||||
Disclosure of subsidiaries [line items] | |||||
Proportion of ownership interest in subsidiary | 100.00% | ||||
Australian subsidiary [member] | |||||
Disclosure of subsidiaries [line items] | |||||
Proportion of ownership interest in subsidiary | 100.00% | ||||
Canadian subsidiary [member] | |||||
Disclosure of subsidiaries [line items] | |||||
Proportion of ownership interest in subsidiary | 100.00% | ||||
French subsidiary [member] | |||||
Disclosure of subsidiaries [line items] | |||||
Proportion of ownership interest in subsidiary | 100.00% |
Accounting Principles - Additio
Accounting Principles - Additional Information (Detail) | 1 Months Ended | 12 Months Ended | |||
Jul. 31, 2016EUR (€) | Dec. 31, 2018EUR (€)HedgingInstrument | Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€) | Dec. 31, 2019EUR (€) | |
Disclosure of summary of significant accounting policies [line Items] | |||||
Number of hedging instruments held | HedgingInstrument | 0 | ||||
Research tax credit reimbursement | € 9,500,000 | € 7,300,000 | € 5,700,000 | ||
Tax credit reimbursement to be requested | € 10,800,000 | ||||
Potential development, clinical, commercial milestones payment receivable | € 100,000,000 | ||||
Non-refundable upfront payment | € 10,000,000 | ||||
Bottom of range [member] | Software [member] | |||||
Disclosure of summary of significant accounting policies [line Items] | |||||
Depreciation periods | 1 year | ||||
Top of range [member] | Software [member] | |||||
Disclosure of summary of significant accounting policies [line Items] | |||||
Depreciation periods | 3 years |
Accounting Principles - Summary
Accounting Principles - Summary of Depreciation Periods (Detail) | 12 Months Ended |
Dec. 31, 2018 | |
Fixtures and improvements in structures [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 9 years |
Research and development / production tools [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 5 years |
Research equipment and technical facilities [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 5 years |
Computer equipment [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 3 years |
Office equipment and furniture [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation periods | 5 years |
Intangible Assets - Summary of
Intangible Assets - Summary of Intangible Assets (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of detailed information about intangible assets [line items] | |||
Intangible assets other than goodwill | € 29 | € 123 | € 96 |
Total, gross [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Intangible assets other than goodwill | 905 | 864 | 572 |
Total accumulated amortization and depreciation [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Intangible assets other than goodwill | (875) | (741) | (476) |
Patents, licenses, trademarks [member] | Total, gross [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Intangible assets other than goodwill | 201 | 414 | 196 |
Patents, licenses, trademarks [member] | Total accumulated amortization and depreciation [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Intangible assets other than goodwill | (200) | (340) | (125) |
Software [member] | Total, gross [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Intangible assets other than goodwill | 703 | 450 | 376 |
Software [member] | Total accumulated amortization and depreciation [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Intangible assets other than goodwill | € (675) | € (401) | € (351) |
Intangible Assets - Additional
Intangible Assets - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2018EUR (€) | |
Disclosure of detailed information about intangible assets [abstract] | |
Impairment of assets | € 0 |
Property, Plant, and Equipmen_2
Property, Plant, and Equipment - Summary of Property, Plant, and Equipment (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | € 17,808 | € 12,482 | € 5,581 |
Increase in property, plant, and equipment | 12,162 | 5,443 | 6,901 |
Decrease in property, plant, and equipment | (9,750) | (118) | |
Property, plant, and equipment ending balance | 20,219 | 17,808 | 12,482 |
Total, gross [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 22,470 | 15,685 | 7,646 |
Increase in property, plant, and equipment | 14,520 | 7,114 | 8,039 |
Decrease in property, plant, and equipment | (9,762) | (329) | |
Property, plant, and equipment ending balance | 27,228 | 22,470 | 15,685 |
Total, gross [member] | Laboratory equipment [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 5,820 | 3,097 | 2,357 |
Increase in property, plant, and equipment | 6,305 | 2,806 | 740 |
Decrease in property, plant, and equipment | (12) | (83) | |
Property, plant, and equipment ending balance | 12,113 | 5,820 | 3,097 |
Total, gross [member] | Building fixtures [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 5,098 | 4,610 | 938 |
Increase in property, plant, and equipment | 133 | 534 | 3,672 |
Decrease in property, plant, and equipment | (46) | ||
Property, plant, and equipment ending balance | 5,231 | 5,098 | 4,610 |
Total, gross [member] | Office equipment [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 766 | 607 | 209 |
Increase in property, plant, and equipment | 25 | 275 | 398 |
Decrease in property, plant, and equipment | (116) | ||
Property, plant, and equipment ending balance | 790 | 766 | 607 |
Total, gross [member] | Computer equipment [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 1,073 | 986 | 470 |
Increase in property, plant, and equipment | 434 | 116 | 516 |
Decrease in property, plant, and equipment | (30) | ||
Property, plant, and equipment ending balance | 1,507 | 1,073 | 986 |
Total, gross [member] | Property, plant, and equipment in progress [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 9,714 | 6,385 | 3,672 |
Increase in property, plant, and equipment | 7,623 | 3,384 | 2,713 |
Decrease in property, plant, and equipment | (9,750) | (55) | |
Property, plant, and equipment ending balance | 7,587 | 9,714 | 6,385 |
Total accumulated amortization and depreciation [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 4,663 | 3,202 | 2,065 |
Increase in property, plant, and equipment | 2,358 | 1,671 | 1,137 |
Decrease in property, plant, and equipment | (12) | (211) | |
Property, plant, and equipment ending balance | 7,009 | 4,663 | 3,202 |
Total accumulated amortization and depreciation [member] | Scenario, Previously Reported [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 4,663 | ||
Property, plant, and equipment ending balance | 4,663 | ||
Total accumulated amortization and depreciation [member] | Laboratory equipment [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 2,244 | 1,505 | 948 |
Increase in property, plant, and equipment | 1,567 | 802 | 557 |
Decrease in property, plant, and equipment | (63) | ||
Property, plant, and equipment ending balance | 3,811 | 2,244 | 1,505 |
Total accumulated amortization and depreciation [member] | Building fixtures [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 1,580 | 1,109 | 782 |
Increase in property, plant, and equipment | 352 | 484 | 327 |
Decrease in property, plant, and equipment | (12) | (14) | |
Property, plant, and equipment ending balance | 1,919 | 1,580 | 1,109 |
Total accumulated amortization and depreciation [member] | Office equipment [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 320 | 212 | 131 |
Increase in property, plant, and equipment | 129 | 213 | 81 |
Decrease in property, plant, and equipment | (105) | ||
Property, plant, and equipment ending balance | 449 | 320 | 212 |
Total accumulated amortization and depreciation [member] | Computer equipment [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Property, plant, and equipment beginning balance | 520 | 377 | 205 |
Increase in property, plant, and equipment | 310 | 172 | 172 |
Decrease in property, plant, and equipment | (30) | ||
Property, plant, and equipment ending balance | € 830 | € 520 | € 377 |
Non-Current Financial Assets -
Non-Current Financial Assets - Summary of Non-Current Financial Assets (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of non financial assets. | |||
Non-current financial assets | € 6,033 | € 3,012 | € 2,745 |
Deposits [member] | |||
Disclosure of non financial assets. | |||
Non-current financial assets | 1,374 | 577 | 824 |
Pledged securities [member] | |||
Disclosure of non financial assets. | |||
Non-current financial assets | 4,226 | 1,102 | 611 |
Liquidity contract [member] | |||
Disclosure of non financial assets. | |||
Non-current financial assets | € 432 | € 1,333 | € 1,310 |
Non-Current Financial Assets _2
Non-Current Financial Assets - Additional Information (Detail) | Dec. 31, 2018shares |
Liquidity contract [member] | |
Disclosure of non financial assets. | |
Number of treasury shares | 41,159 |
Inventories and Work in Progr_3
Inventories and Work in Progress - Summary of Inventories (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2016 |
Disclosure of inventories [abstract] | ||
Inventories of raw materials | € 69 | |
Work in progress | € 2,338 | |
Allowance for inventory write-down (charged to income statement) | (772) | € (69) |
Total net value of the inventories | € 1,566 |
Inventories and Work in Progr_4
Inventories and Work in Progress - Additional Information (Detail) € in Thousands | Dec. 31, 2018EUR (€) |
Disclosure of inventories [abstract] | |
Inventories of work in progress | € 1,566 |
Customer Accounts Receivable _3
Customer Accounts Receivable and Other Current Assets - Summary of Customer Accounts Receivable and Related Receivables (Detail) - EUR (€) € in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Trade and other receivables [abstract] | ||
Accounts receivable | € 1,265 | € 1,263 |
Valuation allowance (charged to income statement) | (13) | |
Total net value of accounts receivable | € 1,265 | € 1,250 |
Customer Accounts Receivable _4
Customer Accounts Receivable and Other Current Assets - Additional Information (Detail) - EUR (€) € in Thousands | Jun. 25, 2018 | Jul. 04, 2016 | Dec. 31, 2018 | Dec. 31, 2017 |
Trade and other receivables [abstract] | ||||
Trade receivables payment terms | Less than one year | |||
Research tax credit current adjustment | € 900 | € 262 | € 113 | |
Research tax credit final reassessment received | € 58 | |||
Research tax credit current adjustment reversed | € 900 |
Customer Accounts Receivable _5
Customer Accounts Receivable and Other Current Assets - Summary of Other Current Assets (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Disclosure of accounts receivables [abstract] | ||||
Research tax credit | € 10,829 | € 9,217 | € 7,228 | € 5,702 |
Other tax claims | 4,292 | 5,258 | 2,618 | |
Other receivables | 1,745 | 1,192 | 1,883 | |
Prepaid expenses | 4,265 | 2,054 | 2,725 | |
Total | € 21,131 | € 17,721 | € 14,454 |
Customer Accounts Receivable _6
Customer Accounts Receivable and Other Current Assets - Reconciliation of Research Tax Credit (Detail) - EUR (€) € in Thousands | Jul. 04, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Trade and other receivables [abstract] | ||||
Opening balance sheet receivable | € 9,217 | € 7,228 | € 5,702 | |
+ Operating revenue | 10,829 | 9,217 | ||
+ Other income | 7,228 | |||
- Payment received | (9,479) | (7,341) | (5,702) | |
- Adjustment | € 900 | 262 | 113 | |
Closing balance sheet receivable | € 10,829 | € 9,217 | € 7,228 |
Cash and Cash Equivalents - Sum
Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Cash and cash equivalents [abstract] | ||||
Cash | € 77,236 | € 32,054 | € 146,374 | |
Cash equivalent term deposits | 45,534 | 105,826 | 110,100 | |
Total cash and cash equivalent as reported in statement of financial position | 122,770 | 137,880 | 256,473 | € 323,381 |
Bank overdrafts | 0 | 0 | 0 | |
Total net cash and cash equivalents as reported in the statement of cash flow | € 122,770 | € 137,880 | € 256,473 | € 323,381 |
Capital - Additional Informatio
Capital - Additional Information (Detail) | Mar. 23, 2018€ / sharesshares | Mar. 23, 2018$ / sharesshares | Mar. 21, 2018€ / sharesshares | Mar. 21, 2018USD ($)$ / sharesshares | Dec. 09, 2011 | Dec. 31, 2017EUR (€)shares | Dec. 31, 2016EUR (€)shares | Dec. 31, 2018EUR (€)€ / sharesshares | Mar. 26, 2018shares | Dec. 31, 2015shares |
Disclosure of classes of share capital [line items] | ||||||||||
Share Capital | € | € 2,499,000 | € 2,465,000 | € 3,016,000 | |||||||
Number of share authorised | 30,157,777 | |||||||||
Number of share issued | 30,157,777 | |||||||||
Par value per share | € / shares | € 0.10 | |||||||||
Number of shares issued during period shares | 3,309,539 | 2,606,435 | 3,366,296 | |||||||
Fees and commission expense related to share capital | € | € 0 | € 0 | ||||||||
Share split ratio | 0.0667 | |||||||||
Common Shares [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Number of share issued | 24,990,822 | 24,648,828 | 30,157,777 | 24,205,129 | ||||||
Number of shares issued during period shares | 208,802 | |||||||||
Issuances relating to underwritten global offering | 3,527,752 | 3,527,752 | ||||||||
Shares issued | 529,162 | |||||||||
Common Shares [member] | Public offering [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Number of shares issued during period shares | 1,392,015 | 1,392,015 | ||||||||
Common Shares [member] | Concurrent private placement [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Number of shares issued during period shares | 2,135,737 | 2,135,737 | ||||||||
Share offering price | € / shares | € 34.71 | € 34.71 | ||||||||
Common Shares [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Shares issued | 529,162 | 529,162 | ||||||||
American depositary receipts [member] | Common Shares [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Number of shares issued during period shares | 417,604 | |||||||||
Exchange rate | 1.2246 | 1.2246 | 1.2246 | 1.2246 | ||||||
Offering expense discount | $ | $ 0.0499 | |||||||||
American depositary receipts [member] | Common Shares [member] | Public offering [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Number of shares issued during period shares | 2,784,030 | 2,784,030 | ||||||||
Share offering price | $ / shares | $ 21.26 | $ 21.26 | ||||||||
Public offering [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Number of shares issued during period shares | 2,135,737 | 2,135,737 | ||||||||
Number of ordinary shares per american depository shares | € / shares | € 0.5 | |||||||||
Public offering [member] | Common Shares [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Number of shares issued during period shares | 1,392,015 | 1,392,015 | ||||||||
Public offering [member] | American Depositary Shares [Member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Number of shares issued during period shares | 2,784,030 | 2,784,030 | ||||||||
Concurrent private placement [member] | Common Shares [member] | ||||||||||
Disclosure of classes of share capital [line items] | ||||||||||
Issuances relating to underwritten global offering | 3,527,752 |
Capital - Summary of Historical
Capital - Summary of Historical Changes in the Share Capital of the Company (Detail) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of classes of share capital [line items] | |||
Beginning balance | € 129,923,000 | € 242,849,000 | € 322,076,000 |
Ending balance | € 121,286,000 | 129,923,000 | 242,849,000 |
Ending balance | 30,157,777 | ||
Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Beginning balance | € 2,499,000 | 2,465,000 | 2,421,000 |
Ending balance | € 3,016,000 | € 2,499,000 | € 2,465,000 |
Beginning balance | 24,990,822 | 24,648,828 | 24,205,129 |
Ending balance | 30,157,777 | 24,990,822 | 24,648,828 |
Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Beginning balance | € 406,709,000 | € 405,882,000 | € 403,910,000 |
Ending balance | 539,292,000 | 406,709,000 | 405,882,000 |
2/16/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Issue of share subscription warrants | 471,100 | ||
4/6/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 10,200 | ||
4/6/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (10,200) | ||
5/27/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 200 | ||
5/27/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 7,500 | ||
6/3/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 15,600 | ||
6/3/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | (15,600) | ||
6/6/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 6,000 | ||
6/6/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 301,200 | ||
6/10/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
6/10/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 176,000 | ||
7/18/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 2,000 | ||
7/18/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 100,700 | ||
8/4/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 1,000 | ||
8/4/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 50,400 | ||
8/24/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 700 | ||
8/24/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 37,100 | ||
8/30/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
8/30/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
8/31/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
8/31/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/1/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
9/1/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/2/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
9/2/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/5/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
9/5/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/6/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
9/6/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/6/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
9/6/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/8/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
9/8/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/9/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
9/9/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/12/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
9/12/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 66,200 | ||
9/12/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 500 | ||
9/12/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 23,100 | ||
11/25/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 600 | ||
11/25/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 30,200 | ||
1/5/2016 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 600 | ||
1/5/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 32,700 | ||
8/21/2016 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Issue of share subscription warrants | € 106,000 | ||
02/03/2017 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 2,000 | ||
02/03/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 100,700 | ||
05/16/2017 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 4,000 | ||
05/16/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 170,700 | ||
07/12/2017 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 200 | ||
07/12/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 8,300 | ||
08/04/2017 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 100 | ||
08/04/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 64,600 | ||
09/14/2017 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,600 | ||
09/14/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 208,200 | ||
Issue of share subscription warrants | 53,100 | ||
09/29/2017 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 100 | ||
09/29/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 4,000 | ||
09/30/2017 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 23,100 | ||
09/30/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (23,100) | ||
10/02/2017 [Member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 100 | ||
10/02/2017 [Member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 4,000 | ||
12/15/2017 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 1,100 | ||
12/15/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (1,100) | ||
02/09/2017 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Issue of share subscription warrants | € 237,400 | ||
Share Capital Issued On 1/8/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 700 | ||
Share Capital Issued On 1/8/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 52,300 | ||
Share capital issued on 1/9/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 500 | ||
Share capital issued on 1/9/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 25,200 | ||
Share capital issued on 1/16/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 2,000 | ||
Share capital issued on 1/16/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 100,400 | ||
Share capital issued on 1/18/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 12,900 | ||
Share capital issued on 1/18/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 963,600 | ||
Share capital issued on 1/30/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 1,300 | ||
Share capital issued on 1/30/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 97,100 | ||
Share capital issued on 1/31/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 2,000 | ||
Share capital issued on 1/31/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 149,400 | ||
Share capital issued on 2/16/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 23,800 | ||
Share capital issued on 2/16/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (23,800) | ||
Share capital issued on 3/13/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 23,800 | ||
Share capital issued on 3/13/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (23,800) | ||
Share capital issued on 3/23/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 352,800 | ||
Share capital issued on 3/23/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 122,095,500 | ||
Share capital issued on 3/26/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 52,900 | ||
Share capital issued on 3/26/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 18,314,300 | ||
Share capital issued on 4/5/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 1,200 | ||
Share capital issued on 4/5/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 91,900 | ||
Share capital issued on 4/6/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 5,800 | ||
Share capital issued on 4/6/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (5,800) | ||
Share capital issued on April six two thousand and eighteen one [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 1,400 | ||
Share capital issued on April six two thousand and eighteen one [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 105,600 | ||
Share capital issued on 4/9/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 400 | ||
Share capital issued on 4/9/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 26,600 | ||
Share capital issued on 4/16/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 800 | ||
Share capital issued on 4/16/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 88,000 | ||
Share capital issued on 7/2/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 19,300 | ||
Share capital issued on 7/2/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (19,300) | ||
Share capital issued on 8/21/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Issue of share subscription warrants | 163,700 | ||
Share capital issued on 7/5/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,300 | ||
Share capital issued on 7/5/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 164,100 | ||
Share capital issued on 7/11/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 6,400 | ||
Share capital issued on 7/11/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 478,100 | ||
Share capital issued on 8/16/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 1,000 | ||
Share capital issued on 8/16/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (1,000) | ||
Share capital issued on 9/1/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 500 | ||
Share capital issued on 9/1/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (500) | ||
Share capital issued on 12/9/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 2,000 | ||
Share capital issued on 12/9/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | (2,000) | ||
Share capital issued on 9/21/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 500 | ||
Share capital issued on 9/21/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 37,400 | ||
Share capital issued on 12/31/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Fees charged to share premium | (10,292,600) | ||
Share capital issued on 10/27/2018 [member] | Share capital [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 1,500 | ||
Share capital issued on 10/27/2018 [member] | Share premium [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | € (1,500) | ||
Common Shares [member] | |||
Disclosure of classes of share capital [line items] | |||
Beginning balance | 24,990,822 | 24,648,828 | 24,205,129 |
Ending balance | 30,157,777 | 24,990,822 | 24,648,828 |
Beginning balance, Nominal value | € 0.10 | € 0.10 | € 0.10 |
Ending balance, Nominal value | € 0.10 | € 0.10 | |
Common Shares [member] | 2/16/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Issue of share subscription warrants | 0 | ||
Issue of share subscription warrants, Nominal value | € 0.10 | ||
Common Shares [member] | 4/6/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 101,829 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | 5/27/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 1,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 6/3/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 156,000 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 6/6/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 59,890 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 6/10/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 34,985 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 7/18/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 20,010 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 8/4/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 10,020 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 8/24/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 7,380 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 8/30/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 8/31/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/1/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/2/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/5/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/6/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/6/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/8/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/9/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/12/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 9/12/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 4,590 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 11/25/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 6,000 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 1/5/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 6,495 | ||
Common Shares [member] | 8/21/2016 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Issue of share subscription warrants | 0 | ||
Common Shares [member] | 02/03/2017 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 20,010 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 05/16/2017 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 40,365 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 07/12/2017 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 1,650 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 08/04/2017 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 1,200 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 09/14/2017 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 35,925 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 09/29/2017 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 09/30/2017 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 230,843 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | 10/02/2017 [Member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | 12/15/2017 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 11,001 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | Share Capital Issued On 1/8/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 7,000 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 1/9/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 5,010 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 1/16/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 19,950 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 1/18/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 129,000 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 1/30/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 13,000 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 1/31/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 20,000 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 2/16/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 238,337 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 3/13/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 238,319 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | Share capital issued on 3/23/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,527,752 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 3/26/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 529,162 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 4/5/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 12,302 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 4/6/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 57,500 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | Share capital issued on April six two thousand and eighteen one [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 14,138 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 4/9/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 3,560 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 4/16/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 7,500 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 7/2/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 193,000 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | Share capital issued on 8/21/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Issue of share subscription warrants | 0 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 7/5/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 32,625 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 7/11/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 64,000 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | Share capital issued on 8/16/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 10,000 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | Share capital issued on 9/1/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 5,000 | ||
Capital increase by incorporation of reserve, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 12/9/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 19,800 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | Share capital issued on 9/21/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by issuance of common shares | 5,000 | ||
Capital increase by incorporation of reserve | € 0.10 | ||
Common Shares [member] | Share capital issued on 12/31/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Ending balance, Nominal value | € 0.10 | ||
Common Shares [member] | Share capital issued on 10/27/2018 [member] | |||
Disclosure of classes of share capital [line items] | |||
Capital increase by incorporation of reserve | 15,000 |
Capital - Summary of Share Warr
Capital - Summary of Share Warrants and Employee Warrants (Detail) - € / shares | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 6,819,669 | 5,388,616 | 4,275,616 |
Number of warrants null and void | 605,451 | 341,196 | 273,294 |
Number of warrants null and outstanding | 3,258,972 | 3,148,469 | 2,360,945 |
Maximum number of shares to be issued | 3,366,296 | 3,309,539 | 2,606,435 |
12/07/2007 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 1,717 | 1,717 | 1,717 |
Number of warrants null and void | 572 | 572 | 572 |
Number of warrants null and outstanding | 859 | ||
Maximum number of shares to be issued | 12,885 | ||
Strike price per share | € 4.33 | € 4.33 | € 4.33 |
1/21/2009 [Member] | BSA/BSPCE [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 16,380 | 16,380 | 16,380 |
Number of warrants null and outstanding | 2,997 | ||
Maximum number of shares to be issued | 44,955 | ||
Strike price per share | € 4.33 | € 4.33 | € 4.33 |
1/21/2009 [Member] | BSPCE [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 2,296 | 2,296 | 2,296 |
Strike price per share | € 4.33 | € 4.33 | € 4.33 |
6/25/2010 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 1,825 | 1,825 | 1,825 |
Number of warrants null and outstanding | 730 | ||
Maximum number of shares to be issued | 10,950 | ||
Strike price per share | € 4.33 | € 4.33 | € 4.33 |
1/28/2011 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 10,039 | 10,039 | 10,039 |
Number of warrants null and void | 7,529 | 7,529 | 7,529 |
Strike price per share | € 5.13 | € 5.13 | € 5.13 |
6/24/2011 [Member] | BSA/BSPCE [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 32,000 | 32,000 | 32,000 |
Number of warrants null and outstanding | 7,666 | 8,996 | 10,440 |
Maximum number of shares to be issued | 114,990 | 134,940 | 156,600 |
Strike price per share | € 5.13 | € 5.13 | € 5.13 |
11/22/2011 [Member] | BSA/BSPCE [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 11,377 | 11,377 | 11,377 |
Number of warrants null and outstanding | 2,509 | 2,509 | |
Maximum number of shares to be issued | 37,635 | 37,635 | |
Strike price per share | € 5.13 | € 5.13 | € 5.13 |
1/17/2012 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 89,835 | 89,835 | 89,835 |
Strike price per share | € 5.13 | € 5.13 | € 5.13 |
4/2/2012 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 669,796 | 669,796 | 669,796 |
Number of warrants null and void | 1,860 | 1,860 | 1,860 |
7/25/2012 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 134,081 | 134,081 | 134,081 |
9/25/2012 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 30,000 | 30,000 | 30,000 |
Number of warrants null and outstanding | 5,000 | 7,500 | 10,000 |
Maximum number of shares to be issued | 5,000 | 7,500 | 10,000 |
Strike price per share | € 8.59 | € 8.59 | € 8.59 |
11/28/2012 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 35,360 | 35,360 | 35,360 |
7/25/2013 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 73,000 | 73,000 | 73,000 |
Number of warrants null and outstanding | 7,000 | 9,500 | 13,000 |
Maximum number of shares to be issued | 7,000 | 9,500 | 13,000 |
Strike price per share | € 8.10 | € 8.10 | € 8.10 |
9/12/2013 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 501,500 | 501,500 | 501,500 |
Number of warrants null and void | 113,333 | 113,333 | 113,333 |
9/18/2013 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 518,000 | 518,000 | 518,000 |
Number of warrants null and void | 47,000 | 47,000 | 47,000 |
Number of warrants null and outstanding | 203,000 | 471,000 | 471,000 |
Maximum number of shares to be issued | 203,000 | 471,000 | 471,000 |
Strike price per share | € 7.57 | € 7.57 | € 7.57 |
6/3/2014 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 10,000 | 10,000 | 10,000 |
Number of warrants null and outstanding | 2,500 | 5,000 | |
Maximum number of shares to be issued | 2,500 | 5,000 | |
Strike price per share | € 18.79 | € 18.79 | € 18.79 |
6/3/2014 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 186,000 | 186,000 | 186,000 |
Number of warrants null and void | 30,000 | 30,000 | 30,000 |
6/3/2014 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 75,000 | 75,000 | 75,000 |
Number of warrants null and outstanding | 40,000 | 40,000 | 40,000 |
Maximum number of shares to be issued | 40,000 | 40,000 | 40,000 |
Strike price per share | € 19.01 | € 19.01 | € 19.01 |
3/24/2015 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 10,000 | 10,000 | 10,000 |
Number of warrants null and outstanding | 10,000 | 10,000 | 10,000 |
Maximum number of shares to be issued | 10,000 | 10,000 | 10,000 |
Strike price per share | € 43 | € 43 | € 43 |
6/23/2015 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 120,000 | 120,000 | 120,000 |
Number of warrants null and outstanding | 120,000 | 120,000 | 120,000 |
Maximum number of shares to be issued | 120,000 | 120,000 | 120,000 |
Strike price per share | € 48.90 | € 48.90 | € 48.90 |
9/30/2015 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 708,500 | 708,500 | 708,500 |
Number of warrants null and void | 23,000 | 23,000 | 13,000 |
Number of warrants null and outstanding | 454,657 | 695,500 | |
Maximum number of shares to be issued | 454,657 | 695,500 | |
11/19/2015 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 22,500 | 22,500 | 22,500 |
Number of warrants null and void | 7,500 | 7,500 | 7,500 |
Number of warrants null and outstanding | 15,000 | 15,000 | 15,000 |
Maximum number of shares to be issued | 15,000 | 15,000 | 15,000 |
Strike price per share | € 66.06 | € 66.06 | € 66.06 |
11/19/2015 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 195,000 | 195,000 | 195,000 |
Number of warrants null and void | 25,000 | 25,000 | 25,000 |
Number of warrants null and outstanding | 170,000 | 170,000 | 170,000 |
Maximum number of shares to be issued | 170,000 | 170,000 | 170,000 |
Strike price per share | € 66.06 | € 66.06 | € 66.06 |
12/15/2015 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 90,000 | 90,000 | 90,000 |
Number of warrants null and void | 16,500 | 16,500 | 16,500 |
Number of warrants null and outstanding | 73,500 | 73,500 | 73,500 |
Maximum number of shares to be issued | 73,500 | 73,500 | 73,500 |
Strike price per share | € 64.14 | € 64.14 | € 64.14 |
12/15/2015 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 42,000 | 42,000 | 42,000 |
Number of warrants null and void | 9,000 | 9,000 | 6,000 |
Number of warrants null and outstanding | 21,999 | 36,000 | |
Maximum number of shares to be issued | 21,999 | 36,000 | |
1/4/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 75,000 | 75,000 | 75,000 |
Number of warrants null and outstanding | 75,000 | 75,000 | 75,000 |
Maximum number of shares to be issued | 75,000 | 75,000 | 75,000 |
Strike price per share | € 65.68 | € 65.68 | € 65.68 |
4/6/2016 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 63,750 | 63,750 | 63,750 |
Number of warrants null and void | 6,250 | 6,250 | 5,000 |
Number of warrants null and outstanding | 57,500 | 58,750 | |
Maximum number of shares to be issued | 57,500 | 58,750 | |
4/21/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 33,000 | 33,000 | 33,000 |
Number of warrants null and void | 11,000 | ||
Number of warrants null and outstanding | 22,000 | 33,000 | 33,000 |
Maximum number of shares to be issued | 22,000 | 33,000 | 33,000 |
Strike price per share | € 62.82 | € 62.82 | € 62.82 |
5/2/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 22,000 | 22,000 | 22,000 |
Number of warrants null and void | 22,000 | ||
Number of warrants null and outstanding | 22,000 | 22,000 | |
Maximum number of shares to be issued | 22,000 | 22,000 | |
Strike price per share | € 59.04 | € 59.04 | € 59.04 |
6/21/2016 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 20,000 | 20,000 | 20,000 |
Number of warrants null and outstanding | 20,000 | 20,000 | 20,000 |
Maximum number of shares to be issued | 20,000 | 20,000 | 20,000 |
Strike price per share | € 52.97 | € 52.97 | € 52.97 |
6/21/2016 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 208,000 | 208,000 | 208,000 |
Number of warrants null and outstanding | 208,000 | 208,000 | |
Maximum number of shares to be issued | 208,000 | 208,000 | |
6/21/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 110,000 | 110,000 | 110,000 |
Number of warrants null and void | 21,300 | 7,500 | |
Number of warrants null and outstanding | 87,500 | 101,300 | 110,000 |
Maximum number of shares to be issued | 87,500 | 101,300 | 110,000 |
Strike price per share | € 53.96 | € 53.96 | € 53.96 |
8/1/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 10,000 | 10,000 | 10,000 |
Number of warrants null and outstanding | 10,000 | 10,000 | 10,000 |
Maximum number of shares to be issued | 10,000 | 10,000 | 10,000 |
Strike price per share | € 62.24 | € 62.24 | € 62.24 |
9/15/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 9,300 | 9,300 | 9,300 |
Number of warrants null and outstanding | 9,300 | 9,300 | 9,300 |
Maximum number of shares to be issued | 9,300 | 9,300 | 9,300 |
Strike price per share | € 62.80 | € 62.80 | € 62.80 |
10/17/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 16,500 | 16,500 | 16,500 |
Number of warrants null and void | 7,200 | 7,200 | |
Number of warrants null and outstanding | 9,300 | 9,300 | 16,500 |
Maximum number of shares to be issued | 9,300 | 9,300 | 16,500 |
Strike price per share | € 64.39 | € 64.39 | € 64.39 |
10/27/2016 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 15,000 | 15,000 | 15,000 |
Number of warrants null and outstanding | 15,000 | 15,000 | |
Maximum number of shares to be issued | 15,000 | 15,000 | |
11/15/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 8,300 | 8,300 | 8,300 |
Number of warrants null and outstanding | 8,300 | 8,300 | 8,300 |
Maximum number of shares to be issued | 8,300 | 8,300 | 8,300 |
Strike price per share | € 68.33 | € 68.33 | € 68.33 |
12/9/2016 [Member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 59,000 | 59,000 | |
Number of warrants null and void | 24,992 | 24,992 | |
Number of warrants null and outstanding | 34,008 | 34,008 | |
Maximum number of shares to be issued | 34,008 | 34,008 | |
Strike price per share | € 69.75 | € 69.75 | |
12/9/2016 [Member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 23,600 | 23,600 | 23,600 |
Number of warrants null and void | 3,800 | 1,900 | |
Number of warrants null and outstanding | 21,700 | 23,600 | |
Maximum number of shares to be issued | 21,700 | 23,600 | |
12/9/2016 [Member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 74,960 | 74,960 | 74,960 |
Number of warrants null and void | 22,965 | 2,000 | |
Number of warrants null and outstanding | 51,995 | 72,000 | 74,960 |
Maximum number of shares to be issued | 51,995 | 72,000 | 74,960 |
Strike price per share | € 69.75 | € 6,975 | € 6,975 |
9/17/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 80,900 | ||
Number of warrants null and outstanding | 80,900 | ||
Maximum number of shares to be issued | 80,900 | ||
Strike price per share | € 40.94 | ||
10/15/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 76,700 | ||
Number of warrants null and outstanding | 76,700 | ||
Maximum number of shares to be issued | 76,700 | ||
Strike price per share | € 37.28 | ||
11/1/2018 [member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 57,000 | ||
Number of warrants null and void | 10,500 | ||
Number of warrants null and outstanding | 46,500 | ||
Maximum number of shares to be issued | 46,500 | ||
11/15/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 26,000 | ||
Number of warrants null and outstanding | 26,000 | ||
Maximum number of shares to be issued | 26,000 | ||
Strike price per share | € 32.57 | ||
11/29/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 350,000 | ||
Number of warrants null and outstanding | 350,000 | ||
Maximum number of shares to be issued | 350,000 | ||
Strike price per share | € 30.02 | ||
12/12/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 34,000 | ||
Number of warrants null and outstanding | 34,000 | ||
Maximum number of shares to be issued | 34,000 | ||
Strike price per share | € 27.96 | ||
12/12/2018 one [member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 19,250 | ||
Number of warrants null and outstanding | 19,250 | ||
Maximum number of shares to be issued | 19,250 | ||
12/17/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 7,200 | ||
Number of warrants null and outstanding | 7,200 | ||
Maximum number of shares to be issued | 7,200 | ||
Strike price per share | € 26.76 | ||
12/15/2016 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 1,100 | 1,100 | |
Number of warrants null and outstanding | 1,100 | 1,100 | |
Maximum number of shares to be issued | 1,100 | 1,100 | |
Strike price per share | € 69.35 | € 69.35 | |
1/16/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 19,100 | 19,100 | |
Number of warrants null and outstanding | 19,100 | 19,100 | |
Maximum number of shares to be issued | 19,100 | 19,100 | |
Strike price per share | € 66.11 | € 66.11 | |
3/14/2017 [member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 22,500 | 22,500 | |
Number of warrants null and void | 5,500 | 2,500 | |
Number of warrants null and outstanding | 17,000 | 20,000 | |
Maximum number of shares to be issued | 17,000 | 20,000 | |
3/17/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 7,200 | ||
Number of warrants null and outstanding | 7,200 | ||
Maximum number of shares to be issued | 7,200 | ||
Strike price per share | € 66.25 | ||
4/18/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 16,500 | 16,500 | |
Number of warrants null and void | 9,300 | ||
Number of warrants null and outstanding | 7,200 | 16,500 | |
Maximum number of shares to be issued | 7,200 | 16,500 | |
Strike price per share | € 60.77 | € 60.77 | |
4/22/2017 [member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 24,000 | 24,000 | |
Number of warrants null and outstanding | 24,000 | 24,000 | |
Maximum number of shares to be issued | 24,000 | 24,000 | |
6/15/2017 [member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 9,000 | 9,000 | |
Number of warrants null and outstanding | 9,000 | 9,000 | |
Maximum number of shares to be issued | 9,000 | 9,000 | |
Strike price per share | € 59.05 | € 59.05 | |
6/15/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 126,000 | 126,000 | |
Number of warrants null and void | 35,000 | 7,500 | |
Number of warrants null and outstanding | 91,000 | 118,500 | |
Maximum number of shares to be issued | 91,000 | 118,500 | |
Strike price per share | € 59.05 | € 59.05 | |
6/15/2017 [member] | Share Option [member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 111,600 | 111,600 | |
Number of warrants null and outstanding | 111,600 | 111,600 | |
Maximum number of shares to be issued | 111,600 | 111,600 | |
Strike price per share | € 60.54 | € 60.54 | |
7/17/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 30,900 | 30,900 | |
Number of warrants null and void | 23,700 | ||
Number of warrants null and outstanding | 7,200 | 30,900 | |
Maximum number of shares to be issued | 7,200 | 30,900 | |
Strike price per share | € 71.61 | € 71.61 | |
9/15/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 52,600 | 52,600 | |
Number of warrants null and void | 7,200 | ||
Number of warrants null and outstanding | 45,400 | 52,600 | |
Maximum number of shares to be issued | 45,400 | 52,600 | |
Strike price per share | € 74.22 | € 74.22 | |
12/5/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 625,200 | 625,200 | |
Number of warrants null and void | 85,125 | ||
Number of warrants null and outstanding | 540,075 | 625,200 | |
Maximum number of shares to be issued | 540,075 | 625,200 | |
Strike price per share | € 39 | € 39 | |
12/15/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 8,300 | 8,300 | |
Number of warrants null and outstanding | 8,300 | 8,300 | |
Maximum number of shares to be issued | 8,300 | 8,300 | |
Strike price per share | € 38.18 | € 38.08 | |
1/15/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 15,500 | ||
Number of warrants null and void | 7,200 | ||
Number of warrants null and outstanding | 8,300 | ||
Maximum number of shares to be issued | 8,300 | ||
Strike price per share | € 43.60 | ||
4/16/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 16,500 | ||
Number of warrants null and outstanding | 16,500 | ||
Maximum number of shares to be issued | 16,500 | ||
Strike price per share | € 38.64 | ||
5/16/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 16,500 | ||
Number of warrants null and outstanding | 16,500 | ||
Maximum number of shares to be issued | 16,500 | ||
Strike price per share | € 40.84 | ||
6/15/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 23,600 | ||
Number of warrants null and outstanding | 23,600 | ||
Maximum number of shares to be issued | 23,600 | ||
Strike price per share | € 38.92 | ||
6/22/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 50,000 | ||
Number of warrants null and outstanding | 50,000 | ||
Maximum number of shares to be issued | 50,000 | ||
Strike price per share | € 37.22 | ||
6/22/2018 [member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 486,153 | ||
Number of warrants null and void | 21,125 | ||
Number of warrants null and outstanding | 465,028 | ||
Maximum number of shares to be issued | 465,028 | ||
7/2/2018 [member] | BSA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 44,000 | ||
Number of warrants null and outstanding | 44,000 | ||
Maximum number of shares to be issued | 44,000 | ||
Strike price per share | € 37.24 | ||
7/16/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 28,800 | ||
Number of warrants null and outstanding | 28,800 | ||
Maximum number of shares to be issued | 28,800 | ||
Strike price per share | € 33.81 | ||
8/15/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 33,500 | ||
Number of warrants null and outstanding | 33,500 | ||
Maximum number of shares to be issued | 33,500 | ||
Strike price per share | € 32.90 | ||
9/6/2018 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 65,000 | ||
Number of warrants null and outstanding | 65,000 | ||
Maximum number of shares to be issued | 65,000 | ||
Strike price per share | € 36.96 | ||
6/9/2018 [member] | AGA [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 450 | ||
Number of warrants null and outstanding | 450 | ||
Maximum number of shares to be issued | 450 | ||
3/15/2017 [member] | SO [Member] | |||
Disclosure of classes of share capital [line items] | |||
Number of warrants issued | 7,200 | ||
Number of warrants null and outstanding | 7,200 | ||
Maximum number of shares to be issued | 7,200 | ||
Strike price per share | € 66.25 |
Financial and Other Non-Curre_3
Financial and Other Non-Current Liabilities - Additional Information (Detail) | Jun. 30, 2024EUR (€) | Jun. 30, 2023EUR (€) | Jun. 30, 2022EUR (€) | Jun. 30, 2021EUR (€) | Jun. 30, 2017EUR (€) | Sep. 30, 2015EUR (€) | Jan. 22, 2015EUR (€) | Sep. 30, 2014EUR (€) | Apr. 30, 2018EUR (€) | Oct. 31, 2015EUR (€) | Oct. 31, 2014EUR (€) | Apr. 30, 2013EUR (€) | Dec. 31, 2018EUR (€)Contracts | Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€)Installments | Dec. 31, 2014EUR (€) | Dec. 31, 2013EUR (€) | Dec. 31, 2011EUR (€) | Dec. 31, 2015EUR (€) |
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Advances repayable at nominal value | 100.00% | ||||||||||||||||||
Number of advance contracts | Contracts | 2 | ||||||||||||||||||
Income earned on termination of contract | € 146,000 | ||||||||||||||||||
Cash collected from conditional advance | € 0 | € 0 | 0 | ||||||||||||||||
Repayment of conditional advance | 1,800,000 | 578,000 | 275,000 | ||||||||||||||||
Borrowings repaid | € 256,000 | ||||||||||||||||||
Number of installment payments | Installments | 4 | ||||||||||||||||||
Installment payment start date | Sep. 30, 2014 | ||||||||||||||||||
Borrowings paid in installments | € 64,000 | ||||||||||||||||||
Borrowings | 2,479,000 | 4,150,000 | 4,628,000 | € 4,809,000 | |||||||||||||||
Non-current part of deferred revenue | 6,500,000 | ||||||||||||||||||
3rd OSEO contract [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Cash collected from conditional advance | 0 | 0 | 0 | € 128,000 | € 256,000 | € 256,000 | |||||||||||||
Repayment of conditional advance | 64,000 | 128,000 | 128,000 | ||||||||||||||||
Borrowings | 64,000 | 192,000 | 318,000 | ||||||||||||||||
3rd OSEO contract [member] | Top of range [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Cash collected from conditional advance | € 640,000 | ||||||||||||||||||
Cash collected from conditional advance | 0 | 0 | 0 | ||||||||||||||||
Repayment of conditional advance | € 32,000 | € 64,000 | |||||||||||||||||
4th OSEO contract [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Cash collected from conditional advance | € 864,989 | € 481,162 | € 918,000 | € 903,500 | € 903,500 | 0 | 0 | 0 | |||||||||||
Repayment of conditional advance | 1,136,000 | ||||||||||||||||||
Borrowings | € 624,000 | € 1,700,000 | € 1,684,000 | € 1,669,000 | |||||||||||||||
Annual interest rate on advance | 2.05% | 2.05% | 2.05% | 2.05% | |||||||||||||||
Conditional advance, including interest to be paid | € 3,750,000 | ||||||||||||||||||
4th OSEO contract [member] | Collaborative research and clinical development [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Cash collected from conditional advance | € 3,206,162 | ||||||||||||||||||
4th OSEO contract [member] | Top of range [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Cash collected from conditional advance | € 0 | € 0 | € 0 | ||||||||||||||||
4th OSEO contract [member] | Top of range [member] | Scenario Forecast [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Repayment of conditional advance | € 1,450,000 | € 1,100,000 | € 800,000 | € 400,000 | |||||||||||||||
BPI advance [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Cash collected from conditional advance | € 3,000,000 | ||||||||||||||||||
Cash collected from conditional advance | 0 | 0 | 0 | ||||||||||||||||
Repayment of conditional advance | € 150,000 | 600,000 | 450,000 | ||||||||||||||||
Borrowings | 1,854,000 | 2,386,000 | 2,751,000 | 2,666,000 | |||||||||||||||
Number of quarterly repayments | 20 | ||||||||||||||||||
BPI advance [member] | Top of range [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Cash collected from conditional advance | € 0 | 0 | 0 | ||||||||||||||||
COFACE [member] | |||||||||||||||||||
Disclosure of Detailed Information About Financial Instruments [line items] | |||||||||||||||||||
Income earned on termination of contract | 146,000 | ||||||||||||||||||
Cash collected from conditional advance | € 147,000 | ||||||||||||||||||
Cash collected from conditional advance | 0 | ||||||||||||||||||
Repayment of conditional advance | € 147,000 | ||||||||||||||||||
Borrowings | € 156,000 | ||||||||||||||||||
Proportion of revenue to be paid in advance by the company | 7.00% | ||||||||||||||||||
Agreement termination date | Dec. 31, 2016 |
Financial and Other Non-Curre_4
Financial and Other Non-Current Liabilities - Summary of Debt Recorded on Statement of Financial Position (Detail) (Detail) - EUR (€) | Jun. 30, 2017 | Sep. 30, 2015 | Jan. 22, 2015 | Sep. 30, 2014 | Apr. 30, 2018 | Oct. 31, 2015 | Oct. 31, 2014 | Apr. 30, 2013 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2015 |
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Beginning balance | € 4,150,000 | € 4,628,000 | € 4,809,000 | ||||||||||||
Receipts | 0 | 0 | 0 | ||||||||||||
Repayments | (1,800,000) | (578,000) | (275,000) | ||||||||||||
Other transactions | 129,000 | 101,000 | 95,000 | ||||||||||||
Ending balance | 2,479,000 | 4,150,000 | 4,628,000 | ||||||||||||
Of which - Non-current portion | 1,278,000 | 1,825,000 | 4,049,000 | ||||||||||||
Of which - Current portion | 1,201,000 | 2,325,000 | 578,000 | ||||||||||||
3rd OSEO contract [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Beginning balance | 64,000 | 192,000 | 318,000 | ||||||||||||
Receipts | 0 | 0 | 0 | € 128,000 | € 256,000 | € 256,000 | |||||||||
Repayments | (64,000) | (128,000) | (128,000) | ||||||||||||
Other transactions | 1,000 | 2,000 | |||||||||||||
Ending balance | 64,000 | 192,000 | |||||||||||||
4th OSEO contract [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Beginning balance | 1,700,000 | 1,684,000 | 1,669,000 | ||||||||||||
Receipts | € 864,989 | € 481,162 | € 918,000 | € 903,500 | € 903,500 | 0 | 0 | 0 | |||||||
Repayments | (1,136,000) | ||||||||||||||
Other transactions | 60,000 | 16,000 | 16,000 | ||||||||||||
Ending balance | € 624,000 | € 1,700,000 | € 1,684,000 | ||||||||||||
Stated interest rate | 2.05% | 2.05% | 2.05% | 2.05% | |||||||||||
BPI advance [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Beginning balance | € 2,386,000 | € 2,751,000 | € 2,666,000 | ||||||||||||
Receipts | 0 | 0 | 0 | ||||||||||||
Repayments | € (150,000) | (600,000) | (450,000) | ||||||||||||
Other transactions | 69,000 | 84,000 | 85,000 | ||||||||||||
Ending balance | € 1,854,000 | € 2,386,000 | € 2,751,000 | ||||||||||||
Discount rate | 3.20% | 3.20% | 3.20% | ||||||||||||
COFACE [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Beginning balance | € 156,000 | ||||||||||||||
Receipts | 0 | ||||||||||||||
Repayments | (147,000) | ||||||||||||||
Other transactions | € (9,000) | ||||||||||||||
Discount rate | 4.25% | ||||||||||||||
Maturity (in years) | 0 | ||||||||||||||
Bottom of range [member] | 3rd OSEO contract [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Receipts | € 0 | € 0 | € 0 | ||||||||||||
Discount rate | 0.40% | 0.40% | 0.40% | ||||||||||||
Maturity (in years) | 0 | 0 | 0 | ||||||||||||
Bottom of range [member] | 4th OSEO contract [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Receipts | € 0 | € 0 | € 0 | ||||||||||||
Discount rate | 1.50% | 1.50% | 1.50% | ||||||||||||
Maturity (in years) | 7 | 7 | 7 | ||||||||||||
Bottom of range [member] | BPI advance [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Receipts | € 0 | € 0 | € 0 | ||||||||||||
Maturity (in years) | 2 | 2 | 2 | ||||||||||||
Top of range [member] | 3rd OSEO contract [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Receipts | € 0 | € 0 | € 0 | ||||||||||||
Repayments | € (32,000) | € (64,000) | |||||||||||||
Discount rate | 1.90% | 1.90% | 1.90% | ||||||||||||
Maturity (in years) | 3 | 3 | 3 | ||||||||||||
Top of range [member] | 4th OSEO contract [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Receipts | € 0 | € 0 | € 0 | ||||||||||||
Discount rate | 1.80% | 1.80% | 1.80% | ||||||||||||
Maturity (in years) | 9 | 9 | 9 | ||||||||||||
Top of range [member] | BPI advance [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Receipts | € 0 | € 0 | € 0 | ||||||||||||
Maturity (in years) | 7 | 7 | 7 | ||||||||||||
Scenario, Previously Reported [member] | |||||||||||||||
Disclosure of detailed information about borrowings [line items] | |||||||||||||||
Beginning balance | € 4,150,000 | € 4,627,000 | |||||||||||||
Ending balance | € 4,150,000 | € 4,627,000 |
Financial and Other Non-Curre_5
Financial and Other Non-Current Liabilities - Summary of Due Dates of the Financial Liabilities (Detail) - EUR (€) | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of financial liabilities [line items] | |||
Non-current conditional advances | € 1,278,000 | € 1,825,000 | € 4,049,000 |
Current conditional advances | 1,201,000 | 2,325,000 | 578,000 |
Supplier accounts payable and related payables | 0 | ||
Not later than one year [member] | |||
Disclosure of financial liabilities [line items] | |||
Non-current financial rent debts | 0 | 0 | 0 |
Current conditional advances | 1,201,000 | 2,325,000 | 578,000 |
Current financial rent debts | 12,000 | ||
Other current liabilities | 12,506,000 | 15,751,000 | 14,692,000 |
Supplier accounts payable and related payables | 28,567,000 | 16,941,000 | 13,720,000 |
Total financial liabilities | 42,273,000 | 35,017,000 | 29,003,000 |
Later than one year and not later than five years [member] | |||
Disclosure of financial liabilities [line items] | |||
Non-current conditional advances | 1,278,000 | 1,825,000 | 2,531,000 |
Non-current financial rent debts | 0 | 0 | 0 |
Other non-current liabilities | 3,991,000 | 8,421,000 | 10,370,000 |
Total financial liabilities | 5,269,000 | 10,246,000 | 12,900,000 |
More than five years [member] | |||
Disclosure of financial liabilities [line items] | |||
Non-current conditional advances | 1,518,000 | ||
Non-current financial rent debts | 0 | 0 | 0 |
Other non-current liabilities | 114,000 | 448,000 | 377,000 |
Total financial liabilities | 114,000 | 448,000 | 1,895,000 |
Total, gross [member] | |||
Disclosure of financial liabilities [line items] | |||
Non-current conditional advances | 1,278,000 | 1,825,000 | 4,049,000 |
Non-current financial rent debts | 0 | 0 | 0 |
Other non-current liabilities | 4,105,000 | 8,869,000 | 10,746,000 |
Current conditional advances | 1,201,000 | 2,325,000 | 578,000 |
Current financial rent debts | 12,000 | ||
Other current liabilities | 12,506,000 | 15,751,000 | 14,692,000 |
Supplier accounts payable and related payables | 28,567,000 | 16,941,000 | 13,720,000 |
Total financial liabilities | € 47,657,000 | € 45,711,000 | € 43,798,000 |
Non-Current Provisions - Schedu
Non-Current Provisions - Schedule of Non-Current Provisions (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Disclosure of other provisions [abstract] | ||||
Pension retirement obligations | € 1,536 | € 1,260 | € 853 | |
Total | € 1,536 | € 1,260 | € 853 | € 490 |
Non-Current Provisions - Sche_2
Non-Current Provisions - Schedule of Commitments for Compensation Payable to Employees Upon Their Retirement (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of Retirement Benefits [abstract] | |||
Beginning balance | € (1,260) | € (853) | € (490) |
Costs of services rendered (operating expense) | (412) | (219) | (104) |
Interest expense (financial expense) | (24) | (11) | (10) |
Benefit paid | 141 | ||
Actuarial losses | 19 | (177) | (249) |
Ending balance | € (1,536) | € (1,260) | € (853) |
Non-Current Provisions - Sche_3
Non-Current Provisions - Schedule of Retirement Commitments (Detail) | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of sensitivity analysis for actuarial assumptions [abstract] | |||
% social security contributions | 50.00% | 50.00% | 50.00% |
Salary increases | 2.00% | 2.00% | 2.00% |
Discount rate | 1.57% | 1.30% | 1.31% |
Non-Current Provisions - Additi
Non-Current Provisions - Additional Information (Detail) - yr | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure Of Noncurrent Provisions [abstract] | |||
Retirement age of employee | 65 | 65 | 65 |
Supplier Accounts Receivable _3
Supplier Accounts Receivable and Other Current Liabilities - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2018EUR (€) | |
Disclosure Of Supplier Accounts And Other Current Liabilities [abstract] | |
Supplier accounts payable and related payables | € 0 |
Supplier accounts and related payables term | 1 year |
Supplier Accounts Receivable _4
Supplier Accounts Receivable and Other Current Liabilities - Schedule of Other Current Liabilities (Details) (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure Of Supplier Accounts And Other Current Liabilities [abstract] | |||
Social security | € 6,343 | € 12,094 | € 10,794 |
Tax liabilities | 448 | 428 | 504 |
Other debts | 1,354 | 440 | 146 |
Deferred revenues | 4,360 | 2,789 | 3,248 |
Total | € 12,506 | € 15,751 | € 14,692 |
Financial Instruments Recogni_3
Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) - Schedule of Financial Instruments Recognized in the Consolidated Statements of Financial Position and Related Effect on the Consolidated Statements of (Loss) (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | € 129,715 | € 142,534 | € 260,985 |
Financial liabilities | 47,656 | 45,711 | 43,798 |
Long-term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,278 | 1,825 | 4,049 |
Other long term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 4,105 | 8,869 | 10,746 |
Short term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,201 | 2,325 | 578 |
Short term financial rent debt [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 12 | ||
Other short term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 12,506 | 15,751 | 14,692 |
Account payable and other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 28,567 | 16,941 | 13,720 |
Carrying amount [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 47,656 | 45,711 | 43,798 |
Carrying amount [member] | Long-term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,278 | 1,825 | 4,049 |
Carrying amount [member] | Other long term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 4,105 | 8,869 | 10,746 |
Carrying amount [member] | Short term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,201 | 2,325 | 578 |
Carrying amount [member] | Short term financial rent debt [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 12 | ||
Carrying amount [member] | Other short term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 12,506 | 15,751 | 14,692 |
Carrying amount [member] | Account payable and other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 28,567 | 16,941 | 13,720 |
Financial liabilities at amortised cost, category [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 45,711 | 43,798 | |
Financial liabilities at amortised cost, category [member] | Long-term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,825 | 4,049 | |
Financial liabilities at amortised cost, category [member] | Other long term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 8,869 | 10,746 | |
Financial liabilities at amortised cost, category [member] | Short term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 2,325 | 578 | |
Financial liabilities at amortised cost, category [member] | Short term financial rent debt [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 12 | ||
Financial liabilities at amortised cost, category [member] | Other short term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 15,751 | 14,692 | |
Financial liabilities at amortised cost, category [member] | Account payable and other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 16,941 | 13,720 | |
Non-derivative Financial Liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 47,656 | ||
Non-derivative Financial Liabilities [member] | Long-term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,278 | ||
Non-derivative Financial Liabilities [member] | Other long term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 4,105 | ||
Non-derivative Financial Liabilities [member] | Short term conditional advances [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 1,201 | ||
Non-derivative Financial Liabilities [member] | Other short term liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 12,506 | ||
Non-derivative Financial Liabilities [member] | Account payable and other liabilities [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial liabilities | 28,567 | ||
Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 6,033 | 3,012 | 2,745 |
Customer accounts receivables and related receivables [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 1,265 | 1,250 | |
Other current financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 912 | 378 | 516 |
Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets, fair value | 122,770 | 137,880 | 256,473 |
Carrying amount [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 129,715 | 142,534 | 260,985 |
Carrying amount [member] | Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 6,033 | 3,012 | 2,745 |
Carrying amount [member] | Customer accounts receivables and related receivables [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,265 | 1,250 | |
Carrying amount [member] | Other current financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 912 | 378 | 516 |
Carrying amount [member] | Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 122,770 | 137,880 | 256,473 |
Fair value through Consolidated Statements of (Loss) [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 432 | 139,213 | 257,783 |
Fair value through Consolidated Statements of (Loss) [member] | Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 432 | 1,333 | 1,310 |
Fair value through Consolidated Statements of (Loss) [member] | Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 137,880 | 256,473 | |
Loans and receivables, category [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 3,321 | 3,202 | |
Loans and receivables, category [member] | Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,679 | 1,435 | |
Loans and receivables, category [member] | Customer accounts receivables and related receivables [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 1,265 | 1,250 | |
Loans and receivables, category [member] | Other current financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | € 378 | € 516 | |
Financial assets at amortised cost, class [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 129,283 | ||
Financial assets at amortised cost, class [member] | Long-term financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 5,601 | ||
Financial assets at amortised cost, class [member] | Other current financial assets [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | 912 | ||
Financial assets at amortised cost, class [member] | Cash and cash equivalent [member] | |||
Disclosure of Detailed Information About Financial Instruments [line items] | |||
Financial assets | € 122,770 |
Operating Income - Summary of O
Operating Income - Summary of Operating Income (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Analysis of income and expense [abstract] | |||
Revenues | € 14,537 | € 11,909 | € 9,084 |
Research tax credit | 11,034 | 9,330 | 7,228 |
Subsidies | 152 | 271 | 303 |
Other operating income | 3,351 | 2,308 | 1,554 |
Total income | € 14,537 | € 11,909 | € 9,084 |
Operating Expenses - Summary of
Operating Expenses - Summary of Research and Development (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of Other Operating Expense [abstract] | |||
Personnel expenses | € 37,912 | € 37,112 | € 32,777 |
Sub-contracting,collaboration, and consultants | 52,927 | 54,397 | 34,413 |
Small equipments and other supplies | 4,771 | 4,110 | 3,909 |
Rental | 2,703 | 2,018 | 1,903 |
Conferences, travel expenses | 2,591 | 2,807 | 2,387 |
Depreciation and amortization | 2,492 | 2,424 | 1,141 |
Others | 3,776 | 2,364 | 2,298 |
Total research and development expenses | € 107,171 | € 105,232 | € 78,828 |
Operating Expenses - Summary _2
Operating Expenses - Summary of Sales and Marketing Expenses (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of sales and marketing expense [abstract] | |||
Personnel expenses | € 12,553 | € 6,976 | € 4,954 |
Fees | 5,148 | 2,480 | 4,447 |
Communication and travel expenses | 14,021 | 5,984 | 1,393 |
Others | 446 | 384 | 487 |
Total sales and marketing expenses | € 32,169 | € 15,824 | € 11,282 |
Operating Expenses - Summary _3
Operating Expenses - Summary of General and Administrative Expenses (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure Of General And Administrative Expense [abstract] | |||
Personnel expenses | € 19,101 | € 19,742 | € 22,613 |
Fees | 12,718 | 10,347 | 7,701 |
Rental | 911 | 584 | 501 |
Insurance policies | 1,930 | 1,367 | 1,853 |
Communication and travel expenses | 1,576 | 1,599 | 1,136 |
Depreciation and amortization | 1,720 | 422 | 181 |
Others | 3,442 | 1,776 | 1,020 |
Total general and administrative expenses | € 41,399 | € 35,837 | € 35,005 |
Operating Expenses - Additional
Operating Expenses - Additional Information (Detail) - Employees | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of personnel expense [abstract] | |||
Number of employees | 315 | 242 | 164 |
Operating Expenses - Summary _4
Operating Expenses - Summary of Personnel Expenses (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of personnel expense [abstract] | |||
Wages and salaries | € 31,684 | € 22,451 | € 14,651 |
Social security contributions | 8,858 | 7,157 | 3,903 |
Expenses for pension commitments | 2,095 | 1,583 | 982 |
Employer contribution to bonus shares | 1,026 | 1,857 | 6,456 |
Share-based payments | 25,904 | 30,781 | 34,353 |
Total | € 69,567 | € 63,830 | € 60,345 |
Share-Based Payments - Addition
Share-Based Payments - Additional Information (Detail) | Jun. 22, 2018shares | Jun. 15, 2018 | Jun. 02, 2018shares | May 15, 2018 | May 02, 2018 | Apr. 15, 2018 | Dec. 31, 2017shares | Dec. 15, 2017 | Jun. 15, 2017shares | Dec. 15, 2016 | Dec. 09, 2016 | Jun. 24, 2016 | Jun. 21, 2016shares | Apr. 06, 2016 | Jan. 17, 2016 | Dec. 15, 2015 | Nov. 19, 2015 | Sep. 30, 2015 | Sep. 21, 2015 | Jun. 23, 2015shares | Mar. 24, 2015 | Dec. 23, 2014Equity | Jun. 03, 2014shares | Dec. 23, 2013Equity | Sep. 18, 2013 | Jul. 25, 2013 | Jun. 04, 2013shares | Dec. 23, 2012Equity | Sep. 25, 2012 | Jan. 17, 2012 | Dec. 23, 2011Equity | Dec. 09, 2011shares | Nov. 22, 2011 | Jun. 24, 2011 | Jan. 28, 2011 | Dec. 16, 2010shares | Jun. 25, 2010 | Jan. 21, 2009shares | Dec. 07, 2007 | Jun. 14, 2007shares | Dec. 15, 2016 | Sep. 30, 2016 | Jun. 30, 2018shares | Jan. 20, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Nov. 22, 2015Equity | Nov. 22, 2014Equity | Nov. 22, 2013Equity | Nov. 22, 2012Equity |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 23,600 | 16,500 | 16,500 | ||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 181,008 | 217,508 | 181,008 | 147,359 | |||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 25, 2010 | Jan. 21, 2009 | |||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | P10Y | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 1,036 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 1 year | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 2 years | 2 years | |||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 3 years | 3 years | |||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 4 years | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCEX [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 2,296 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 9,000 | 54,008 | 88,500 | 20,000 | 73,000 | 194,552 | 194,552 | 194,552 | |||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 7,500 | 9,359 | 89,835 | ||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 7, 2007 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Share-based Payment Arrangement Tranche Three [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 3 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Share-based Payment Arrangement Tranche Four [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Share-based Payment Arrangement Tranche One [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Share-based Payment Arrangement Tranche Two [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 2 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Share-based Payment Arrangement Tranche Three [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Share-based Payment Arrangement Tranche Four [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Share-based Payment Arrangement Tranche One [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Share-based Payment Arrangement Tranche Two [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jan. 17, 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Share-based Payment Arrangement Tranche Three [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 3 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Share-based Payment Arrangement Tranche Four [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Share-based Payment Arrangement Tranche One [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Share-based Payment Arrangement Tranche Two [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 2 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 89,835 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Sep. 25, 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Three [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 3 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Four [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 4 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche One [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Two [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 2 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 7/25/2013 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jul. 25, 2013 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 0 years | 10 years | |||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 7/25/2013 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 73,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 6/3/2014 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 3, 2014 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 0 years | 10 years | |||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 6/3/2014 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 03/24/2015 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Mar. 24, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 03/24/2015 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 11/19/2015 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Nov. 19, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/15/2015 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 15, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 73,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 06/21/2016 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 21, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 06/21/2016 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/9/2016 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 9, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 12/9/2016 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 34,008 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 06/15/2017 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 15, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Date of Grant 06/15/2017 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 9,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Grant Date 5/2/2018 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | May 2, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Grant Date 5/2/2018 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 44,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA 2 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 10,716 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Bons De Createurs D Entreprise Bce Four [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 5,358 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA 2010 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 19,377 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSAX [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 2,131 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSPCE2010 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 34,039 | ||||||||||||||||||||||||||||||||||||||||||||||||||
OPTIONS 2013 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 518,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Free shares [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 562,853 | 241,844 | 186,000 | 1,340,737 | |||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 1,107,350 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Options [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payment arrangement shares issued on authorization | 752,100 | 900,700 | 918,960 | 72,100 | |||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 2,691 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 2,411 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 0 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 1,340 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 536 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 2 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 536 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 3 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 2,411 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Top of range [member] | First Anniversary [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 1,340 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Top of range [member] | Second Anniversary [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 536 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Top of range [member] | Third Anniversary [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 536 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE 4 [member] | Top of range [member] | Fourth Anniversary [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 535 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA [member] | Bottom of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jan. 28, 2011 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | Equity | 2,509 | 2,510 | 2,510 | 2,510 | 334 | 334 | 335 | 335 | |||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | 25.00% | 25.00% | 25.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 110 | 434 | |||||||||||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 335 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 77 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 335 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 77 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 334 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 77 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 334 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 77 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | Date of Grant 12/9/2016 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 59,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 69.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BSA2010 [member] | Date of Grant 06/15/2017 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 9,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 59.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 3,839 | 1,334 | 3,635 | ||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 11,005 | 7,166 | 11,005 | 12,339 | |||||||||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 24, 2011 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before the 09/30/2025 | At the latest within before the 11/22/2021 | |||||||||||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before the 12/15/2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||
BCE2010 [member] | Date of Grant 1/17/2012 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Sep. 18, 2013 | Nov. 22, 2011 | |||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Number of options granted | 824,200 | 998,500 | 359,060 | ||||||||||||||||||||||||||||||||||||||||||||||||
Basis of exercise by beneficiary | 755,650 | 847,464 | 755,650 | 85,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 268,000 | 1,200 | 35,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/7/2007 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 3, 2014 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before the 06/03/2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/7/2007 [member] | Top of range [member] | Share-based Payment Arrangement Tranche Four [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 75,000 | 518,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 23, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before the 06/24/2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 9/25/2012 [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 7/25/2013 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Sep. 30, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 195,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 6/3/2014 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Apr. 6, 2016 | Dec. 15, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 03/24/2015 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | At the latest before 10 years of the date of the Grant | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 55,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Jun. 21, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | 10 years | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 1,100 | 154,100 | |||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | ||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | ||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | ||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | Dec. 9, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, vesting period | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 74,960 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 18,740 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 9,370 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Date of Grant 06/21/2016 [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Date of grant (Board of Directors) | 12/15/2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six A [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 8,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six A [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 8,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six A [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 8,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six A [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 8,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | Top of range [member] | Not later than one year [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 5,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | Top of range [member] | Later Than One Year and Not Later Than Two Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 5,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | Top of range [member] | Later Than Two Years and Not Later Than Three Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 5,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Share Option [member] | Grant Date Six B [member] | Top of range [member] | Later Than Three Years and Not Later Than Four Years [member] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||||||||||||||
Share based payment arrangement, shares exercised | 5,500 |
Share-Based Payments - Summary
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BSA (Detail) | Nov. 19, 2025EUR (€)€ / shares | Mar. 24, 2025EUR (€)€ / shares | Jun. 15, 2018 | May 15, 2018 | May 02, 2018EUR (€)€ / sharesshares | Apr. 15, 2018 | Jun. 15, 2017EUR (€)€ / sharesshares | Dec. 09, 2016EUR (€)€ / sharesshares | Jun. 21, 2016EUR (€)€ / shares | Dec. 15, 2015EUR (€)€ / shares | Jun. 03, 2014EUR (€)€ / shares | Jul. 25, 2013EUR (€)€ / shares | Sep. 25, 2012EUR (€)€ / shares | Jan. 17, 2012EUR (€)€ / shares | Dec. 07, 2007EUR (€)€ / shares | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Number of options granted | 23,600 | 16,500 | 16,500 | |||||||||||||||
BSA [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Number of BSA granted | 44,000 | 68,000 | 93,500 | |||||||||||||||
Exercise price (in euros) | 7,500 | 9,359 | 89,835 | |||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche One [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||
Plan expiration date | Sep. 25, 2022 | |||||||||||||||||
Number of BSA granted | 7,500 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 8.59 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 5.5 | |||||||||||||||||
Discount rate | 1.21% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.29 | |||||||||||||||||
Grant date share fair value (in euros) | € 8.40 | |||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Two [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 2 years | |||||||||||||||||
Plan expiration date | Sep. 25, 2022 | |||||||||||||||||
Number of BSA granted | 7,500 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 8.59 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 6 | |||||||||||||||||
Discount rate | 1.21% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.43 | |||||||||||||||||
Grant date share fair value (in euros) | € 8.40 | |||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Three [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||
Plan expiration date | Sep. 25, 2022 | |||||||||||||||||
Number of BSA granted | 7,500 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 8.59 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 6.5 | |||||||||||||||||
Discount rate | 1.53% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.61 | |||||||||||||||||
Grant date share fair value (in euros) | € 8.40 | |||||||||||||||||
BSA [member] | Date of Grant 9/25/2012 [member] | Share-based Payment Arrangement Tranche Four [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 4 years | |||||||||||||||||
Plan expiration date | Sep. 25, 2022 | |||||||||||||||||
Number of BSA granted | 7,500 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 8.59 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 7 | |||||||||||||||||
Discount rate | 1.53% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.74 | |||||||||||||||||
Grant date share fair value (in euros) | € 8.40 | |||||||||||||||||
BSA [member] | Date of Grant 7/25/2013 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 0 years | 10 years | ||||||||||||||||
Plan expiration date | Jul. 25, 2023 | |||||||||||||||||
Number of BSA granted | 73,000 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 8.10 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Discount rate | 1.16% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.18 | |||||||||||||||||
Grant date share fair value (in euros) | € 8.15 | |||||||||||||||||
BSA [member] | Date of Grant 6/3/2014 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 0 years | 10 years | ||||||||||||||||
Plan expiration date | Jun. 3, 2024 | |||||||||||||||||
Number of BSA granted | 10,000 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 18.79 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Discount rate | 0.71% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 4.98 | |||||||||||||||||
Grant date share fair value (in euros) | € 19.01 | |||||||||||||||||
BSA [member] | Date of Grant 03/24/2015 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
Plan expiration date | Mar. 24, 2025 | |||||||||||||||||
Number of BSA granted | 10,000 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 43 | |||||||||||||||||
Expected volatility | 36.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Discount rate | 0.68% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 9.90 | |||||||||||||||||
Grant date share fair value (in euros) | € 43 | |||||||||||||||||
BSA [member] | Date of Grant 11/19/2015 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
Plan expiration date | Nov. 19, 2025 | |||||||||||||||||
Number of BSA granted | 15,000 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 66.06 | |||||||||||||||||
Expected volatility | 50.91% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Discount rate | 0.81% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 22.60 | |||||||||||||||||
Grant date share fair value (in euros) | € 66.06 | |||||||||||||||||
BSA [member] | Date of Grant 12/15/2015 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
Plan expiration date | Dec. 15, 2015 | |||||||||||||||||
Number of BSA granted | 90,000 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 6,414 | |||||||||||||||||
Expected volatility | 51.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Discount rate | (0.09%) | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 7.28 | |||||||||||||||||
Grant date share fair value (in euros) | € 42.61 | |||||||||||||||||
BSA [member] | Date of Grant 06/21/2016 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
Plan expiration date | Jun. 21, 2016 | |||||||||||||||||
Number of BSA granted | 20,000 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 52.97 | |||||||||||||||||
Expected volatility | 47.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Discount rate | (0.41%) | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 21.59 | |||||||||||||||||
Grant date share fair value (in euros) | € 61.25 | |||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Share-based Payment Arrangement Tranche One [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||
Plan expiration date | Dec. 8, 2017 | |||||||||||||||||
Number of BSA granted | 431 | |||||||||||||||||
Share entitlement per BSA | € 15 | |||||||||||||||||
Exercise price (in euros) | € | € 65 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 65 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 4.5 | |||||||||||||||||
Discount rate | 4.06% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 22.18 | |||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Share-based Payment Arrangement Tranche Two [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 2 years | |||||||||||||||||
Plan expiration date | Dec. 8, 2017 | |||||||||||||||||
Number of BSA granted | 431 | |||||||||||||||||
Share entitlement per BSA | € 15 | |||||||||||||||||
Exercise price (in euros) | € | € 65 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 65 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Discount rate | 4.09% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 23.62 | |||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Share-based Payment Arrangement Tranche Three [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||
Plan expiration date | Dec. 8, 2017 | |||||||||||||||||
Number of BSA granted | 428 | |||||||||||||||||
Share entitlement per BSA | € 15 | |||||||||||||||||
Exercise price (in euros) | € | € 65 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 65 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 5.5 | |||||||||||||||||
Discount rate | 4.09% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 24.95 | |||||||||||||||||
BSA [member] | Date of Grant 12/7/2007 [member] | Share-based Payment Arrangement Tranche Four [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 4 years | |||||||||||||||||
Plan expiration date | Dec. 8, 2017 | |||||||||||||||||
Number of BSA granted | 427 | |||||||||||||||||
Share entitlement per BSA | € 15 | |||||||||||||||||
Exercise price (in euros) | € | € 65 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 65 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 6 | |||||||||||||||||
Discount rate | 4.10% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 26.22 | |||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Share-based Payment Arrangement Tranche One [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||
Plan expiration date | Jan. 17, 2022 | |||||||||||||||||
Number of BSA granted | 22,459 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 5.13 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 5.13 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 5.5 | |||||||||||||||||
Discount rate | 2.33% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.05 | |||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Share-based Payment Arrangement Tranche Two [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 2 years | |||||||||||||||||
Plan expiration date | Jan. 17, 2022 | |||||||||||||||||
Number of BSA granted | 22,459 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 5.13 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 5.13 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 6 | |||||||||||||||||
Discount rate | 2.33% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.14 | |||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Share-based Payment Arrangement Tranche Three [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||
Plan expiration date | Jan. 17, 2022 | |||||||||||||||||
Number of BSA granted | 22,459 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 5.13 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 5.13 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 6.5 | |||||||||||||||||
Discount rate | 2.61% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.26 | |||||||||||||||||
BSA [member] | Date of Grant 1/17/2012 [member] | Share-based Payment Arrangement Tranche Four [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 4 years | |||||||||||||||||
Plan expiration date | Jan. 17, 2022 | |||||||||||||||||
Number of BSA granted | 22,458 | |||||||||||||||||
Share entitlement per BSA | € 1 | |||||||||||||||||
Exercise price (in euros) | € | € 5.13 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 5.13 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 7 | |||||||||||||||||
Discount rate | 2.61% | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Fair value per BSA (in euros) | € 2.34 | |||||||||||||||||
BSA [member] | Date of Grant 12/9/2016 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
BSA [member] | Date of Grant 06/15/2017 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Vesting period (years) | 10 years | |||||||||||||||||
BSA2010 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Number of options granted | 0 | 0 | 0 | |||||||||||||||
BSA2010 [member] | Date of Grant 12/9/2016 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Plan expiration date | Dec. 9, 2026 | |||||||||||||||||
Expected volatility | 40.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Vesting period (years) | 0 years | |||||||||||||||||
Number of options granted | 59,000 | |||||||||||||||||
Share entitlement per BSA | shares | 1 | |||||||||||||||||
Exercise price (in euros) | 69.75 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 63.18 | |||||||||||||||||
Discount rate | (0.04%) | |||||||||||||||||
Fair value per BSA (in euros) | € 12.94 | |||||||||||||||||
BSA2010 [member] | Date of Grant 06/15/2017 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Plan expiration date | Jun. 15, 2027 | |||||||||||||||||
Expected volatility | 39.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Vesting period (years) | 0 years | |||||||||||||||||
Number of options granted | 9,000 | |||||||||||||||||
Share entitlement per BSA | shares | 1 | |||||||||||||||||
Exercise price (in euros) | 59.05 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 73.32 | |||||||||||||||||
Discount rate | (0.12%) | |||||||||||||||||
Fair value per BSA (in euros) | € 24.02 | |||||||||||||||||
BSA2010 [member] | Grant Date 6/15/2018 [member] | ||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||
Plan expiration date | May 2, 2028 | |||||||||||||||||
Expected volatility | 50.00% | |||||||||||||||||
Average life of BSA (in years) | 5 | |||||||||||||||||
Expected dividends | 0.00% | |||||||||||||||||
Vesting period (years) | 0 years | |||||||||||||||||
Number of options granted | 44,000 | |||||||||||||||||
Share entitlement per BSA | shares | 1 | |||||||||||||||||
Exercise price (in euros) | 37.24 | |||||||||||||||||
Grant date share fair value (in euros) | € | € 37.74 | |||||||||||||||||
Discount rate | (0.15%) | |||||||||||||||||
Fair value per BSA (in euros) | € 9.02 |
Share-Based Payments - Summar_2
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BSA (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2017 | |
BSA [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Description of price per share entitlement | The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BSA warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BSA plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. |
Share-Based Payments - Summar_3
Share-Based Payments - Summary of Change in BSA Outstanding Number (Detail) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Balance at beginning of period | 181,008 | 147,359 | |
Balance at end of period | 217,508 | 181,008 | 147,359 |
BSA [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Balance at beginning of period | 181,008 | 147,359 | 143,694 |
Granted during the period | 44,000 | 68,000 | 93,500 |
Forfeited during the period | 24,902 | ||
Exercised during the period | 7,500 | 9,359 | 89,835 |
Expired during the period | 0 | 0 | 0 |
Balance at end of period | 217,508 | 181,008 | 147,359 |
Share-Based Payments - Schedule
Share-Based Payments - Schedule of Breakdown of the Closing Balance BSA (Detail) | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 217,508 | 181,008 | 147,359 | |
Exercisable | 217,508 | 181,008 | 147,359 | |
Bons de souscriptiond actions 2010 [member] | Exercise price 65 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 859 | |||
Exercisable | 859 | |||
Bons de souscriptiond actions 2010 [member] | Exercise price 8.59 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 5,000 | 7,500 | 10,000 | |
Exercisable | 5,000 | 7,500 | 10,000 | |
Bons de souscriptiond actions 2010 [member] | Exercise price 8.1 [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 7,000 | 9,500 | 13,000 | |
Exercisable | 7,000 | 9,500 | 13,000 | |
Bons de souscriptiond actions 2010 [member] | Exercise price18.79 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 2,500 | 5,000 | ||
Exercisable | 2,500 | 5,000 | ||
BSA [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 217,508 | 181,008 | 147,359 | 143,694 |
BSA [member] | Exercise price 43.00 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 10,000 | 10,000 | 10,000 | |
Exercisable | 10,000 | 10,000 | 10,000 | |
BSA [member] | Exercise price 66.06 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 15,000 | 15,000 | 15,000 | |
Exercisable | 15,000 | 15,000 | 15,000 | |
BSA [member] | Exercise price 64.14 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 73,500 | 73,500 | 73,500 | |
Exercisable | 73,500 | 73,500 | 73,500 | |
BSA [member] | Exercise price 52.97 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 20,000 | 20,000 | 20,000 | |
Exercisable | 20,000 | 20,000 | 20,000 | |
BSA [member] | Exercise price 69.75 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 34,008 | 34,008 | ||
Exercisable | 34,008 | 34,008 | ||
BSA [member] | Exercise price 59.05 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 9,000 | 9,000 | ||
Exercisable | 9,000 | 9,000 | ||
BSA [member] | Exercise Price Thirteen [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 44,000 | |||
Exercisable | 44,000 |
Share-Based Payments - Schedu_2
Share-Based Payments - Schedule of Breakdown of the Closing Balance (Detail) | Dec. 31, 2018$ / shares |
Bons de souscriptiond actions 2010 [member] | Exercise price 65 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | $ 65 |
Bons de souscriptiond actions 2010 [member] | Exercise price 5.13 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 5.13 |
Bons de souscriptiond actions 2010 [member] | Exercise price 8.59 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 8.59 |
Bons de souscriptiond actions 2010 [member] | Exercise price 8.1 [Member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 8.10 |
Bons de souscriptiond actions 2010 [member] | Exercise price18.79 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 18.79 |
BSA [member] | Exercise price 43.00 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 43 |
BSA [member] | Exercise price 66.06 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 66.06 |
BSA [member] | Exercise price 64.14 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 64.14 |
BSA [member] | Exercise price 52.97 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 52.97 |
BSA [member] | Exercise price 69.75 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 69.75 |
BSA [member] | Exercise price 59.05 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | 59.05 |
BSA [member] | Exercise Price Thirteen [Member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | $ 37.24 |
Share-Based Payments - Summar_4
Share-Based Payments - Summary Details of BCE4 (Detail) | Jun. 15, 2018 | May 15, 2018 | Apr. 15, 2018 | Jan. 20, 2019EUR (€) | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Number of options granted | 23,600 | 16,500 | 16,500 | ||||
BCE 4 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Number of options granted | 0 | 0 | 0 | ||||
Not later than one year [member] | BCE 4 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||
Vesting period (years) | 0 years | ||||||
Plan expiration date | Jan. 20, 2019 | ||||||
Number of options granted | 2,411 | ||||||
Share entitlement per BCE4 | 1500.00% | ||||||
Exercise price (in euros) | € 65 | ||||||
Not later than one year [member] | BCE 4 [member] | Black and Scholes Method [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Grant date share fair value (in euros) | € 70 | ||||||
Expected volatility | 40.00% | ||||||
Average life of BCE4 (in years) | 5 | ||||||
Discount rate | 2.71% | ||||||
Expected dividends | 0.00% | ||||||
Performance conditions | 0.00% | ||||||
Fair value per BCE4 (in euros) | 2906.00% | ||||||
Later Than One Year and Not Later Than Two Years [member] | BCE 4 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||
Vesting period (years) | 1 year | ||||||
Plan expiration date | Jan. 20, 2019 | ||||||
Number of options granted | 1,340 | ||||||
Share entitlement per BCE4 | 1500.00% | ||||||
Exercise price (in euros) | € 65 | ||||||
Later Than One Year and Not Later Than Two Years [member] | BCE 4 [member] | Black and Scholes Method [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Grant date share fair value (in euros) | € 70 | ||||||
Expected volatility | 40.00% | ||||||
Average life of BCE4 (in years) | 5.5 | ||||||
Discount rate | 2.71% | ||||||
Expected dividends | 0.00% | ||||||
Performance conditions | 0.00% | ||||||
Fair value per BCE4 (in euros) | 3033.00% | ||||||
Later Than Two Years and Not Later Than Three Years [member] | BCE 4 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||
Vesting period (years) | 2 years | ||||||
Plan expiration date | Jan. 20, 2019 | ||||||
Number of options granted | 536 | ||||||
Share entitlement per BCE4 | 1500.00% | ||||||
Exercise price (in euros) | € 65 | ||||||
Later Than Two Years and Not Later Than Three Years [member] | BCE 4 [member] | Black and Scholes Method [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Grant date share fair value (in euros) | € 70 | ||||||
Expected volatility | 40.00% | ||||||
Average life of BCE4 (in years) | 6 | ||||||
Discount rate | 2.98% | ||||||
Expected dividends | 0.00% | ||||||
Performance conditions | 0.00% | ||||||
Fair value per BCE4 (in euros) | 3190.00% | ||||||
Later Than Three Years and Not Later Than Four Years [member] | BCE 4 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||
Vesting period (years) | 3 years | ||||||
Plan expiration date | Jan. 20, 2019 | ||||||
Number of options granted | 536 | ||||||
Share entitlement per BCE4 | 1500.00% | ||||||
Exercise price (in euros) | € 65 | ||||||
Later Than Three Years and Not Later Than Four Years [member] | BCE 4 [member] | Black and Scholes Method [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Grant date share fair value (in euros) | € 70 | ||||||
Expected volatility | 40.00% | ||||||
Average life of BCE4 (in years) | 6.5 | ||||||
Discount rate | 2.98% | ||||||
Expected dividends | 0.00% | ||||||
Performance conditions | 0.00% | ||||||
Fair value per BCE4 (in euros) | 3306.00% | ||||||
Later Than Four Years and Not Later Than Five Years [member] | BCE 4 [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Date of grant (Board of Directors) | Jan. 21, 2009 | ||||||
Vesting period (years) | 4 years | ||||||
Plan expiration date | Jan. 20, 2019 | ||||||
Number of options granted | 535 | ||||||
Share entitlement per BCE4 | 1500.00% | ||||||
Exercise price (in euros) | € 65 | ||||||
Later Than Four Years and Not Later Than Five Years [member] | BCE 4 [member] | Black and Scholes Method [member] | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Grant date share fair value (in euros) | € 70 | ||||||
Expected volatility | 40.00% | ||||||
Average life of BCE4 (in years) | 7 | ||||||
Discount rate | 3.11% | ||||||
Expected dividends | 0.00% | ||||||
Performance conditions | 0.00% | ||||||
Fair value per BCE4 (in euros) | 3435.00% |
Share-Based Payments - Summar_5
Share-Based Payments - Summary Details of BCE4 (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2018 | |
BCE 4 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Description of price per share entitlement | The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE4 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE4 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans. |
Share-Based Payments - Summar_6
Share-Based Payments - Summary of Change in Number of BCE2 Outstanding (Detail) | Jun. 15, 2018 | May 15, 2018 | Apr. 15, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Granted during the period | 23,600 | 16,500 | 16,500 | |||
BCE 4 [member] | ||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Balance at beginning of period | 2,691 | 2,691 | ||||
Granted during the period | 0 | 0 | 0 | |||
Forfeited during the period | 0 | 0 | 0 | |||
Exercised during the period | 2,691 | |||||
Expired during the period | 0 | 0 | 0 | |||
Balance at end of period | 2,691 |
Share-Based Payments - Schedu_3
Share-Based Payments - Schedule of Breakdown of the Closing Balance BCE4 (Detail) - BCE 4 [member] | Dec. 31, 2016 | Dec. 31, 2015 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Outstanding | 2,691 | 2,691 |
Exercisable | 2,691 | |
Exercise price 65 [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Outstanding | 2,691 | |
Exercisable | 2,691 |
Share-Based Payments - Summar_7
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BSA 2010 (Detail) | Jun. 15, 2018 | May 15, 2018 | Apr. 15, 2018 | Nov. 22, 2011EUR (€)€ / sharesshares | Jun. 24, 2011EUR (€)€ / sharesshares | Jan. 28, 2011EUR (€)€ / sharesshares | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Number of options granted | 23,600 | 16,500 | 16,500 | ||||||
BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Number of options granted | 0 | 0 | 0 | ||||||
Not later than one year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 1 year | ||||||||
Plan expiration date | Nov. 22, 2021 | ||||||||
Number of options granted | 335 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 5.5 | ||||||||
Discount rate | 2.23% | ||||||||
Expected dividends | 0.00% | ||||||||
Fair value per BSA (in euros) | € / shares | € 30.70 | ||||||||
Later Than One Year and Not Later Than Two Years [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 2 years | ||||||||
Plan expiration date | Nov. 22, 2021 | ||||||||
Number of options granted | 335 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 6 | ||||||||
Discount rate | 2.60% | ||||||||
Expected dividends | 0.00% | ||||||||
Fair value per BSA (in euros) | € / shares | € 32.58 | ||||||||
Later Than Two Years and Not Later Than Three Years [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 3 years | ||||||||
Plan expiration date | Nov. 22, 2021 | ||||||||
Number of options granted | 334 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 6.5 | ||||||||
Discount rate | 2.60% | ||||||||
Expected dividends | 0.00% | ||||||||
Fair value per BSA (in euros) | € / shares | € 33.89 | ||||||||
Later Than Three Years and Not Later Than Four Years [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 4 years | ||||||||
Plan expiration date | Nov. 22, 2021 | ||||||||
Number of options granted | 334 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 7 | ||||||||
Discount rate | 2.85% | ||||||||
Expected dividends | 0.00% | ||||||||
Fair value per BSA (in euros) | € / shares | € 35.54 | ||||||||
0.9 Year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 10 months 25 days | ||||||||
Plan expiration date | Jan. 27, 2021 | ||||||||
Number of options granted | 2,510 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 5.5 | ||||||||
Discount rate | 2.70% | ||||||||
Expected dividends | 0.00% | ||||||||
Performance conditions | NA | ||||||||
Fair value per BSA (in euros) | € / shares | € 31.33 | ||||||||
1.9 Year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 1 year 10 months 25 days | ||||||||
Plan expiration date | Jan. 27, 2021 | ||||||||
Number of options granted | 2,510 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 6 | ||||||||
Discount rate | 2.82% | ||||||||
Expected dividends | 0.00% | ||||||||
Performance conditions | NA | ||||||||
Fair value per BSA (in euros) | € / shares | € 32.90 | ||||||||
2.9 Year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 2 years 10 months 25 days | ||||||||
Plan expiration date | Jan. 27, 2021 | ||||||||
Number of options granted | 2,510 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 6.5 | ||||||||
Discount rate | 2.82% | ||||||||
Expected dividends | 0.00% | ||||||||
Performance conditions | NA | ||||||||
Fair value per BSA (in euros) | € / shares | € 34.23 | ||||||||
3.9 Year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 3 years 10 months 25 days | ||||||||
Plan expiration date | Jan. 27, 2021 | ||||||||
Number of options granted | 2,509 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 7 | ||||||||
Discount rate | 3.04% | ||||||||
Expected dividends | 0.00% | ||||||||
Performance conditions | NA | ||||||||
Fair value per BSA (in euros) | € / shares | € 35.84 | ||||||||
0.5 Year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 6 months | ||||||||
Plan expiration date | Nov. 22, 2021 | ||||||||
Number of options granted | 2,000 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 5.5 | ||||||||
Discount rate | 2.55% | ||||||||
Expected dividends | 0.00% | ||||||||
Performance conditions | NA | ||||||||
Fair value per BSA (in euros) | € / shares | € 31.15 | ||||||||
1.5 Year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 1 year 6 months | ||||||||
Plan expiration date | Nov. 22, 2021 | ||||||||
Number of options granted | 2,000 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 6 | ||||||||
Discount rate | 2.68% | ||||||||
Expected dividends | 0.00% | ||||||||
Performance conditions | NA | ||||||||
Fair value per BSA (in euros) | € / shares | € 32.70 | ||||||||
2.5 Year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 2 years 6 months | ||||||||
Plan expiration date | Nov. 22, 2021 | ||||||||
Number of options granted | 2,000 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 6.5 | ||||||||
Discount rate | 2.68% | ||||||||
Expected dividends | 0.00% | ||||||||
Performance conditions | NA | ||||||||
Fair value per BSA (in euros) | € / shares | € 34.02 | ||||||||
3.5 Year [member] | BSA2010 [member] | |||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||
Vesting period (years) | 3 years 6 months | ||||||||
Plan expiration date | Nov. 22, 2021 | ||||||||
Number of options granted | 2,000 | ||||||||
Share entitlement per BSA | shares | 15 | ||||||||
Exercise price (in euros) | 77 | ||||||||
Grant date share fair value (in euros) | € | € 77 | ||||||||
Expected volatility | 40.00% | ||||||||
Average life of BSA (in years) | 7 | ||||||||
Discount rate | 2.87% | ||||||||
Expected dividends | 0.00% | ||||||||
Performance conditions | NA | ||||||||
Fair value per BSA (in euros) | € / shares | € 35.57 |
Share-Based Payments - Share-Ba
Share-Based Payments - Share-Based Payments - Summary Of Change in Number of BSA 2010 Outstanding (Detail) | Jun. 15, 2018 | May 15, 2018 | Apr. 15, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Granted during the period | 23,600 | 16,500 | 16,500 | |||
BSA2010 [member] | ||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Balance at beginning of period | 500 | 610 | 1,044 | |||
Granted during the period | 0 | 0 | 0 | |||
Forfeited during the period | 0 | 0 | 0 | |||
Exercised during the period | 110 | 434 | ||||
Expired during the period | 0 | 0 | 0 | |||
Balance at end of period | 500 | 500 | 610 |
Share-Based Payments - Share-_2
Share-Based Payments - Share-Based Payments - Disclosure of Details of Breakdown of the Closing Balance BSA 2010 (Detail) - BSA2010 [member] | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 500 | 500 | 610 | 1,044 |
Exercisable | 500 | 500 | 610 |
Share-Based Payments - Share-_3
Share-Based Payments - Share-Based Payments - Disclosure of Details of Breakdown of the Closing Balance BSA 2010 (Parenthetical) (Detail) | Dec. 31, 2018EUR (€) |
BSA2010 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | € 77 |
Share-Based Payments - Summar_8
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BSAX (Detail) - BSAX [member] - EUR (€) | Jun. 25, 2010 | Jan. 21, 2009 | Dec. 31, 2018 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Exercise price (in euros) | € 65 | ||
Not later than one year [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Vesting period (years) | 1 year | 1 year | |
Plan expiration date | Jun. 24, 2020 | Jan. 20, 2019 | |
Number of BSAX granted | € 457 | € 77 | |
Share entitlement per BSAX | € 15 | € 15 | |
Exercise price (in euros) | € 65 | € 65 | |
Not later than one year [member] | Option pricing model [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Grant date share fair value (in euros) | € 70 | € 70 | |
Expected volatility | 40.00% | 40.00% | |
Average life of BSAX (in years) | 5.5 | 5.5 | |
Discount rate | 2.04% | 2.71% | |
Expected dividends | 0.00% | 0.00% | |
Performance conditions | NA | NA | |
Fair value per BSAX (in euros) | € 29.47 | € 30.32 | |
Later Than One Year and Not Later Than Two Years [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Vesting period (years) | 2 years | 2 years | |
Plan expiration date | Jun. 24, 2020 | Jan. 20, 2019 | |
Number of BSAX granted | € 457 | € 77 | |
Share entitlement per BSAX | € 15 | € 15 | |
Exercise price (in euros) | € 65 | € 65 | |
Later Than One Year and Not Later Than Two Years [member] | Option pricing model [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Grant date share fair value (in euros) | € 70 | € 70 | |
Expected volatility | 40.00% | 40.00% | |
Average life of BSAX (in years) | 6 | 6 | |
Discount rate | 2.23% | 2.98% | |
Expected dividends | 0.00% | 0.00% | |
Performance conditions | NA | NA | |
Fair value per BSAX (in euros) | € 30.88 | € 31.89 | |
Later Than Two Years and Not Later Than Three Years [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Vesting period (years) | 3 years | 3 years | |
Plan expiration date | Jun. 24, 2020 | Jan. 20, 2019 | |
Number of BSAX granted | € 456 | € 77 | |
Share entitlement per BSAX | € 15 | € 15 | |
Exercise price (in euros) | € 65 | € 65 | |
Later Than Two Years and Not Later Than Three Years [member] | Option pricing model [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Grant date share fair value (in euros) | € 70 | € 70 | |
Expected volatility | 40.00% | 40.00% | |
Average life of BSAX (in years) | 6.5 | 6.5 | |
Discount rate | 2.23% | 2.98% | |
Expected dividends | 0.00% | 0.00% | |
Performance conditions | NA | NA | |
Fair value per BSAX (in euros) | € 31.99 | € 33.05 | |
Later Than Three Years and Not Later Than Four Years [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Vesting period (years) | 4 years | 4 years | |
Plan expiration date | Jun. 24, 2020 | Jan. 20, 2019 | |
Number of BSAX granted | € 455 | € 75 | |
Share entitlement per BSAX | € 15 | € 15 | |
Exercise price (in euros) | € 65 | € 65 | |
Later Than Three Years and Not Later Than Four Years [member] | Option pricing model [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Grant date share fair value (in euros) | € 70 | € 70 | |
Expected volatility | 40.00% | 40.00% | |
Average life of BSAX (in years) | 7 | 7 | |
Discount rate | 2.50% | 3.11% | |
Expected dividends | 0.00% | 0.00% | |
Performance conditions | NA | NA | |
Fair value per BSAX (in euros) | € 33.44 | € 33.45 |
Share-Based Payments - Summar_9
Share-Based Payments - Summary Of Change in Number of BSAX Outstanding (Detail) | Jun. 15, 2018 | May 15, 2018 | Apr. 15, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Granted during the period | 23,600 | 16,500 | 16,500 | |||
BSAX [member] | ||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Balance at beginning of period | 1,036 | |||||
Granted during the period | 0 | 0 | 0 | |||
Forfeited during the period | 0 | 0 | 0 | |||
Exercised during the period | 1,036 | |||||
Expired during the period | 0 | 0 | 0 | |||
Balance at end of period | 1,036 | |||||
BSAX [member] | Scenario, Previously Reported [member] | ||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Balance at beginning of period | 1,036 |
Share-Based Payments - Disclosu
Share-Based Payments - Disclosure of Details of Breakdown of the Closing Balance BSAX (Detail) - BSAX [member] | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Outstanding | 1,036 |
Exercisable | 1,036 |
Share-Based Payments - Disclo_2
Share-Based Payments - Disclosure of Details of Breakdown of the Closing Balance BSAX (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2018EUR (€) | |
BSAX [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price | € 65 |
Share-Based Payments - Summa_10
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BCE 2010 (Detail) - BCE2010 [member] | Nov. 22, 2011EUR (€)€ / shares | Jun. 24, 2011EUR (€)€ / shares | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Number of BCE2010 granted | 0 | 0 | 0 | ||
Not later than one year [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 6 months | ||||
Plan expiration date | Nov. 22, 2021 | ||||
Number of BCE2010 granted | 6,000 | ||||
Share entitlement per BCE2010(1) | € / shares | € 15 | ||||
Exercise price | € | € 77 | ||||
Not later than one year [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Valuation method used | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 5.5 | ||||
Discount rate(2) | 2.55% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € / shares | € 31.16 | ||||
Not later than one year [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 1 year | ||||
Plan expiration date | Nov. 22, 2021 | ||||
Number of BCE2010 granted | 2,510 | ||||
Share entitlement per BCE2010(1) | € / shares | € 15 | ||||
Exercise price | € | € 77 | ||||
Not later than one year [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Valuation method used | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 5.4 | ||||
Discount rate(2) | 2.05% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € / shares | € 30.42 | ||||
Later Than One Year and Not Later Than Two Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 1 year 6 months | ||||
Plan expiration date | Nov. 22, 2021 | ||||
Number of BCE2010 granted | 6,000 | ||||
Share entitlement per BCE2010(1) | € / shares | € 15 | ||||
Exercise price | € | € 77 | ||||
Later Than One Year and Not Later Than Two Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Valuation method used | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 6 | ||||
Discount rate(2) | 2.68% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € / shares | € 32.71 | ||||
Later Than One Year and Not Later Than Two Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 2 years | ||||
Plan expiration date | Nov. 22, 2021 | ||||
Number of BCE2010 granted | 2,510 | ||||
Share entitlement per BCE2010(1) | € / shares | € 15 | ||||
Exercise price | € | € 77 | ||||
Later Than One Year and Not Later Than Two Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Valuation method used | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 5.9 | ||||
Discount rate(2) | 2.42% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € / shares | € 32.29 | ||||
Later Than Two Years and Not Later Than Three Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 2 years 6 months | ||||
Plan expiration date | Nov. 22, 2021 | ||||
Number of BCE2010 granted | 6,000 | ||||
Share entitlement per BCE2010(1) | € / shares | € 15 | ||||
Exercise price | € | € 77 | ||||
Later Than Two Years and Not Later Than Three Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Valuation method used | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 6.5 | ||||
Discount rate(2) | 2.68% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € / shares | € 34.03 | ||||
Later Than Two Years and Not Later Than Three Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 3 years | ||||
Plan expiration date | Nov. 22, 2021 | ||||
Number of BCE2010 granted | 2,510 | ||||
Share entitlement per BCE2010(1) | € / shares | € 15 | ||||
Exercise price | € | € 77 | ||||
Later Than Two Years and Not Later Than Three Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Valuation method used | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 6.4 | ||||
Discount rate(2) | 2.42% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € / shares | € 33.58 | ||||
Later Than Three Years and Not Later Than Four Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 3 years 6 months | ||||
Plan expiration date | Nov. 22, 2021 | ||||
Number of BCE2010 granted | 6,000 | ||||
Share entitlement per BCE2010(1) | € / shares | € 15 | ||||
Exercise price | € | € 77 | ||||
Later Than Three Years and Not Later Than Four Years [member] | Date of Grant 12/7/2007 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Valuation method used | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 7 | ||||
Discount rate(2) | 2.87% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € / shares | € 35.58 | ||||
Later Than Three Years and Not Later Than Four Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | |||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||
Vesting period (years) | 4 years | ||||
Plan expiration date | Nov. 22, 2021 | ||||
Number of BCE2010 granted | 2,509 | ||||
Share entitlement per BCE2010(1) | € / shares | € 15 | ||||
Exercise price | € | € 77 | ||||
Later Than Three Years and Not Later Than Four Years [member] | Date of Grant 1/17/2012 [member] | Board of Director [member] | Black and Scholes Method [member] | |||||
Valuation method used | |||||
Grant date share fair value | € | € 77 | ||||
Expected volatility | 40.00% | ||||
Average life of BCE2010 | 6.9 | ||||
Discount rate(2) | 2.66% | ||||
Expected dividends | 0.00% | ||||
Fair value per BCE2010 | € / shares | € 35.20 |
Share-Based Payments - Summa_11
Share-Based Payments - Summary of Details of Share Based Payment Arrangement BCE 2010 (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2018 | |
BCE2010 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Description of payment entitlement | The number of shares takes into account an exercise parity adjusted by the division by 15 of the nominal value of the shares decided by the general meeting on December 9, 2011; each BCE2010 warrant now gives the right to subscribe to 15 new shares instead of 1 new share. For the same reason, the exercise price of each BCE2010 plan was adjusted as a result and is thus equal to 1/15th of the price initially determined by the general meeting that authorized each of the plans |
Share-Based Payments - Summa_12
Share-Based Payments - Summary Of Change in Number of BCE 2010 Outstanding (Detail) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Balance at beginning of period | 181,008 | 147,359 | |
Balance at end of period | 217,508 | 181,008 | 147,359 |
BCE2010 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Balance at beginning of period | 11,005 | 12,339 | 15,974 |
Granted during the period | 0 | 0 | 0 |
Forfeited during the period | 0 | 0 | 0 |
Exercised during the period | 3,839 | 1,334 | 3,635 |
Expired during the period | 0 | 0 | 0 |
Balance at end of period | 7,166 | 11,005 | 12,339 |
Share-Based Payments - Disclo_3
Share-Based Payments - Disclosure of Details of Breakdown of the Closing Balance BCE 2010 (Detail) | Dec. 31, 2018EUR (€) | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 217,508 | 181,008 | 147,359 | |
Exercisable | 217,508 | 181,008 | 147,359 | |
BCE2010 [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Outstanding | 7,166 | 11,005 | 12,339 | 15,974 |
Exercisable | 7,166 | 11,005 | 12,339 | |
Exercise price, Exercisable | € 77 |
Share-Based Payments - Disclo_4
Share-Based Payments - Disclosure of Details of Breakdown of the Closing Balance BCE 2010 (Parenthetical) (Detail) | Dec. 31, 2018EUR (€) |
BCE2010 [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Exercise price, outstanding | € 77 |
Share-Based Payment - Additiona
Share-Based Payment - Additional information (Detail) | Jun. 15, 2018 | May 15, 2018 | Apr. 15, 2018 | Dec. 15, 2017 | Dec. 15, 2016 | Dec. 09, 2016 | Jun. 21, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Number of options granted | 23,600 | 16,500 | 16,500 | |||||||
Share Option [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, shares exercised | 268,000 | 1,200 | 35,000 | |||||||
Number of options granted | 824,200 | 998,500 | 359,060 | |||||||
Share Option [member] | Date of Grant 11/19/2015 [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, date of grant | Jun. 21, 2016 | |||||||||
Share based payment arrangement, shares exercised | 1,100 | 154,100 | ||||||||
Vesting period (years) | 10 years | 10 years | 10 years | |||||||
Share Option [member] | Date of Grant 12/15/2015 [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, date of grant | Dec. 9, 2016 | |||||||||
Share based payment arrangement, shares exercised | 74,960 | |||||||||
Vesting period (years) | 10 years | |||||||||
Share Option [member] | Date of Grant 06/21/2016 [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, date of grant | 12/15/2016 | |||||||||
Share Option [member] | 2018 grant date eight [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Vesting period (years) | 10 years | |||||||||
Share Option [member] | 2018 grant date nine [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Vesting period (years) | 10 years | |||||||||
Share Option [member] | Top of range [member] | Date of Grant 11/19/2015 [member] | Not later than one year [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 25.00% | 25.00% | 25.00% | |||||||
Share Option [member] | Top of range [member] | Date of Grant 11/19/2015 [member] | Later Than One Year and Not Later Than Two Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | |||||||
Share Option [member] | Top of range [member] | Date of Grant 11/19/2015 [member] | 24 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | |||||||
Share Option [member] | Top of range [member] | Date of Grant 11/19/2015 [member] | Later Than Two Years and Not Later Than Three Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | |||||||
Share Option [member] | Top of range [member] | Date of Grant 11/19/2015 [member] | 36 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | |||||||
Share Option [member] | Top of range [member] | Date of Grant 11/19/2015 [member] | Later Than Three Years and Not Later Than Four Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | |||||||
Share Option [member] | Top of range [member] | Date of Grant 11/19/2015 [member] | 48 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | 12.50% | 12.50% | |||||||
Share Option [member] | Top of range [member] | Date of Grant 12/15/2015 [member] | Not later than one year [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, shares exercised | 18,740 | |||||||||
Share Option [member] | Top of range [member] | Date of Grant 12/15/2015 [member] | Later Than One Year and Not Later Than Two Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, shares exercised | 9,370 | |||||||||
Share Option [member] | Top of range [member] | Date of Grant 12/15/2015 [member] | 24 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, shares exercised | 9,370 | |||||||||
Share Option [member] | Top of range [member] | Date of Grant 12/15/2015 [member] | Later Than Two Years and Not Later Than Three Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, shares exercised | 9,370 | |||||||||
Share Option [member] | Top of range [member] | Date of Grant 12/15/2015 [member] | 36 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, shares exercised | 9,370 | |||||||||
Share Option [member] | Top of range [member] | Date of Grant 12/15/2015 [member] | Later Than Three Years and Not Later Than Four Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, shares exercised | 9,370 | |||||||||
Share Option [member] | Top of range [member] | Date of Grant 12/15/2015 [member] | 48 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, shares exercised | 9,370 | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date eight [member] | Not later than one year [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 25.00% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date eight [member] | Later Than One Year and Not Later Than Two Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date eight [member] | 24 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date eight [member] | Later Than Two Years and Not Later Than Three Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date eight [member] | 36 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date eight [member] | Later Than Three Years and Not Later Than Four Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date eight [member] | 48 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date nine [member] | Not later than one year [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 25.00% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date nine [member] | Later Than One Year and Not Later Than Two Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date nine [member] | 24 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date nine [member] | Later Than Two Years and Not Later Than Three Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date nine [member] | 36 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date nine [member] | Later Than Three Years and Not Later Than Four Years [member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% | |||||||||
Share Option [member] | Top of range [member] | 2018 grant date nine [member] | 48 months [Member] | ||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||
Share based payment arrangement, vesting percentage | 12.50% |
Share-Based Payments - Summa_13
Share-Based Payments - Summary of Details of Share Based Payment Arrangement SO (Detail) | Dec. 17, 2018EUR (€)€ / shares | Dec. 12, 2018EUR (€)€ / shares | Nov. 29, 2018EUR (€)€ / shares | Nov. 15, 2018EUR (€)€ / shares | Oct. 15, 2018EUR (€)€ / shares | Sep. 17, 2018EUR (€)€ / shares | Aug. 15, 2018EUR (€)€ / shares | Jul. 16, 2018EUR (€)€ / shares | Jun. 22, 2018EUR (€)€ / shares | Jun. 15, 2018EUR (€)€ / shares | Jun. 09, 2018EUR (€)€ / shares | May 15, 2018EUR (€)€ / shares | Apr. 16, 2018EUR (€)€ / shares | Apr. 15, 2018 | Jan. 15, 2018EUR (€)€ / shares | Dec. 05, 2017EUR (€)€ / shares | Sep. 15, 2017EUR (€)€ / shares | Jul. 17, 2017EUR (€)€ / shares | Jun. 15, 2017EUR (€)€ / shares | Apr. 18, 2017EUR (€)€ / shares | Mar. 15, 2017EUR (€)€ / shares | Jan. 16, 2017EUR (€)€ / shares | Dec. 15, 2016EUR (€)€ / shares | Dec. 09, 2016EUR (€)€ / shares | Nov. 15, 2016EUR (€)€ / shares | Oct. 17, 2016EUR (€)€ / shares | Sep. 15, 2016EUR (€)€ / shares | Aug. 01, 2016EUR (€)€ / shares | Jun. 21, 2016EUR (€)€ / shares | May 02, 2016EUR (€)€ / shares | Apr. 21, 2016EUR (€)€ / shares | Jan. 04, 2016EUR (€)€ / shares | Nov. 19, 2015EUR (€)€ / shares | Jun. 23, 2015EUR (€)€ / shares | Jun. 03, 2014EUR (€)€ / shares | Sep. 18, 2013EUR (€)€ / shares | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Number of options granted | 23,600 | 16,500 | 16,500 | ||||||||||||||||||||||||||||||||||||
Share Option [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Number of options granted | 824,200 | 998,500 | 359,060 | ||||||||||||||||||||||||||||||||||||
Grant Date 9/18/2013 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Plan expiration date | 09/18/2023 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 518,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 7.57 | ||||||||||||||||||||||||||||||||||||||
Grant Date 9/18/2013 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 7.90 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 40.00% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 1.72% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 3.57 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 6/3/2014 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||||||||||||||||
Plan expiration date | 06/03/2024 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 75,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 19.01 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 6/3/2014 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 19.01 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 40.00% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 6 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.89% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 7.46 | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/23/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 06/23/2025 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 120,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 48.90 | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/23/2015 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 48.90 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 51.00% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.89% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 25.28 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 11/19/2015 [member] | Share Option [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 10 years | 10 years | 10 years | ||||||||||||||||||||||||||||||||||||
Date of Grant 11/19/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/19/2025 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 195,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 66.06 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 11/19/2015 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 66.06 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 51.00% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.81% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 34.05 | ||||||||||||||||||||||||||||||||||||||
Grant Date 1/4/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 01/04/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 75,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 65.68 | ||||||||||||||||||||||||||||||||||||||
Grant Date 1/4/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 65.68 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.39% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 4/21/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 04/21/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 33,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 62.82 | ||||||||||||||||||||||||||||||||||||||
Grant Date 4/21/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 62.82 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.04% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 5/2/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 05/02/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 22,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 59.04 | ||||||||||||||||||||||||||||||||||||||
Grant Date 5/2/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 58.62 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.10% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Date of Grant 06/21/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 06/21/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 110,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 53.96 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 06/21/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 52.97 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.01%) | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 8/1/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 08/01/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 10,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 62.24 | ||||||||||||||||||||||||||||||||||||||
Grant Date 8/1/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 62.24 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.25%) | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 09/15/2016 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 9,300 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 62.80 | ||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 62.80 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.18%) | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 10/17/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 10/17/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 16,500 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 64.39 | ||||||||||||||||||||||||||||||||||||||
Grant Date 10/17/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 64.39 | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 11/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/15/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 8,300 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 68.33 | ||||||||||||||||||||||||||||||||||||||
Grant Date 11/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 68.33 | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Date of Grant 12/9/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/09/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 74,960 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 69.75 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 12/9/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 69.75 | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/15/2026 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 1,100 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 69.35 | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 69.35 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 40.44% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/22/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/22/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 06/22/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 50,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 37.22 | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/22/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 34.32 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 45.85% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 07/16/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 28,800 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 33.81 | ||||||||||||||||||||||||||||||||||||||
Grant Date 7/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 32.16 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 46.51% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 8/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 15/08/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 33,500 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 32.90 | ||||||||||||||||||||||||||||||||||||||
Grant Date 8/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 32.90 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 46.67% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 9/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 09/17/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 80,900 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 40.94 | ||||||||||||||||||||||||||||||||||||||
Grant Date 9/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 40.94 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 46.92% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 10/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 10/15/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 76,700 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 37.28 | ||||||||||||||||||||||||||||||||||||||
Grant Date 10/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 31.74 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.12% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 11/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/15/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 26,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 32.57 | ||||||||||||||||||||||||||||||||||||||
Grant Date 11/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 28.66 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.44% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/17/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 7,200 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 26.76 | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 26.76 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.90% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/9/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Plan expiration date | 09/06/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 65,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 36.96 | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/9/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 36.96 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 46.85% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 11/29/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 11/29/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 350,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 30.02 | ||||||||||||||||||||||||||||||||||||||
Grant Date 11/29/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 27.44 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.51% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/12/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/12/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 34,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 27.96 | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/12/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 27.96 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.87% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Date of Grant 1/16/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 01/16/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 19,100 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 66.11 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 1/16/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 66.11 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 40.21% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 3/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 03/15/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 7,200 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 66.25 | ||||||||||||||||||||||||||||||||||||||
Grant Date 3/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 65.42 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 39.82% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Date of Grant 4/18/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 04/18/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 16,500 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 60.77 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 4/18/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 59.73 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 39.63% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Date of Grant 06/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 06/15/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 126,000 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 59.05 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 06/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 59.05 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 39.23% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 06/15/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 111.600 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 60.54 | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 59.05 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 39.23% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Date of Grant 7/17/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 07/17/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 30,900 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 71.61 | ||||||||||||||||||||||||||||||||||||||
Date of Grant 7/17/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 71.61 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 38.84% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 09/15/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 52,600 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 74.22 | ||||||||||||||||||||||||||||||||||||||
Grant Date 9/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 71.80 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 38.57% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/5/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/05/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 625,200 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 39 | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 35.73 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 43.23% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 12/15/2027 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 8,300 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 38.18 | ||||||||||||||||||||||||||||||||||||||
Grant Date 12/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 36.43 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 43.13% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 1/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 01/15/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 15,500 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 43.60 | ||||||||||||||||||||||||||||||||||||||
Grant Date 1/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 43.60 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 45.57% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 4/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 04/16/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 16,500 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 38.64 | ||||||||||||||||||||||||||||||||||||||
Grant Date 4/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 38.64 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 46.37% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 5/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 05/15/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 16,500 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 40.84 | ||||||||||||||||||||||||||||||||||||||
Grant Date 5/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 40.84 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 46.15% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Plan expiration date | 06/15/2028 | ||||||||||||||||||||||||||||||||||||||
Number of options granted | 23,600 | ||||||||||||||||||||||||||||||||||||||
Share entitlement per SO | € 1 | ||||||||||||||||||||||||||||||||||||||
Exercise price | € | € 38.92 | ||||||||||||||||||||||||||||||||||||||
Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Grant date share fair value | € | € 35.48 | ||||||||||||||||||||||||||||||||||||||
Expected volatility | 45.95% | ||||||||||||||||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/18/2013 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/23/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 11/19/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/4/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/4/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.30% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 29.5 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/21/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/21/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.40% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 28.3 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/2/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/2/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.30% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 26.4 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 06/21/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 06/21/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.10% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 23.4 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 8/1/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 8/1/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.80% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 27.3 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.60% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 27.4 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 10/17/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 10/17/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.00% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.32%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 27.6 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.80% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.11%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 29.4 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 12/9/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 12/9/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 47.70% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.20%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 29.7 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.18%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 25.2 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/22/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/22/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.19% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 13.42 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.14% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 13.02 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 8/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 8/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.17% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 13.85 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.27% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 17.39 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 10/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 10/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.37% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 12.12 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.29% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 11.18 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.26% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 11.57 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/9/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/9/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.21% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 15.65 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/29/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 11/29/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.27% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 11.08 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/12/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/12/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.27% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 12.09 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 1/16/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 1/16/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.17%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 23.9 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.21% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 23.6 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 4/18/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 4/18/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.02% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 21.2 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 06/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 06/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.21%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 20.8 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.21%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 20.4 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 7/17/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Date of Grant 7/17/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.01% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 25.3 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 9/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.14%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 24.3 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.23%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 12.9 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 12/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.23%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 13.5 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.32% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 18.1 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.35% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 16.3 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.41% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 17.2 | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||||||||||||||||
Bottom of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 5 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.23% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 13.8 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/23/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 11/19/2015 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/4/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/4/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.80% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 32.6 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/21/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/21/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 50.70% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 30.9 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/2/16 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/2/16 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 50.60% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 28.8 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 06/21/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 06/21/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 50.30% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 25.5 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 8/1/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 8/1/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.80% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 29.9 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 49.40% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 30.1 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 10/17/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 10/17/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.90% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | (0.15%) | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 30.6 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.80% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.16% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 32.7 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 12/9/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 12/9/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Expected volatility | 48.50% | ||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.18% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 33.4 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/15/2016 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/15/2016 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.16% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 28.7 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/22/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/22/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 15.11 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 7/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 14.59 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 8/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 8/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 15.43 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 19.37 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 10/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 10/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 13.78 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 12.66 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/17/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/17/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 12.88 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/9/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/9/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 17.43 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/29/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 11/29/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 12.47 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/12/2018 [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/12/2018 [member] | Black and Scholes Method [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 13.46 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 1/16/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 1/16/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.19% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 27.20 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 3/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.61% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 27.10 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 4/18/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 4/18/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.39% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 24.20 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 06/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 06/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 23.60 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 23.22 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 7/17/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Date of Grant 7/17/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.34% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 28.20 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 9/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.19% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 27.80 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/5/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 14.7 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/15/2017 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 12/15/2017 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Discount rate | 0.07% | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 15.4 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 1/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 20.2 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 4/16/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 18.2 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 5/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 19.2 | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Vesting period (years) | 4 years | ||||||||||||||||||||||||||||||||||||||
Top of range [member] | Grant Date 6/15/2018 [member] | Share Option [member] | Black and Scholes Method [member] | Board of Director [member] | |||||||||||||||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||||||||||||||||
Average life of SO | 7 | ||||||||||||||||||||||||||||||||||||||
Fair value per SO | € 15.6 |
Share-Based Payments - Disclo_5
Share-Based Payments - Disclosure of Change in Number of Share Options Outstanding (Detail) | Jun. 15, 2018 | May 15, 2018 | Apr. 15, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Granted during the period | 23,600 | 16,500 | 16,500 | |||
Share Option [member] | ||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||
Balance at beginning of period | 2,133,100 | 1,160,060 | 861,000 | |||
Granted during the period | 824,200 | 998,500 | 359,060 | |||
Forfeited during the period | 227,730 | 24,260 | 25,000 | |||
Exercised during the period | 268,000 | 1,200 | 35,000 | |||
Expired during the period | 0 | 0 | 0 | |||
Balance at end of period | 2,461,570 | 2,133,100 | 1,160,060 |
Share-Based Payments - Disclo_6
Share-Based Payments - Disclosure of Details of Breakdown of the Closing Balance SO (Detail) | Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€) |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 217,508 | 181,008 | 147,359 |
Exercisable | 217,508 | 181,008 | 147,359 |
Share Option [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 2,461,570 | 2,133,100 | 1,160,000 |
Exercisable | 847,464 | 755,650 | 85,000 |
Share Option [member] | Exercise Price of Euro 7.57 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 203,000 | 471,000 | 471,000 |
Exercisable | 203,000 | 471,000 | |
Exercise price, outstanding | € 7.57 | € 7.57 | € 7.57 |
Exercise price, Exercisable | € 7.57 | ||
Share Option [member] | Exercise Price of Euro 19.01 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 40,000 | 40,000 | 40,000 |
Exercisable | 40,000 | 40,000 | 40,000 |
Exercise price, outstanding | € 19.01 | € 19.01 | € 19.01 |
Exercise price, Exercisable | € 19.01 | ||
Share Option [member] | Exercise Price of Euro 48.90 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 120,000 | 120,000 | 120,000 |
Exercisable | 90,000 | 75,000 | 45,000 |
Exercise price, outstanding | € 48.90 | € 48.90 | € 48.90 |
Exercise price, Exercisable | € 48.90 | ||
Share Option [member] | Exercise Price of Euro 66.06 [Member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 170,000 | 170,000 | 170,000 |
Exercisable | 127,500 | 85,000 | |
Exercise price, outstanding | € 66.06 | € 66.06 | € 66.06 |
Exercise price, Exercisable | € 66.06 | ||
Share Option [member] | Exercise Price of Euro 65.68 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 75,000 | 75,000 | 75,000 |
Exercisable | 37,500 | 18,750 | |
Exercise price, outstanding | € 65.68 | € 65.68 | |
Exercise price, Exercisable | € 65.68 | ||
Share Option [member] | Exercise Price of Euro 62.82 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 22,000 | 33,000 | 33,000 |
Exercisable | 11,000 | 8,250 | |
Exercise price, outstanding | € 62.82 | € 62.82 | |
Exercise price, Exercisable | 62.82 | ||
Share Option [member] | Exercise Price of Euro 59.04 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 22,000 | 22,000 | |
Exercisable | 5,500 | ||
Exercise price, outstanding | 59.04 | € 59.04 | |
Exercise price, Exercisable | € 59.04 | ||
Share Option [member] | Exercise Price of Euro 53.96 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 87,500 | 101,300 | 110,000 |
Exercisable | 54,687 | 24,425 | |
Exercise price, outstanding | € 53.96 | € 53.96 | |
Exercise price, Exercisable | € 53.96 | ||
Share Option [member] | Exercise Price of Euro 62.24 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 10,000 | 10,000 | 10,000 |
Exercisable | 5,000 | 2,500 | |
Exercise price, outstanding | € 62.24 | € 62.24 | |
Exercise price, Exercisable | € 62.24 | ||
Share Option [member] | Exercise Price of Euro 62.80 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 9,300 | 9,300 | 9,300 |
Exercisable | 4,650 | 2,325 | |
Exercise price, outstanding | € 62.80 | € 62.80 | |
Exercise price, Exercisable | € 62.80 | ||
Share Option [member] | Exercise Price of Euro 64.39 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 9,300 | 9,300 | 16,500 |
Exercisable | 4,650 | 2,325 | |
Exercise price, outstanding | € 64.39 | € 64.39 | |
Exercise price, Exercisable | € 64.39 | ||
Share Option [member] | Exercise Price of Euro 68.33 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 8,300 | 8,300 | 8,300 |
Exercisable | 4,150 | 2,075 | |
Exercise price, outstanding | € 68.33 | € 68.33 | |
Exercise price, Exercisable | € 68.33 | ||
Share Option [member] | Exercise Price of Euro 69.75 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 51,995 | 72,900 | 74,960 |
Exercisable | 25,997 | 18,225 | |
Exercise price, outstanding | € 69.75 | € 69.75 | |
Exercise price, Exercisable | € 69.75 | ||
Share Option [member] | Exercise price of Euro 66.35 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 1,100 | 1,100 | |
Exercisable | 550 | 275 | |
Exercise price, outstanding | € 66.35 | ||
Exercise price, Exercisable | € 66.35 | ||
Share Option [member] | Exercise price of Euro 66.11 [Member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 19,100 | 19,100 | |
Exercisable | 7,162 | ||
Exercise price, outstanding | € 66.11 | ||
Exercise price, Exercisable | € 66.11 | ||
Share Option [member] | Exercise price of Euro 66.25 [Member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 7,200 | 7,200 | |
Exercisable | 2,700 | ||
Exercise price, outstanding | € 66.25 | ||
Exercise price, Exercisable | € 66.25 | ||
Share Option [member] | Exercise price of Euro 60.77 [Member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 7,200 | 16,500 | |
Exercisable | 2,700 | ||
Exercise price, outstanding | € 60.77 | ||
Exercise price, Exercisable | € 60.77 | ||
Share Option [member] | Exercise price of Euro 59.05 [Member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 91,000 | 118,500 | |
Exercisable | 34,125 | ||
Exercise price, outstanding | € 59.05 | ||
Exercise price, Exercisable | € 59.05 | ||
Share Option [member] | Exercise price of Euro 60.54 [Member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 111,600 | 111,600 | |
Exercisable | 41,850 | ||
Exercise price, outstanding | € 60.54 | ||
Exercise price, Exercisable | € 60.54 | ||
Share Option [member] | Exercise price of Euro 71.61 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 7,200 | 30,900 | |
Exercisable | 1,800 | ||
Exercise price, outstanding | € 71.61 | ||
Exercise price, Exercisable | € 71.61 | ||
Share Option [member] | Exercise price of Euro 74.22 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 45,400 | 52,600 | |
Exercisable | 11,350 | ||
Exercise price, outstanding | € 74.22 | ||
Exercise price, Exercisable | € 74.22 | ||
Share Option [member] | Exercise price of Euro 39.00 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 540,075 | 625,200 | |
Exercisable | 135,018 | ||
Exercise price, outstanding | € 39 | ||
Exercise price, Exercisable | € 39 | ||
Share Option [member] | Exercise price of Euro 38.18 [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 8,300 | 8,300 | |
Exercisable | 2,075 | ||
Exercise price, outstanding | € 38.18 | ||
Exercise price, Exercisable | € 38.18 | ||
Share Option [member] | Exercise price forty three point six zero [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 8,300 | ||
Exercise price, outstanding | € 43.60 | ||
Share Option [member] | Exercise price thirty eight point six four [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 16,500 | ||
Exercise price, outstanding | € 38.64 | ||
Share Option [member] | Exercise price forty point eighty four [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 16,500 | ||
Exercise price, outstanding | € 40.84 | ||
Share Option [member] | Exercise price thirty eight point nine two [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 23,600 | ||
Exercise price, outstanding | € 38.92 | ||
Share Option [member] | Exercise price thirty seven point two two [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 50,000 | ||
Exercise price, outstanding | € 37.22 | ||
Share Option [member] | Exercise price thirty three point eight one [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 28,800 | ||
Exercise price, outstanding | € 33.81 | ||
Share Option [member] | Exercise price thirty two point nine zero [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 33,500 | ||
Exercise price, outstanding | € 32.90 | ||
Share Option [member] | Exercise price thirty six point nine six [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 65,000 | ||
Exercise price, outstanding | € 36.96 | ||
Share Option [member] | Exercise price forty point nine four [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 80,900 | ||
Exercise price, outstanding | € 40.94 | ||
Share Option [member] | Exercise price thirty seven point two eight [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 76,700 | ||
Exercise price, outstanding | € 37.28 | ||
Share Option [member] | Exercise price thirty two point five seven [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 26,000 | ||
Exercise price, outstanding | € 32.57 | ||
Share Option [member] | Exercise price thirty point zero two [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 350,000 | ||
Exercise price, outstanding | € 30.02 | ||
Share Option [member] | Exercise price twenty seven point nine six [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 34,000 | ||
Exercise price, outstanding | € 27.96 | ||
Share Option [member] | Exercise price thirty seven point two four [member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Outstanding | 7,200 | ||
Exercise price, outstanding | € 37.24 |
Disclosure - Share-Based Paymen
Disclosure - Share-Based Payments - Summary of Details of Share Based Payment Arrangement Free Shares (Detail) | Dec. 12, 2018€ / shares | Nov. 01, 2018€ / shares | Jun. 22, 2018€ / shares | Jun. 15, 2018 | Jun. 09, 2018€ / shares | May 15, 2018 | Apr. 15, 2018 | Apr. 20, 2017€ / shares | Mar. 14, 2017€ / shares | Dec. 09, 2016EUR (€)€ / shares | Oct. 27, 2016EUR (€)€ / shares | Sep. 01, 2016EUR (€)€ / shares | Aug. 16, 2016EUR (€)€ / shares | Jun. 21, 2016EUR (€)€ / shares | Apr. 06, 2016EUR (€)€ / shares | Jun. 03, 2014EUR (€)€ / shares | Sep. 12, 2013EUR (€)€ / shares | Nov. 28, 2012EUR (€)€ / shares | Jul. 25, 2012EUR (€)€ / shares | Apr. 02, 2012EUR (€)€ / shares | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 15, 2015$ / shares | Sep. 30, 2015$ / shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Number of options granted | 23,600 | 16,500 | 16,500 | ||||||||||||||||||||||
Free Share [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Number of options granted | 562,853 | 46,500 | 310,350 | ||||||||||||||||||||||
Date of Grant 4/2/2012 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 669,796 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 8.86 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | Yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 1.00% | ||||||||||||||||||||||||
Date of Grant 7/25/2012 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 134,081 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 8.20 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | Yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 1.00% | ||||||||||||||||||||||||
Date of Grant 11/28/2015 [Member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 35,360 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 8.70 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | No | ||||||||||||||||||||||||
Expected turnover during the vesting period | 1.00% | ||||||||||||||||||||||||
Date of Grant 07/25/2013 & 09/12/2013 [Member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 501,500 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 7.96 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | Yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 1.00% | ||||||||||||||||||||||||
Date of Grant 6/3/2014 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 186,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 19.01 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | Yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 1.00% | ||||||||||||||||||||||||
Grant Date 4/6/2016 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 63,750 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 62.40 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Date of Grant 06/21/2016 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 193,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 52.97 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Grant Date 8/16/2016 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 10,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 60.68 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Grant Date 9/1/2016 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 5,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 61.49 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Grant Date 10/27/2016 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 15,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 67.44 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Date of Grant 12/9/2016 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Number of options granted | 23,600 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € | € 69.75 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Grant Date 3/14/2017 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Number of free shares granted | 22,500 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € 68.07 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Lockup period | 0 years | ||||||||||||||||||||||||
Grant Date 4/20/2017 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Number of free shares granted | 24,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € 61.20 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Lockup period | 0 years | ||||||||||||||||||||||||
Grant Date 6/22/2018 [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Number of free shares granted | 486,153 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € 34.32 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Lockup period | 2 years | ||||||||||||||||||||||||
Grant Date 6/9/2018 [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||
Number of options granted | 65,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Number of free shares granted | 450 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € 36.96 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Lockup period | 2 years | ||||||||||||||||||||||||
Grant Date 1/11/2018 [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Number of free shares granted | 57,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € 33.33 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||||||||||||||
Lockup period | 2 years | ||||||||||||||||||||||||
Grant Date 12/12/2018 [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||
Number of options granted | 34,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Number of free shares granted | 16,250 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € 27.96 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||||||||||||||
Lockup period | 2 years | ||||||||||||||||||||||||
Grant Date 12/17/2018 and 12/12/2018 [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 1 year | ||||||||||||||||||||||||
Performance conditions | yes | ||||||||||||||||||||||||
Number of free shares granted | 3,000 | ||||||||||||||||||||||||
Share entitlement per free share | € 1 | ||||||||||||||||||||||||
Grant date share fair value | € 26.76 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 5.00% | ||||||||||||||||||||||||
Lockup period | 2 years | ||||||||||||||||||||||||
Date of Grant 9/30/2015 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Performance conditions | Yes | ||||||||||||||||||||||||
Number of free shares granted | 708,500 | ||||||||||||||||||||||||
Share entitlement per free share | $ / shares | $ 1 | ||||||||||||||||||||||||
Grant date share fair value | $ / shares | $ 0.6299 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% | ||||||||||||||||||||||||
Date of Grant 11/19/2015 [member] | Free Share [member] | Board of Director [member] | |||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||||||
Vesting period (years) | 2 years | ||||||||||||||||||||||||
Performance conditions | Yes | ||||||||||||||||||||||||
Number of free shares granted | 42,000 | ||||||||||||||||||||||||
Share entitlement per free share | $ / shares | $ 1 | ||||||||||||||||||||||||
Grant date share fair value | $ / shares | $ 0.6414 | ||||||||||||||||||||||||
Expected dividends | 0.00% | ||||||||||||||||||||||||
Expected turnover during the vesting period | 0.00% |
Disclosure - Share-Based Paym_2
Disclosure - Share-Based Payments - Summary of Details of Share Based Payment Arrangement Free Shares (Parenthetical) (Detail) - Free Share [member] | 12 Months Ended |
Dec. 31, 2018 | |
Grant Date One And Two [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for certain individuals (the "Key Managers"), including Dr. Benhamou, upon the achievement of the three performance criteria |
Grant date eight, nine, ten and eleven [member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for all the employees, including Dr. Benhamou, upon the achievement of the three performance criteria |
Share-Based Payments - Summa_14
Share-Based Payments - Summary of Details of Free Shares (Parenthetical) (Detail) - shares | 1 Months Ended | 12 Months Ended |
Sep. 30, 2016 | Dec. 31, 2018 | |
Viaskin Peanut [Member] | Top of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | Half of the shares | |
Vesting period (years) | 2 years | |
Viaskin Peanut [member] | Bottom of range [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 4 years | |
Viaskin Peanut [member] | Top of range [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 11 years | |
Viaskin Milk [member] | Bottom of range [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 2 years | |
Viaskin Milk [member] | Top of range [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 17 years | |
Date of Grant 07/25/2013 & 09/12/2013 [Member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for the Key Managers, including Dr. Benhamou, upon the achievement of the three performance criteria | |
Date of Grant 07/25/2013 & 09/12/2013 [Member] | Inclusion Of 100th Patient In VIPES Phase II Study [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One-third of the shares | |
Vesting period (years) | 2 years | |
Date of Grant 07/25/2013 & 09/12/2013 [Member] | Adoption Of 2013 Free Share Allocation Plan [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One-third of the shares | |
Vesting period (years) | 2 years | |
Number of consecutive days | 5 | |
Date of Grant 07/25/2013 & 09/12/2013 [Member] | Adoption Of 2013 Free Share Allocation Plan [member] | Bottom of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Percentage increase in share price | 50.00% | |
Date of Grant 07/25/2013 & 09/12/2013 [Member] | On achievement of phase three Pepites trial for Viaskin Peanut [Member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One-third of the shares | |
Vesting period (years) | 2 years | |
Date of Grant 6/3/2014 [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for the Key Managers, including Dr. Benhamou, upon the achievement of the two performance criteria | |
Date of Grant 6/3/2014 [member] | Viaskin Peanut [Member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | Half of the shares | |
Vesting period (years) | 2 years | |
Date of Grant 9/30/2015 and 12/15/2015 [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for all the employees, including Dr. Benhamou, upon the achievement of the three performance criteria | |
Date of Grant 9/30/2015 and 12/15/2015 [member] | Phase I I I Pepites Trial For Viaskin Peanut [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One third of the shares | |
Vesting period (years) | 2 years | |
Date of Grant 9/30/2015 and 12/15/2015 [member] | Viaskin Peanut [member] | Bottom of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 4 years | |
Date of Grant 9/30/2015 and 12/15/2015 [member] | Viaskin Peanut [member] | Top of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 11 years | |
Date of Grant 9/30/2015 and 12/15/2015 [member] | Phase II Miles Trial For Viaskin Milk [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One third of the shares | |
Vesting period (years) | 2 years | |
Date of Grant 9/30/2015 and 12/15/2015 [member] | Viaskin Platform [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One third of the shares | |
Vesting period (years) | 2 years | |
Grant date twelve and thirteen [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for key and new employees upon the achievement of the two performance criteria | |
Grant date twelve and thirteen [member] | Viaskin Peanut [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | Half | |
Vesting period (years) | 2 years | |
Grant date twelve and thirteen [member] | Viaskin Peanut [member] | Bottom of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 4 years | |
Grant date twelve and thirteen [member] | Viaskin Peanut [member] | Top of range [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Age of patients evaluated | 11 years | |
Grant date twelve and thirteen [member] | Viaskin Milk [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | Half | |
Vesting period (years) | 2 years | |
Grant Date Fourteen And Fifteen [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for key and new employees upon the achievement of the two performance criteria | |
Grant Date Fourteen And Fifteen [member] | Viaskin Peanut [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting period (years) | 2 years | |
Acquisition of shares on achievement of performance criteria | 0 | |
Grant Date Fourteen And Fifteen [member] | Viaskin Milk [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting period (years) | 2 years | |
Acquisition of shares on achievement of performance criteria | 0 | |
Grant Date One And Two [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for certain individuals (the "Key Managers"), including Dr. Benhamou, upon the achievement of the three performance criteria | |
Grant Date One And Two [member] | Inclusion Of 100th Patient In VIPES Phase II Study [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One-third of the shares | |
Vesting period (years) | 2 years | |
Grant Date One And Two [member] | Achievement Of Principal Evaluation Criterion In VIPES Phase II Study [Member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One-third of the shares | |
Vesting period (years) | 2 years | |
Grant Date One And Two [member] | Inclusion Of First Patient In Viaskin Milk Phase II Study [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One-third of the shares | |
Vesting period (years) | 2 years | |
Grant date eight, nine, ten and eleven [member] | Free Share [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Acquisition of shares on achievement of performance criteria | One third | |
Vesting period (years) | 2 years | |
Acquisition of free shares upon achievement of performance criteria, description | The acquisition of free shares is contingent for all the employees, including Dr. Benhamou, upon the achievement of the three performance criteria |
Share-Based Payments - Change i
Share-Based Payments - Change in Number of Free Shares Outstanding (Detail) | Jun. 15, 2018 | May 15, 2018 | Apr. 15, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Changes In Number Of Shares Outstanding [line items] | ||||||
Granted during the period | 23,600 | 16,500 | 16,500 | |||
Free Share [member] | ||||||
Changes In Number Of Shares Outstanding [line items] | ||||||
Balance at beginning of period | 822,856 | 1,036,850 | 1,008,329 | |||
Granted during the period | 562,853 | 46,500 | 310,350 | |||
Forfeited during the period | 36,525 | 18,650 | 24,000 | |||
Exercised during the period | 776,956 | 241,844 | 257,829 | |||
Expired during the period | 0 | 0 | 0 | |||
Balance at end of period | 572,228 | 822,856 | 1,036,850 |
Financial Revenue and Expense_2
Financial Revenue and Expenses - Summary of Financial Income and Expenses (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure Of Detail Information About Financial Income And Expenses [line items] | |||
Financial revenues | € 493 | € 616 | € 1,516 |
Financial expenses | (351) | (3,325) | (16) |
Total | € 141 | € (2,709) | 1,500 |
Scenario, Previously Reported [member] | |||
Disclosure Of Detail Information About Financial Income And Expenses [line items] | |||
Financial revenues | 1,646 | ||
Financial expenses | € (145) |
Income Tax Expense - Additional
Income Tax Expense - Additional Information (Detail) € in Millions | 12 Months Ended | |||
Dec. 31, 2018EUR (€) | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2018USD ($) | |
Disclosure of reconciliation of effective and applicable income tax expenses [line items] | ||||
Deferred tax assets | $ | $ 0 | |||
Amount of losses carried forward | € 531 | |||
Parent [member] | ||||
Disclosure of reconciliation of effective and applicable income tax expenses [line items] | ||||
Amount of losses carried forward | € 527 | |||
French (Member) | ||||
Disclosure of reconciliation of effective and applicable income tax expenses [line items] | ||||
Effective income tax rate | 28.00% | 33.33% | 33.33% |
Income Tax Expense - Summary of
Income Tax Expense - Summary of Reconciliation of Effective and Nominal Tax Expense (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Major components of tax expense (income) [abstract] | |||
(Loss) before taxes | € (166,061) | € (147,692) | € (114,531) |
Theoretical group tax rate | 28.00% | 33.33% | 33.33% |
Nominal tax expense | € 46,497 | € 49,226 | € 38,173 |
Permanent differences | 0 | 0 | 0 |
Research tax credit | 3,089 | 3,110 | 2,409 |
Share-based compensation | (7,253) | (10,260) | (11,451) |
Non recognition of deferred tax assets related to tax losses and temporary differences | (54,205) | (41,453) | (29,195) |
Other differences | 11,887 | 622 | 64 |
Effective tax expenses | € (15) | € (1) | € 0 |
Effective tax rate | 0.01% | 0.00% | 0.00% |
Commitments - Additional Inform
Commitments - Additional Information (Detail) € in Thousands, $ in Thousands | 1 Months Ended | 12 Months Ended | ||||
Nov. 30, 2017ft² | Jun. 30, 2017ft² | Dec. 31, 2018EUR (€)ft²m²Facilities | Dec. 31, 2018USD ($)Facilities | May 31, 2017USD ($) | Apr. 30, 2016USD ($) | |
Disclosure of commitments [line items] | ||||||
Future rental payments | € 30,267 | |||||
Other agreements [member] | Contract Research Organizations [member] | Viaskin Peanuts And Viaskin Milk Products [member] | ||||||
Disclosure of commitments [line items] | ||||||
Launching value of clinical studies | 101,300 | |||||
Remaining value of clinical studies | 34,900 | |||||
CIC banking institution [member] | ||||||
Disclosure of commitments [line items] | ||||||
Sum of term deposit | 3,500 | |||||
Maximum collateral foreign exchange pledged security | 50,000 | |||||
Monetary market fund [member] | Other agreements [member] | ||||||
Disclosure of commitments [line items] | ||||||
Sum of term deposit | € 227 | |||||
Term deposit period | 3 years | |||||
Property, plant and equipment subject to operating leases [member] | Letter of credit 1 [member] | Other agreements [member] | ||||||
Disclosure of commitments [line items] | ||||||
Future rental payments | $ | $ 164 | $ 300 | $ 143 | |||
Not later than one year [member] | ||||||
Disclosure of commitments [line items] | ||||||
Future rental payments | € 3,965 | |||||
Later Than One Year and Not Later Than Two Years [member] | ||||||
Disclosure of commitments [line items] | ||||||
Future rental payments | 4,047 | |||||
Later Than Two Years and Not Later Than Three Years [member] | ||||||
Disclosure of commitments [line items] | ||||||
Future rental payments | 4,064 | |||||
Office equipment and vehicles [member] | Not later than one year [member] | ||||||
Disclosure of commitments [line items] | ||||||
Future rental payments | 77 | |||||
Office equipment and vehicles [member] | Later Than One Year and Not Later Than Two Years [member] | ||||||
Disclosure of commitments [line items] | ||||||
Future rental payments | 70 | |||||
Office equipment and vehicles [member] | Later Than Two Years and Not Later Than Three Years [member] | ||||||
Disclosure of commitments [line items] | ||||||
Future rental payments | € 16 | |||||
North america [member] | Rental agreements [member] | ||||||
Disclosure of commitments [line items] | ||||||
Area of office and laboratory space | ft² | 3,780 | 3,913 | ||||
Subleases expiration period | Jun. 30, 2017 | |||||
Additional initial Period of sublease | 5 years | |||||
Bagneux [member] | Monetary market fund [member] | Other agreements [member] | ||||||
Disclosure of commitments [line items] | ||||||
Guarantee for ordinary rental agreements of the premises | € 400 | |||||
Facility [member] | Rental agreements [member] | ||||||
Disclosure of commitments [line items] | ||||||
Office and laboratory space | m² | 4,770 | |||||
Number of facilities | Facilities | 2 | 2 | ||||
Lease agreement date | Mar. 9, 2015 | |||||
Leases expires period | Mar. 8, 2024 | |||||
Second Facility [member] | Rental agreements [member] | ||||||
Disclosure of commitments [line items] | ||||||
Office and laboratory space | m² | 1,479 | |||||
Leases expires period | May 31, 2020 | |||||
Commercial Facility [member] | Bottom of range [member] | ||||||
Disclosure of commitments [line items] | ||||||
Lease extension period | 2 years | |||||
Commercial Facility [member] | Top of range [member] | ||||||
Disclosure of commitments [line items] | ||||||
Lease extension period | 5 years | |||||
Commercial Facility [member] | Rental agreements [member] | ||||||
Disclosure of commitments [line items] | ||||||
Office and laboratory space | ft² | 8,919 | |||||
Lease commenced period | Eight years and four months. |
Commitments - Schedule of Futur
Commitments - Schedule of Future Rents and Charges (Detail) € in Thousands | Dec. 31, 2018EUR (€) |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | € 30,267 |
Not later than one year [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 3,965 |
Later Than One Year and Not Later Than Two Years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 4,047 |
Later Than Two Years and Not Later Than Three Years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 4,064 |
Later Than Three Years and Not Later Than Four Years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 4,058 |
Later Than Four Years and Not Later Than Five Years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 3,785 |
Later than five years and not later than six years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 3,211 |
Later than six years and not later than seven years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 1,998 |
Later than seven years and not later than eight years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 2,014 |
Later than eight years and not later than nine years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 1,700 |
Later than nine years and not later than ten years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | 1,031 |
Later than ten years [member] | |
Disclosure of finance lease and operating lease by lessee [line items] | |
Amount of future rents and charges | € 393 |
Relationships with Related Pa_3
Relationships with Related Parties - Additional Information (Detail) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Nov. 28, 2018 | |
Disclosure of transactions between related parties [line items] | ||||
Compensation awarded to corporate officers and executive committee | € 17,478 | € 15,353 | € 16,891 | |
Payment of severance | € 876 | |||
Commercial deployment expense | 49 | 45 | ||
Commercial strategy consulting works [member] | ||||
Disclosure of transactions between related parties [line items] | ||||
Compensation awarded to corporate officers and executive committee | € 45 | € 45 |
Relationships with Related Pa_4
Relationships with Related Parties - Summary of Relationships with Related Parties (Detail) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of transactions between related parties [line items] | |||
Related party compensation | € 17,478 | € 15,353 | € 16,891 |
Executive Committee [member] | |||
Disclosure of transactions between related parties [line items] | |||
Related party compensation | 3,325 | 2,184 | 2,268 |
Corporate Officers [member] | |||
Disclosure of transactions between related parties [line items] | |||
Related party compensation | 1,496 | 745 | 714 |
Members of the Board of Directors [member] | |||
Disclosure of transactions between related parties [line items] | |||
Share-based payments to members of the Board of Directors | 12,189 | 12,018 | 13,714 |
Directors Fees [member] | |||
Disclosure of transactions between related parties [line items] | |||
Related party compensation | € 469 | € 407 | € 195 |
Relationships with Related Pa_5
Relationships with Related Parties - Schedule of Amounts Payable to Related Parties (Detail) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Disclosure of amount payables to related parties [line items] | |||
Amounts Payable | € 954 | € 1,523 | € 1,304 |
Directors Fees [member] | |||
Disclosure of amount payables to related parties [line items] | |||
Amounts Payable | 469 | 432 | 195 |
Compensation [member] | |||
Disclosure of amount payables to related parties [line items] | |||
Amounts Payable | 66 | 689 | 767 |
Pension obligation [member] | |||
Disclosure of amount payables to related parties [line items] | |||
Amounts Payable | € 419 | € 402 | € 342 |
Earnings Per Share - Additional
Earnings Per Share - Additional Information (Detail) - shares | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Earnings per share [line items] | |||
Description of types of warranties | Multiplying it by 15 | ||
Anti-dilutive instruments | 3,366,296 | 3,309,539 | 2,360,945 |
Common Shares [member] | |||
Earnings per share [line items] | |||
Weighted average number of shares outstanding | 28,924,976 | 24,757,176 | 24,454,850 |
Earnings Per Share - Summary of
Earnings Per Share - Summary of Earnings Per Share (Detail) - EUR (€) € / shares in Units, € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Earnings per share [abstract] | |||
Net income of the reporting period | € (166,076) | € (147,693) | € (114,531) |
Adjusted weighted average number of outstanding shares | 28,924,976 | 24,757,176 | 24,454,850 |
Basic / Diluted earnings per share (€/share) | € (5.74) | € (5.97) | € (4.68) |
Management of Financial Risks -
Management of Financial Risks - Additional Information (Detail) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Disclosure Of Financial Risk Management [line items] | ||||
Cash and cash equivalents | € 122,770 | € 137,880 | € 256,473 | € 323,381 |
Operating losses and cash out flows from operation | (166,076) | (147,693) | (114,531) | |
Accumulated deficit and reserves | 254,900 | |||
Net cash used in operating activities | € 136,620 | € 114,314 | € 59,538 | |
Percentage of purchases and other external expenses made in U.S. dollars | 34.00% | |||
Top of range [member] | ||||
Disclosure Of Financial Risk Management [line items] | ||||
Percentage of purchases and other external expenses made in U.S. dollars | 12.00% | 12.00% |
Events After the Close of the_2
Events After the Close of the Fiscal Year - Additional Information (Detail) - Events after reporting period [member] | Mar. 04, 2019Director | Jan. 03, 2019 | Sep. 30, 2019 |
Disclosure of non-adjusting events after reporting period [line items] | |||
Number of Board of directors | 8 | ||
Bottom of range [member] | |||
Disclosure of non-adjusting events after reporting period [line items] | |||
Peanut allergy treatment covering age as per BLA | 4 | 4 | |
Top of range [member] | |||
Disclosure of non-adjusting events after reporting period [line items] | |||
Peanut allergy treatment covering age as per BLA | 11 | 11 |